<!DOCTYPE html>
<html class="client-nojs" lang="en" dir="ltr">
<head>
<meta charset="UTF-8"/>
<title>Mylan - Wikipedia</title>
<script>document.documentElement.className="client-js";RLCONF={"wgBreakFrames":!1,"wgSeparatorTransformTable":["",""],"wgDigitTransformTable":["",""],"wgDefaultDateFormat":"dmy","wgMonthNames":["","January","February","March","April","May","June","July","August","September","October","November","December"],"wgRequestId":"XpoMUQpAAEYAAJpfMfQAAABA","wgCSPNonce":!1,"wgCanonicalNamespace":"","wgCanonicalSpecialPageName":!1,"wgNamespaceNumber":0,"wgPageName":"Mylan","wgTitle":"Mylan","wgCurRevisionId":951205826,"wgRevisionId":951205826,"wgArticleId":2565857,"wgIsArticle":!0,"wgIsRedirect":!1,"wgAction":"view","wgUserName":null,"wgUserGroups":["*"],"wgPageContentLanguage":"en","wgPageContentModel":"wikitext","wgRelevantPageName":"Mylan","wgRelevantArticleId":2565857,"wgIsProbablyEditable":!0,"wgRelevantPageIsProbablyEditable":!0,"wgRestrictionEdit":[],"wgRestrictionMove":[],"wgRedirectedFrom":"Mylan_N.V.","wgMediaViewerOnClick":!0,"wgMediaViewerEnabledByDefault":!0,
"wgPopupsReferencePreviews":!1,"wgPopupsConflictsWithNavPopupGadget":!1,"wgVisualEditor":{"pageLanguageCode":"en","pageLanguageDir":"ltr","pageVariantFallbacks":"en"},"wgMFMode":"stable","wgMFAmc":!1,"wgMFAmcOutreachActive":!1,"wgMFAmcOutreachUserEligible":!1,"wgMFLazyLoadImages":!0,"wgMFDisplayWikibaseDescriptions":{"search":!0,"nearby":!0,"watchlist":!0,"tagline":!1},"wgMFIsPageContentModelEditable":!0,"wgWMESchemaEditAttemptStepOversample":!1,"wgULSCurrentAutonym":"English","wgNoticeProject":"wikipedia","wgInternalRedirectTargetUrl":"/wiki/Mylan","wgWikibaseItemId":"Q899010","wgCentralAuthMobileDomain":!0,"wgEditSubmitButtonLabelPublish":!0,"wgMinervaPermissions":{"watch":!0,"talk":!1},"wgMinervaFeatures":{"beta":!1,"mobileOptionsLink":!0,"categories":!1,"pageIssues":!0,"talkAtTop":!1,"historyInPageActions":!1,"overflowSubmenu":!1,"tabsOnSpecials":!1,"personalMenu":!1,"mainMenuExpanded":!1,"simplifiedTalk":!0},
"wgMinervaDownloadNamespaces":[0]};RLSTATE={"site.styles":"ready","noscript":"ready","user.styles":"ready","user":"ready","user.options":"loading","ext.cite.styles":"ready","skins.minerva.base.styles":"ready","skins.minerva.content.styles":"ready","skins.minerva.content.styles.images":"ready","mediawiki.hlist":"ready","mediawiki.ui.icon":"ready","mediawiki.ui.button":"ready","skins.minerva.icons.wikimedia":"ready","skins.minerva.mainMenu.icons":"ready","skins.minerva.mainMenu.styles":"ready","mobile.init.styles":"ready","ext.wikimediaBadges":"ready"};RLPAGEMODULES=["mediawiki.action.view.redirect","site","mediawiki.page.startup","skins.minerva.options","skins.minerva.scripts","ext.gadget.switcher","ext.centralauth.centralautologin","ext.popups","mobile.init","ext.relatedArticles.readMore.bootstrap","ext.eventLogging","ext.wikimediaEvents","ext.navigationTiming","mw.externalguidance.init","ext.quicksurveys.init","ext.centralNotice.geoIP","ext.centralNotice.startUp"];</script>
<script>(RLQ=window.RLQ||[]).push(function(){mw.loader.implement("user.options@1hzgi",function($,jQuery,require,module){/*@nomin*/mw.user.tokens.set({"patrolToken":"+\\","watchToken":"+\\","csrfToken":"+\\"});
});});</script>
<link rel="stylesheet" href="/w/load.php?lang=en&amp;modules=ext.cite.styles%7Cext.wikimediaBadges%7Cmediawiki.hlist%7Cmediawiki.ui.button%2Cicon%7Cmobile.init.styles%7Cskins.minerva.base.styles%7Cskins.minerva.content.styles%7Cskins.minerva.content.styles.images%7Cskins.minerva.icons.wikimedia%7Cskins.minerva.mainMenu.icons%2Cstyles&amp;only=styles&amp;skin=minerva"/>
<script async="" src="/w/load.php?lang=en&amp;modules=startup&amp;only=scripts&amp;raw=1&amp;skin=minerva&amp;target=mobile"></script>
<meta name="generator" content="MediaWiki 1.35.0-wmf.28"/>
<meta name="referrer" content="origin"/>
<meta name="referrer" content="origin-when-crossorigin"/>
<meta name="referrer" content="origin-when-cross-origin"/>
<meta name="theme-color" content="#eaecf0"/>
<meta name="viewport" content="initial-scale=1.0, user-scalable=yes, minimum-scale=0.25, maximum-scale=5.0, width=device-width"/>
<link rel="manifest" href="/w/api.php?action=webapp-manifest"/>
<link rel="alternate" type="application/x-wiki" title="Edit this page" href="/w/index.php?title=Mylan&amp;action=edit"/>
<link rel="edit" title="Edit this page" href="/w/index.php?title=Mylan&amp;action=edit"/>
<link rel="apple-touch-icon" href="/static/apple-touch/wikipedia.png"/>
<link rel="shortcut icon" href="/static/favicon/wikipedia.ico"/>
<link rel="search" type="application/opensearchdescription+xml" href="/w/opensearch_desc.php" title="Wikipedia (en)"/>
<link rel="EditURI" type="application/rsd+xml" href="//en.wikipedia.org/w/api.php?action=rsd"/>
<link rel="license" href="//creativecommons.org/licenses/by-sa/3.0/"/>
<link rel="canonical" href="https://en.wikipedia.org/wiki/Mylan"/>
<link rel="dns-prefetch" href="//login.wikimedia.org"/>
<link rel="dns-prefetch" href="//meta.wikimedia.org" />
<!--[if lt IE 9]><script src="/w/resources/lib/html5shiv/html5shiv.js"></script><![endif]-->
</head>
<body class="mediawiki ltr sitedir-ltr mw-hide-empty-elt ns-0 ns-subject mw-editable page-Mylan rootpage-Mylan stable issues-group-B skin-minerva action-view">
<div id="mw-mf-viewport">
	<div id="mw-mf-page-center">
		<a class="mw-mf-page-center__mask" href="#"></a>
		<header class="header-container header-chrome">
			<form class="header" action="/w/index.php" method="get">
				<nav class="navigation-drawer toggle-list view-border-box">
					<input type="checkbox" id="main-menu-input" class="toggle-list__checkbox" role="button" aria-labelledby="mw-mf-main-menu-button">
					<label for="main-menu-input" id="mw-mf-main-menu-button"
						class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-menu-base20 mw-ui-icon-flush-left toggle-list__toggle"
						title="Open main menu" data-event-name="ui.mainmenu">Open main menu</label>
					<div id="mw-mf-page-left" class="menu toggle-list__list view-border-box">
	<ul id="p-navigation">
			<li class="">
			    <a href="/wiki/Main_Page" class="mw-ui-icon mw-ui-icon-before mw-ui-icon-minerva-home" data-event-name="menu.home"><span>Home</span></a>
			</li>
			<li class="">
			    <a href="/wiki/Special:Random#/random" class="mw-ui-icon mw-ui-icon-before mw-ui-icon-minerva-die " data-event-name="menu.random"><span>Random</span></a>
			</li>
			<li class="jsonly">
			    <a href="/wiki/Special:Nearby" class="mw-ui-icon mw-ui-icon-before mw-ui-icon-minerva-mapPin nearby" data-event-name="menu.nearby"><span>Nearby</span></a>
			</li>
	</ul>
	<ul id="p-personal">
			<li class="">
			    <a href="/w/index.php?title=Special:UserLogin&amp;returnto=Mylan" class="menu__item--login mw-ui-icon mw-ui-icon-before mw-ui-icon-minerva-logIn " data-event-name="menu.login"><span>Log in</span></a>
			</li>
	</ul>
	<ul id="pt-preferences">
			<li class="jsonly">
			    <a href="/w/index.php?title=Special:MobileOptions&amp;returnto=Mylan" class="menu__item--settings mw-ui-icon mw-ui-icon-before mw-ui-icon-minerva-settings " data-event-name="menu.settings"><span>Settings</span></a>
			</li>
	</ul>
	<ul class="hlist">
			<li class="">
			    <a href="/wiki/Wikipedia:About" class="" data-event-name=""><span>About Wikipedia</span></a>
			</li>
			<li class="">
			    <a href="/wiki/Wikipedia:General_disclaimer" class="" data-event-name=""><span>Disclaimers</span></a>
			</li>
	</ul>
</div>

					<label class="main-menu-mask" for="main-menu-input"></label>
				</nav>
				<div class="branding-box">
					<a href="/wiki/Main_Page">
						<span><img src="/static/images/mobile/copyright/wikipedia-wordmark-en.svg" width="116" height="18" alt="Wikipedia"/></span>
						
					</a>
				</div>
				<div class="search-box">
					<input class="search mw-ui-background-icon-search skin-minerva-search-trigger" type="search" name="search" id="searchInput"
						autocomplete="off" placeholder="Search Wikipedia" aria-label="Search Wikipedia"
						value="">
				</div>
				<nav class="minerva-user-navigation" aria-label="User navigation">
					<div><button id="searchIcon" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-search-base20 skin-minerva-search-trigger" type="submit">Search</button></div>
					
				</nav>
			</form>
		</header>
		<main id="content" class="mw-body">
			<div class="banner-container">
			<div id="siteNotice"></div>
			</div>
			
			<div class="pre-content heading-holder">
				<div class="page-heading">
					<h1 id="section_0">Mylan</h1>
					<div class="tagline"></div>
				</div>
				<nav class="page-actions-menu">
	<ul id="page-actions" class="page-actions-menu__list">
		<li id="language-selector" class="page-actions-menu__list-item">
				<a id="" href="/wiki/Special:MobileLanguages/Mylan" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-language-base20 mw-ui-icon-with-label-desktop language-selector"
					data-mw="interface"
					data-event-name="menu.languages" role="button" title="Language">Language</a>
		</li>
		<li id="page-actions-watch" class="page-actions-menu__list-item">
				<a id="ca-watch" href="/w/index.php?title=Special:UserLogin&amp;returnto=Mylan" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-star-base20 mw-ui-icon-with-label-desktop watch-this-article mw-watchlink menu__item--page-actions-watch"
					data-mw="interface"
					data-event-name="menu.watch" role="button" title="Watch">Watch</a>
		</li>
		<li id="page-actions-edit" class="page-actions-menu__list-item">
				<a id="ca-edit" href="/w/index.php?title=Mylan&amp;action=edit&amp;section=0" class="edit-page menu__item--page-actions-edit mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 mw-ui-icon-with-label-desktop"
					data-mw="interface"
					data-event-name="menu.edit" role="button" title="Edit the lead section of this page">Edit</a>
		</li>
	</ul>
</nav>
<!-- version 1.0.2 (change every time you update a partial) -->

				
				
				<div class="minerva__subtitle"><span class="mw-redirectedfrom">&#160;&#160;(Redirected from <a href="/w/index.php?title=Mylan_N.V.&amp;redirect=no" class="mw-redirect" title="Mylan N.V.">Mylan N.V.</a>)</span></div>
			</div>
			
			<div id="bodyContent" class="content"><div id="mw-content-text" lang="en" dir="ltr" class="mw-content-ltr"><script>function mfTempOpenSection(id){var block=document.getElementById("mf-section-"+id);block.className+=" open-block";block.previousSibling.className+=" open-block";}</script><div class="mw-parser-output"><section class="mf-section-0" id="mf-section-0">
<p class="mw-empty-elt">
</p>
<p><b>Mylan N.V.</b> is a global <a href="/wiki/Generic_drug" title="Generic drug">generic</a> and specialty <a href="/wiki/Pharmaceuticals" class="mw-redirect" title="Pharmaceuticals">pharmaceuticals</a> company domiciled in the <a href="/wiki/Netherlands" title="Netherlands">Netherlands</a>, with principal executive offices in <a href="/wiki/Hatfield,_Hertfordshire" title="Hatfield, Hertfordshire">Hatfield, Hertfordshire</a>, UK<sup id="cite_ref-201510K_2-0" class="reference"><a href="#cite_note-201510K-2">[2]</a></sup> and a "Global Center" in <a href="/wiki/Canonsburg,_Pennsylvania" title="Canonsburg, Pennsylvania">Canonsburg, Pennsylvania</a>, US.  In 2007, Mylan acquired a controlling interest in <a href="/wiki/India" title="India">India</a>-based Matrix Laboratories Limited, a top producer of <a href="/wiki/Active_pharmaceutical_ingredients" class="mw-redirect" title="Active pharmaceutical ingredients">active pharmaceutical ingredients</a> (APIs) for generic drugs,<sup id="cite_ref-Pittsburgh_Biz_Times_3-0" class="reference"><a href="#cite_note-Pittsburgh_Biz_Times-3">[3]</a></sup> and the generics business of <a href="/wiki/Germany" title="Germany">Germany</a>-based <a href="/wiki/Merck_KGaA" class="mw-redirect" title="Merck KGaA">Merck KGaA</a>.<sup id="cite_ref-Medical_News_Today_4-0" class="reference"><a href="#cite_note-Medical_News_Today-4">[4]</a></sup> Through these acquisitions, Mylan grew from the third-largest generic and pharmaceuticals company in the <a href="/wiki/United_States" title="United States">United States</a> to the second-largest generic and specialty pharmaceuticals company in the world.<sup id="cite_ref-Pittsburgh_Trib_5-0" class="reference"><a href="#cite_note-Pittsburgh_Trib-5">[5]</a></sup></p><table class="infobox vcard" style="width:22em"><caption class="fn org">Mylan N.V.</caption><tbody><tr><td colspan="2" class="logo" style="text-align:center"><a href="/wiki/File:Mylan_Logo.svg" class="image"><img alt="Mylan Logo.svg" src="//upload.wikimedia.org/wikipedia/commons/thumb/b/b1/Mylan_Logo.svg/250px-Mylan_Logo.svg.png" decoding="async" width="250" height="74" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/b/b1/Mylan_Logo.svg/375px-Mylan_Logo.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/b/b1/Mylan_Logo.svg/500px-Mylan_Logo.svg.png 2x" data-file-width="98" data-file-height="29"></a></td></tr><tr><th scope="row" style="padding-right: 0.5em;"><div style="padding:0.1em 0;line-height:1.2em;"><a href="/wiki/Trade_name" title="Trade name">Trade name</a></div></th><td style="line-height: 1.35em;">Mylan N.V.</td></tr><tr><th scope="row" style="padding-right: 0.5em;"><div style="padding:0.1em 0;line-height:1.2em;">Formerly</div></th><td class="nickname" style="line-height: 1.35em;">Milan</td></tr><tr><th scope="row" style="padding-right: 0.5em;"><div style="padding:0.1em 0;line-height:1.2em;"><a href="/wiki/List_of_legal_entity_types_by_country" title="List of legal entity types by country">Type</a></div></th><td class="category" style="line-height: 1.35em;"><a href="/wiki/Naamloze_vennootschap" title="Naamloze vennootschap">Public</a> <span style="font-size:85%;">(under Dutch law)</span></td></tr><tr><th scope="row" style="padding-right: 0.5em;"><a href="/wiki/Ticker_symbol" title="Ticker symbol">Traded as</a></th><td style="line-height: 1.35em;"><div class="plainlist"><ul><li><a href="/wiki/NASDAQ" class="mw-redirect" title="NASDAQ">NASDAQ</a>: <a rel="nofollow" class="external text" href="https://www.nasdaq.com/symbol/myl">MYL</a></li><li><a href="/wiki/NASDAQ_Biotechnology_Index" title="NASDAQ Biotechnology Index">NASDAQ Biotechnology Component</a></li><li><a href="/wiki/S%26P_500" class="mw-redirect" title="S&amp;P 500">S&amp;P 500</a> component</li></ul></div></td></tr><tr><th scope="row" style="padding-right: 0.5em;"><a href="/wiki/International_Securities_Identification_Number" title="International Securities Identification Number">ISIN</a></th><td style="line-height: 1.35em;"><span class="plainlinks nourlexpansion"><a class="external text" href="https://tools.wmflabs.org/isin/?language=en&amp;isin=NL0011031208">NL0011031208</a></span></td></tr><tr><th scope="row" style="padding-right: 0.5em;">Industry</th><td class="category" style="line-height: 1.35em;"><a href="/wiki/Pharmaceuticals" class="mw-redirect" title="Pharmaceuticals">Pharmaceuticals</a></td></tr><tr><th scope="row" style="padding-right: 0.5em;">Founded</th><td style="line-height: 1.35em;">1961<span class="noprint">; 59 years ago</span><span style="display:none"> (<span class="bday dtstart published updated">1961</span>)</span> in <a href="/wiki/White_Sulphur_Springs,_West_Virginia" title="White Sulphur Springs, West Virginia">White Sulphur Springs, West Virginia</a>, <a href="/wiki/United_States" title="United States">United States</a></td></tr><tr><th scope="row" style="padding-right: 0.5em;">Founders</th><td class="agent" style="line-height: 1.35em;"><a href="/wiki/Milan_Puskar" title="Milan Puskar">Milan Puskar</a><br><a href="/wiki/Don_Panoz" title="Don Panoz">Don Panoz</a></td></tr><tr><th scope="row" style="padding-right: 0.5em;">Headquarters</th><td class="adr" style="line-height: 1.35em;"><div style="display: inline;" class="locality"><a href="/wiki/Canonsburg,_Pennsylvania" title="Canonsburg, Pennsylvania">Canonsburg, Pennsylvania</a></div>, <div style="display: inline;" class="country-name"><a href="/wiki/United_States_of_America" class="mw-redirect" title="United States of America">United States of America</a></div></td></tr><tr><th scope="row" style="padding-right: 0.5em;"><div style="padding:0.1em 0;line-height:1.2em;">Area served</div></th><td style="line-height: 1.35em;">Worldwide</td></tr><tr><th scope="row" style="padding-right: 0.5em;"><div style="padding:0.1em 0;line-height:1.2em;">Key people</div></th><td class="agent" style="line-height: 1.35em;"><a href="/wiki/Heather_Bresch" title="Heather Bresch">Heather Bresch</a>, <a href="/wiki/Chief_executive_officer" title="Chief executive officer">CEO</a></td></tr><tr><th scope="row" style="padding-right: 0.5em;">Products</th><td style="line-height: 1.35em;">Generic and specialty pharmaceuticals and <a href="/wiki/Active_pharmaceutical_ingredients" class="mw-redirect" title="Active pharmaceutical ingredients">active pharmaceutical ingredients</a></td></tr><tr><th scope="row" style="padding-right: 0.5em;">Revenue</th><td style="line-height: 1.35em;"><img alt="Decrease" src="//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/11px-Decrease2.svg.png" decoding="async" title="Decrease" width="11" height="11" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/17px-Decrease2.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/22px-Decrease2.svg.png 2x" data-file-width="300" data-file-height="300"> <span style="white-space: nowrap"><a href="/wiki/United_States_dollar" title="United States dollar">US$</a>11.434 billion</span> <span style="font-size:85%;">(2018)<sup id="cite_ref-10-K_1-0" class="reference"><a href="#cite_note-10-K-1">[1]</a></sup></span></td></tr><tr><th scope="row" style="padding-right: 0.5em;"><div style="padding:0.1em 0;line-height:1.2em;"><a href="/wiki/Earnings_before_interest_and_taxes" title="Earnings before interest and taxes">Operating income</a></div></th><td style="line-height: 1.35em;"><img alt="Decrease" src="//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/11px-Decrease2.svg.png" decoding="async" title="Decrease" width="11" height="11" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/17px-Decrease2.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/22px-Decrease2.svg.png 2x" data-file-width="300" data-file-height="300"> <span style="white-space: nowrap">US$906 million</span> <span style="font-size:85%;">(2018)<sup id="cite_ref-10-K_1-1" class="reference"><a href="#cite_note-10-K-1">[1]</a></sup></span></td></tr><tr><th scope="row" style="padding-right: 0.5em;"><div style="padding:0.1em 0;line-height:1.2em;"><a href="/wiki/Net_income" title="Net income">Net income</a></div></th><td style="line-height: 1.35em;"><img alt="Decrease" src="//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/11px-Decrease2.svg.png" decoding="async" title="Decrease" width="11" height="11" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/17px-Decrease2.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/22px-Decrease2.svg.png 2x" data-file-width="300" data-file-height="300"> <span style="white-space: nowrap">US$353 million</span> <span style="font-size:85%;">(2018)<sup id="cite_ref-10-K_1-2" class="reference"><a href="#cite_note-10-K-1">[1]</a></sup></span></td></tr><tr><th scope="row" style="padding-right: 0.5em;"><span class="nowrap"><a href="/wiki/Asset" title="Asset">Total assets</a></span></th><td style="line-height: 1.35em;"><img alt="Decrease" src="//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/11px-Decrease2.svg.png" decoding="async" title="Decrease" width="11" height="11" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/17px-Decrease2.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/22px-Decrease2.svg.png 2x" data-file-width="300" data-file-height="300"> <span style="white-space: nowrap">US$32.735 billion</span> <span style="font-size:85%;">(2018)<sup id="cite_ref-10-K_1-3" class="reference"><a href="#cite_note-10-K-1">[1]</a></sup></span></td></tr><tr><th scope="row" style="padding-right: 0.5em;"><span class="nowrap"><a href="/wiki/Equity_(finance)" title="Equity (finance)">Total equity</a></span></th><td style="line-height: 1.35em;"><img alt="Decrease" src="//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/11px-Decrease2.svg.png" decoding="async" title="Decrease" width="11" height="11" srcset="//upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/17px-Decrease2.svg.png 1.5x, //upload.wikimedia.org/wikipedia/commons/thumb/e/ed/Decrease2.svg/22px-Decrease2.svg.png 2x" data-file-width="300" data-file-height="300"> <span style="white-space: nowrap">US$12.167 billion</span> <span style="font-size:85%;">(2018)<sup id="cite_ref-10-K_1-4" class="reference"><a href="#cite_note-10-K-1">[1]</a></sup></span></td></tr><tr><th scope="row" style="padding-right: 0.5em;"><div style="padding:0.1em 0;line-height:1.2em;">Number of employees</div></th><td style="line-height: 1.35em;">~35,000 <span style="font-size:85%;">(December 2018)<sup id="cite_ref-10-K_1-5" class="reference"><a href="#cite_note-10-K-1">[1]</a></sup></span></td></tr><tr><th scope="row" style="padding-right: 0.5em;"><a href="/wiki/Division_(business)" title="Division (business)">Divisions</a></th><td style="line-height: 1.35em;"><i>see <a href="/wiki/Mylan#Operations" title="Mylan">Operations</a></i></td></tr><tr><th scope="row" style="padding-right: 0.5em;"><a href="/wiki/Subsidiary" title="Subsidiary">Subsidiaries</a></th><td style="line-height: 1.35em;">Meda<br>Famy Care</td></tr><tr><th scope="row" style="padding-right: 0.5em;">Website</th><td style="line-height: 1.35em;"><span class="url"><a rel="nofollow" class="external text" href="http://mylan.com">mylan<wbr></wbr>.com</a></span></td></tr></tbody></table><p>Mylan went public on the OTC market in February 1973.<sup id="cite_ref-6" class="reference"><a href="#cite_note-6">[6]</a></sup> It is listed on the NASDAQ,<sup id="cite_ref-7" class="reference"><a href="#cite_note-7">[7]</a></sup> and its shares are a component of the <a href="/wiki/NASDAQ_Biotechnology" class="mw-redirect" title="NASDAQ Biotechnology">NASDAQ Biotechnology</a><sup id="cite_ref-8" class="reference"><a href="#cite_note-8">[8]</a></sup> and the <a href="/wiki/S%26P_500" class="mw-redirect" title="S&amp;P 500">S&amp;P 500</a> indices.<sup id="cite_ref-9" class="reference"><a href="#cite_note-9">[9]</a></sup></p><p>The company develops and produces medicines for a wide range of medical disciplines, including <a href="/wiki/Oncology" title="Oncology">oncology</a>, <a href="/wiki/Anaphylaxis" title="Anaphylaxis">anaphylaxis</a>, <a href="/wiki/Management_of_HIV/AIDS" title="Management of HIV/AIDS">antiretrovirals</a>, <a href="/wiki/Circulatory_system" title="Circulatory system">cardiovascular</a>, <a href="/wiki/Respiratory_system" title="Respiratory system">respiratory</a>, <a href="/wiki/Dermatology" title="Dermatology">dermatology</a>, <a href="/wiki/Immunology" title="Immunology">immunology</a>, <a href="/wiki/Anesthesia" title="Anesthesia">anesthesia</a> and <a href="/wiki/Pain_management" title="Pain management">pain management</a>, <a href="/wiki/Infection" title="Infection">infectious disease</a>, <a href="/wiki/Gastroenterology" title="Gastroenterology">gastroenterology</a>, diabetology/<a href="/wiki/Endocrinology" title="Endocrinology">endocrinology</a>, and women's healthcare.<sup id="cite_ref-10" class="reference"><a href="#cite_note-10">[10]</a></sup></p><p>In 2016, Mylan's pricing of the EpiPen, an <a href="/wiki/Epinephrine_autoinjector" title="Epinephrine autoinjector">epinephrine autoinjector</a>, became controversial and was widely referred to as "price gouging".  As a result, investigations were opened into whether Mylan had misclassified the EpiPen under the <a href="/wiki/Medicaid_Drug_Rebate_Program" title="Medicaid Drug Rebate Program">Medicaid Drug Rebate Program</a>, a common form of <a href="/wiki/Pharmaceutical_fraud" title="Pharmaceutical fraud">pharmaceutical fraud</a>.  In October 2016, Mylan settled these investigations with the U.S. Department of Justice, agreeing to pay $465 million and enter into a <a href="/wiki/Corporate_integrity_agreement" title="Corporate integrity agreement">corporate integrity agreement</a> concerning the rebate program. In a report published on June 12, 2017 <a href="/wiki/Institutional_Shareholder_Services" title="Institutional Shareholder Services">Institutional Shareholder Services</a> criticized Mylan for the "outsized compensation" of Mylan's directors. Former CEO Robert Coury received a $98 million 2016 pay package in spite of shareholder losses and the perceived harm to the company inflicted by the EpiPen controversies. The report urged Mylan's shareholders to oust all of Mylan's existing directors.<sup id="cite_ref-CNN_CEO_revolt_11-0" class="reference"><a href="#cite_note-CNN_CEO_revolt-11">[11]</a></sup></p>
<div id="toc" class="toc" role="navigation" aria-labelledby="mw-toc-heading"><input type="checkbox" role="button" id="toctogglecheckbox" class="toctogglecheckbox" style="display:none"><div class="toctitle" lang="en" dir="ltr"><h2 id="mw-toc-heading">Contents</h2><span class="toctogglespan"><label class="toctogglelabel" for="toctogglecheckbox"></label></span></div>
<ul><li class="toclevel-1 tocsection-1"><a href="#Operations"><span class="tocnumber">1</span> <span class="toctext">Operations</span></a>
<ul><li class="toclevel-2 tocsection-2"><a href="#North_&amp;_South_America"><span class="tocnumber">1.1</span> <span class="toctext">North &amp; South America</span></a></li>
<li class="toclevel-2 tocsection-3"><a href="#Oceania_&amp;_parts_of_Asia"><span class="tocnumber">1.2</span> <span class="toctext">Oceania &amp; parts of Asia</span></a></li>
<li class="toclevel-2 tocsection-4"><a href="#Europe,_Africa,_&amp;_West_Asia"><span class="tocnumber">1.3</span> <span class="toctext">Europe, Africa, &amp; West Asia</span></a></li>
</ul></li>
<li class="toclevel-1 tocsection-5"><a href="#Corporate_headquarters"><span class="tocnumber">2</span> <span class="toctext">Corporate headquarters</span></a></li>
<li class="toclevel-1 tocsection-6"><a href="#Stock"><span class="tocnumber">3</span> <span class="toctext">Stock</span></a></li>
<li class="toclevel-1 tocsection-7"><a href="#History"><span class="tocnumber">4</span> <span class="toctext">History</span></a>
<ul><li class="toclevel-2 tocsection-8"><a href="#Founding_to_1980"><span class="tocnumber">4.1</span> <span class="toctext">Founding to 1980</span></a></li>
<li class="toclevel-2 tocsection-9"><a href="#1980s"><span class="tocnumber">4.2</span> <span class="toctext">1980s</span></a>
<ul><li class="toclevel-3 tocsection-10"><a href="#Dyazide_&amp;_Maxzide"><span class="tocnumber">4.2.1</span> <span class="toctext">Dyazide &amp; Maxzide</span></a></li>
<li class="toclevel-3 tocsection-11"><a href="#Acquisitions_begin"><span class="tocnumber">4.2.2</span> <span class="toctext">Acquisitions begin</span></a></li>
</ul></li>
<li class="toclevel-2 tocsection-12"><a href="#1990s"><span class="tocnumber">4.3</span> <span class="toctext">1990s</span></a></li>
<li class="toclevel-2 tocsection-13"><a href="#2000s"><span class="tocnumber">4.4</span> <span class="toctext">2000s</span></a>
<ul><li class="toclevel-3 tocsection-14"><a href="#Attempted_King_Pharmaceuticals_acquisition"><span class="tocnumber">4.4.1</span> <span class="toctext">Attempted King Pharmaceuticals acquisition</span></a></li>
<li class="toclevel-3 tocsection-15"><a href="#Matrix_acquisition"><span class="tocnumber">4.4.2</span> <span class="toctext">Matrix acquisition</span></a></li>
<li class="toclevel-3 tocsection-16"><a href="#EpiPen_acquisition"><span class="tocnumber">4.4.3</span> <span class="toctext">EpiPen acquisition</span></a></li>
</ul></li>
<li class="toclevel-2 tocsection-17"><a href="#2010s"><span class="tocnumber">4.5</span> <span class="toctext">2010s</span></a>
<ul><li class="toclevel-3 tocsection-18"><a href="#Generic_Advair_agreement"><span class="tocnumber">4.5.1</span> <span class="toctext">Generic Advair agreement</span></a></li>
<li class="toclevel-3 tocsection-19"><a href="#EpiPen4Schools_Launch"><span class="tocnumber">4.5.2</span> <span class="toctext">EpiPen4Schools Launch</span></a></li>
<li class="toclevel-3 tocsection-20"><a href="#Agila_acquisition"><span class="tocnumber">4.5.3</span> <span class="toctext">Agila acquisition</span></a></li>
<li class="toclevel-3 tocsection-21"><a href="#Abbott_acquisition"><span class="tocnumber">4.5.4</span> <span class="toctext">Abbott acquisition</span></a></li>
<li class="toclevel-3 tocsection-22"><a href="#Attempted_Perrigo_acquisition"><span class="tocnumber">4.5.5</span> <span class="toctext">Attempted Perrigo acquisition</span></a></li>
<li class="toclevel-3 tocsection-23"><a href="#Attempted_purchase_by_Teva"><span class="tocnumber">4.5.6</span> <span class="toctext">Attempted purchase by Teva</span></a></li>
<li class="toclevel-3 tocsection-24"><a href="#New_COPD_drug"><span class="tocnumber">4.5.7</span> <span class="toctext">New COPD drug</span></a></li>
<li class="toclevel-3 tocsection-25"><a href="#Meda_acquisition"><span class="tocnumber">4.5.8</span> <span class="toctext">Meda acquisition</span></a></li>
<li class="toclevel-3 tocsection-26"><a href="#Generic_Advair_approval"><span class="tocnumber">4.5.9</span> <span class="toctext">Generic Advair approval</span></a></li>
<li class="toclevel-3 tocsection-27"><a href="#Merger_with_Pfizer's_off-patent_drug_business"><span class="tocnumber">4.5.10</span> <span class="toctext">Merger with Pfizer's off-patent drug business</span></a></li>
<li class="toclevel-3 tocsection-28"><a href="#Valsartan_recall"><span class="tocnumber">4.5.11</span> <span class="toctext">Valsartan recall</span></a></li>
</ul></li>
<li class="toclevel-2 tocsection-29"><a href="#Acquisition_history"><span class="tocnumber">4.6</span> <span class="toctext">Acquisition history</span></a></li>
</ul></li>
<li class="toclevel-1 tocsection-30"><a href="#Criticism"><span class="tocnumber">5</span> <span class="toctext">Criticism</span></a>
<ul><li class="toclevel-2 tocsection-31"><a href="#EpiPen_pricing"><span class="tocnumber">5.1</span> <span class="toctext">EpiPen pricing</span></a></li>
<li class="toclevel-2 tocsection-32"><a href="#Execution_drugs"><span class="tocnumber">5.2</span> <span class="toctext">Execution drugs</span></a></li>
</ul></li>
<li class="toclevel-1 tocsection-33"><a href="#Products"><span class="tocnumber">6</span> <span class="toctext">Products</span></a>
<ul><li class="toclevel-2 tocsection-34"><a href="#Generic_Medicines"><span class="tocnumber">6.1</span> <span class="toctext">Generic Medicines</span></a></li>
<li class="toclevel-2 tocsection-35"><a href="#Branded_Medicines"><span class="tocnumber">6.2</span> <span class="toctext">Branded Medicines</span></a></li>
</ul></li>
<li class="toclevel-1 tocsection-36"><a href="#Management"><span class="tocnumber">7</span> <span class="toctext">Management</span></a></li>
<li class="toclevel-1 tocsection-37"><a href="#References"><span class="tocnumber">8</span> <span class="toctext">References</span></a></li>
<li class="toclevel-1 tocsection-38"><a href="#External_links"><span class="tocnumber">9</span> <span class="toctext">External links</span></a></li>
</ul></div>

</section><h2 class="section-heading" onclick="javascript:mfTempOpenSection(1)"><div class="mw-ui-icon mw-ui-icon-element indicator mw-ui-icon-small mw-ui-icon-flush-left"></div><span class="mw-headline" id="Operations">Operations</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=1" title="Edit section: Operations" data-section="1" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h2><section class="mf-section-1 collapsible-block" id="mf-section-1">
<p>Mylan Inc. operates several divisions and subsidiaries in various regions around the world:
</p>
<h3 class="in-block"><span id="North_.26_South_America"></span><span class="mw-headline" id="North_&amp;_South_America">North &amp; South America</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=2" title="Edit section: North &amp; South America" data-section="2" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h3>
<ul><li>Mylan Pharmaceuticals, based in <a href="/wiki/Morgantown,_West_Virginia" title="Morgantown, West Virginia">Morgantown</a>, West Virginia <sup id="cite_ref-12" class="reference"><a href="#cite_note-12">[12]</a></sup></li>
<li>Mylan Pharmaceuticals <a href="/wiki/Unlimited_liability_corporation" title="Unlimited liability corporation">ULC</a>, based in Etobicoke, Ontario <sup id="cite_ref-13" class="reference"><a href="#cite_note-13">[13]</a></sup></li>
<li>Mylan Technologies Inc. (MTI) - <a href="/wiki/Transdermal_drug_delivery_systems" class="mw-redirect" title="Transdermal drug delivery systems">transdermal drug delivery systems</a> (TDDS) and related technologies based in St. Albans, Vermont <sup id="cite_ref-14" class="reference"><a href="#cite_note-14">[14]</a></sup></li>
<li>UDL Laboratories Inc. based in Rockford, Illinois</li>
<li>Somerset Pharmaceuticals Inc.  a <a href="/wiki/Research_and_development" title="Research and development">research and development</a> company based in <a href="/wiki/Tampa,_Florida" title="Tampa, Florida">Tampa, Florida</a>, owned by Mylan.<sup id="cite_ref-15" class="reference"><a href="#cite_note-15">[15]</a></sup> Somerset develops <a href="/wiki/Emsam" class="mw-redirect" title="Emsam">Emsam</a>, manufactured by Mylan Technologies and marketed in the United States by Dey, later renamed Mylan Specialty <sup id="cite_ref-16" class="reference"><a href="#cite_note-16">[16]</a></sup><sup id="cite_ref-17" class="reference"><a href="#cite_note-17">[17]</a></sup><sup id="cite_ref-18" class="reference"><a href="#cite_note-18">[18]</a></sup></li>
<li>Mylan Laboratories Limited, based in Campos dos Goytacazes, Brazil<sup id="cite_ref-19" class="reference"><a href="#cite_note-19">[19]</a></sup></li></ul><h3 class="in-block"><span id="Oceania_.26_parts_of_Asia"></span><span class="mw-headline" id="Oceania_&amp;_parts_of_Asia">Oceania &amp; parts of Asia</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=3" title="Edit section: Oceania &amp; parts of Asia" data-section="3" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h3>
<ul><li>Mylan New Zealand Limited, based in Auckland, <a href="/wiki/New_Zealand" title="New Zealand">New Zealand</a></li>
<li>Mylan Laboratories Limited - headquartered in <a href="/wiki/Hyderabad,_India" class="mw-redirect" title="Hyderabad, India">Hyderabad, India</a> and operates approximately a dozen manufacturing facilities located in India and <a href="/wiki/People%27s_Republic_of_China" class="mw-redirect" title="People's Republic of China">China</a> <sup id="cite_ref-20" class="reference"><a href="#cite_note-20">[20]</a></sup></li>
<li>Mylan Seiyaku Ltd. based in Tokyo, <a href="/wiki/Japan" title="Japan">Japan</a> <sup id="cite_ref-21" class="reference"><a href="#cite_note-21">[21]</a></sup></li>
<li><a href="/wiki/Alphapharm" title="Alphapharm">Alphapharm</a>  based in <a href="/wiki/Australia" title="Australia">Australia</a> <sup id="cite_ref-22" class="reference"><a href="#cite_note-22">[22]</a></sup></li>
<li>Agila Specialties Pvt. Ltd. based in <a href="/wiki/Bangalore" title="Bangalore">Bangalore</a>, <a href="/wiki/Karnataka" title="Karnataka">Karnataka</a>, <a href="/wiki/India" title="India">India</a> <sup id="cite_ref-23" class="reference"><a href="#cite_note-23">[23]</a></sup></li>
<li>OncoTherapies Ltd. based in <a href="/wiki/Bangalore" title="Bangalore">Bangalore</a>, <a href="/wiki/Karnataka" title="Karnataka">Karnataka</a>, <a href="/wiki/India" title="India">India</a> <sup id="cite_ref-24" class="reference"><a href="#cite_note-24">[24]</a></sup><sup id="cite_ref-Global_25-0" class="reference"><a href="#cite_note-Global-25">[25]</a></sup></li></ul><h3 class="in-block"><span id="Europe.2C_Africa.2C_.26_West_Asia"></span><span class="mw-headline" id="Europe,_Africa,_&amp;_West_Asia">Europe, Africa, &amp; West Asia</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=4" title="Edit section: Europe, Africa, &amp; West Asia" data-section="4" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h3>
<ul><li>Divisions under the Mylan name in Republic of Ireland, Austria, Belgium, the Czech Republic, Denmark, Finland, France, Germany, Hungary, Italy, the Netherlands, Norway, Poland, Portugal, Slovakia, Slovenia, Spain, Sweden, Switzerland, &amp; the United Kingdom.</li>
<li>Arcana Arzneimittel <a href="/wiki/Gesellschaft_mit_beschr%C3%A4nkter_Haftung" title="Gesellschaft mit beschränkter Haftung">GmbH</a> based in <a href="/wiki/Germany" title="Germany">Germany</a> <sup id="cite_ref-26" class="reference"><a href="#cite_note-26">[26]</a></sup></li>
<li>Generics Pharma Hellas based in <a href="/wiki/Greece" title="Greece">Greece</a><sup id="cite_ref-27" class="reference"><a href="#cite_note-27">[27]</a></sup></li>
<li>Gerard Laboratories based in <a href="/wiki/Ireland" title="Ireland">Ireland</a> <sup id="cite_ref-28" class="reference"><a href="#cite_note-28">[28]</a></sup></li>
<li>Docpharma - generic pharmaceutical distribution company based in Belgium,<sup id="cite_ref-29" class="reference"><a href="#cite_note-29">[29]</a></sup> the Netherlands and Luxembourg <sup id="cite_ref-Global_25-1" class="reference"><a href="#cite_note-Global-25">[25]</a></sup></li></ul></section><h2 class="section-heading" onclick="javascript:mfTempOpenSection(2)"><div class="mw-ui-icon mw-ui-icon-element indicator mw-ui-icon-small mw-ui-icon-flush-left"></div><span class="mw-headline" id="Corporate_headquarters">Corporate headquarters</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=5" title="Edit section: Corporate headquarters" data-section="5" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h2><section class="mf-section-2 collapsible-block" id="mf-section-2">
<p>Founded in 1961, the company was first located in an abandoned skating rink in <a href="/wiki/White_Sulphur_Springs,_West_Virginia" title="White Sulphur Springs, West Virginia">White Sulphur Springs</a>, <a href="/wiki/West_Virginia" title="West Virginia">West Virginia</a>.<sup id="cite_ref-PuskarObit_30-0" class="reference"><a href="#cite_note-PuskarObit-30">[30]</a></sup><sup id="cite_ref-31" class="reference"><a href="#cite_note-31">[31]</a></sup> The facility was moved to Pennsauken, New Jersey in 1962,<sup id="cite_ref-32" class="reference"><a href="#cite_note-32">[32]</a></sup> to Princeton, West Virginia in 1963, and then <a href="/wiki/Morgantown,_West_Virginia" title="Morgantown, West Virginia">Morgantown</a>, West Virginia, in 1965, and in 1976 it relocated its corporate headquarters to the <a href="/wiki/Pittsburgh" title="Pittsburgh">Pittsburgh</a> suburb <a href="/wiki/Canonsburg" class="mw-redirect" title="Canonsburg">Canonsburg</a>, <a href="/wiki/Pennsylvania" title="Pennsylvania">Pennsylvania</a>. Finally in 2004 it moved to a new office center in nearby <a href="/wiki/Southpointe" title="Southpointe">Southpointe</a>, a suburban business park located in the Pittsburgh suburb of <a href="/wiki/Cecil_Township,_Pennsylvania" class="mw-redirect" title="Cecil Township, Pennsylvania">Cecil Township</a>, where it is still located.<sup id="cite_ref-33" class="reference"><a href="#cite_note-33">[33]</a></sup></p>
</section><h2 class="section-heading" onclick="javascript:mfTempOpenSection(3)"><div class="mw-ui-icon mw-ui-icon-element indicator mw-ui-icon-small mw-ui-icon-flush-left"></div><span class="mw-headline" id="Stock">Stock</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=6" title="Edit section: Stock" data-section="6" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h2><section class="mf-section-3 collapsible-block" id="mf-section-3">
<p>On February 23, 1973, Mylan had its initial public offering (IPO),<sup id="cite_ref-34" class="reference"><a href="#cite_note-34">[34]</a></sup> becoming a <a href="/wiki/Publicly_traded" class="mw-redirect" title="Publicly traded">publicly traded</a> company on the <a href="/wiki/Over-the-counter_(finance)" title="Over-the-counter (finance)">OTC</a> market under the <a href="/wiki/Ticker_symbol" title="Ticker symbol">ticker symbol</a> MYLN. In 1976 the stock moved to <a href="/wiki/NASDAQ" class="mw-redirect" title="NASDAQ">NASDAQ</a>. Their final stock move was in 1986, when their stock became available for trade on the <a href="/wiki/New_York_Stock_Exchange" title="New York Stock Exchange">New York Stock Exchange</a> under the ticker symbol MYL. Currently, the stock is traded on the <a href="/wiki/NASDAQ" class="mw-redirect" title="NASDAQ">NASDAQ</a>.
</p>
</section><h2 class="section-heading" onclick="javascript:mfTempOpenSection(4)"><div class="mw-ui-icon mw-ui-icon-element indicator mw-ui-icon-small mw-ui-icon-flush-left"></div><span class="mw-headline" id="History">History</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=7" title="Edit section: History" data-section="7" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h2><section class="mf-section-4 collapsible-block" id="mf-section-4">
<h3 class="in-block"><span class="mw-headline" id="Founding_to_1980">Founding to 1980</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=8" title="Edit section: Founding to 1980" data-section="8" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h3>
<p>Mylan Pharmaceuticals was founded as a drug distributor in 1961 by <a href="/wiki/Milan_Puskar" title="Milan Puskar">Milan Puskar</a> and <a href="/wiki/Don_Panoz" title="Don Panoz">Don Panoz</a>.<sup id="cite_ref-PuskarObit_30-1" class="reference"><a href="#cite_note-PuskarObit-30">[30]</a></sup> In 1966 Mylan began manufacturing <a href="/wiki/Penicillin_G" class="mw-redirect" title="Penicillin G">penicillin G</a> tablets as well as vitamins and other dietary supplements.<sup id="cite_ref-PuskarObit_30-2" class="reference"><a href="#cite_note-PuskarObit-30">[30]</a></sup><sup id="cite_ref-NYTexpose1989_35-0" class="reference"><a href="#cite_note-NYTexpose1989-35">[35]</a></sup></p><p>Panoz left Mylan in 1969 and Puskar quit the company in 1973, as it grew and experienced financial difficulties. The board hired Roy McKnight as board chairman, who convinced Puskar to return in 1976.<sup id="cite_ref-NYTexpose1989_35-1" class="reference"><a href="#cite_note-NYTexpose1989-35">[35]</a></sup></p><p>Mylan discontinued operating as a <a href="/wiki/Contract_manufacturing_organization" title="Contract manufacturing organization">contract manufacturing organization</a> in 1980 and instead chose to market their products under their own "Mylan-labeled" brand.<sup id="cite_ref-36" class="reference"><a href="#cite_note-36">[36]</a></sup></p>
<h3 class="in-block"><span class="mw-headline" id="1980s">1980s</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=9" title="Edit section: 1980s" data-section="9" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h3>
<p>With the passage of the <a href="/wiki/Drug_Price_Competition_and_Patent_Term_Restoration_Act" title="Drug Price Competition and Patent Term Restoration Act">Hatch-Waxman Act</a> in 1984, Mylan and other small generic companies gained value; in the eighteen months following passage of the law Mylan's earnings grew 166% to $12.5 million and its stock value rose 800%.<sup id="cite_ref-37" class="reference"><a href="#cite_note-37">[37]</a></sup></p>
<h4 class="in-block"><span id="Dyazide_.26_Maxzide"></span><span class="mw-headline" id="Dyazide_&amp;_Maxzide">Dyazide &amp; Maxzide</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=10" title="Edit section: Dyazide &amp; Maxzide" data-section="10" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h4>
<p>In the 1980s one of the most prescribed drugs in the US was Dyazide, a <a href="/wiki/Diuretic" title="Diuretic">diuretic</a> that was a <a href="/wiki/Combination_drug" title="Combination drug">combination drug</a> containing <a href="/wiki/Triamterene" title="Triamterene">triamterene</a> and <a href="/wiki/Hydrochlorothiazide" title="Hydrochlorothiazide">hydrochlorothiazide</a>; it had been on the market since 1965 and its patents had expired in 1980.<sup id="cite_ref-Philly1987_38-0" class="reference"><a href="#cite_note-Philly1987-38">[38]</a></sup>  Complications arose with the introductions of generics versions, because the formulation of Dyazide resulted in variable batches that made it impossible for generic manufacturers to show that their versions were bioequivalent.<sup id="cite_ref-auto_39-0" class="reference"><a href="#cite_note-auto-39">[39]</a></sup><sup id="cite_ref-MylanHistDyazide_40-0" class="reference"><a href="#cite_note-MylanHistDyazide-40">[40]</a></sup></p><p>Some generic companies committed fraud trying to bring a generic version of Dyazide.  Bolar Pharmaceutical had the first generic version approved in 1987,<sup id="cite_ref-Philly1987_38-1" class="reference"><a href="#cite_note-Philly1987-38">[38]</a></sup>  but it turned out that Bolar had fraudulently substituted Dyazide for its own version to conduct studies that were submitted to the FDA. By 1989 the FDA rescinded its approval based on its suspicions and filed criminal charges against Bolar, to which Bolar eventually pled guilty in 1991.<sup id="cite_ref-Siege_41-0" class="reference"><a href="#cite_note-Siege-41">[41]</a></sup><sup id="cite_ref-42" class="reference"><a href="#cite_note-42">[42]</a></sup><sup id="cite_ref-43" class="reference"><a href="#cite_note-43">[43]</a></sup></p><p>Mylan chose to develop a new version of a triamterene/hydrochlorothiazide combination drug instead of going the generic route;  it developed a different, more stable formulation<sup id="cite_ref-MylanHistDyazide_40-1" class="reference"><a href="#cite_note-MylanHistDyazide-40">[40]</a></sup> and used different dosages of each active ingredient (50 mg hydrochlorothiazide and 75 mg triamterene, compared with Dyazide's 25 mg hydrochlorothiazide and 50 mg triamterene).<sup id="cite_ref-MaxApprovable_44-0" class="reference"><a href="#cite_note-MaxApprovable-44">[44]</a></sup> This drug had to get approval as a new drug, as opposed to a generic. Their product was called Maxzide and was approved in 1984.<sup id="cite_ref-MaxApprovable_44-1" class="reference"><a href="#cite_note-MaxApprovable-44">[44]</a></sup><sup id="cite_ref-45" class="reference"><a href="#cite_note-45">[45]</a></sup>  The higher dose allowed once per day dosing, which Mylan and its marketing partner, Lederle, believed would help it compete against Dyazide, which had $210M in sales in 1983.<sup id="cite_ref-MaxApprovable_44-2" class="reference"><a href="#cite_note-MaxApprovable-44">[44]</a></sup>  However, Mylan's patents on the drug were declared invalid in court, and its marketing exclusivity expired in 1987, prompting a rush of generic competition<sup id="cite_ref-46" class="reference"><a href="#cite_note-46">[46]</a></sup></p><p>Mylan had concerns about the practices of its competitors and the FDA in general, and also with regard to companies seeking to bring generic versions of Maxzide.  Mylan hired private investigators to examine its competitors' practices, and when it found evidence of corruption, it submitted it to the <a href="/wiki/United_States_House_Energy_Subcommittee_on_Oversight_and_Investigations" title="United States House Energy Subcommittee on Oversight and Investigations">House Oversight and Investigations Committee</a>, which investigated and found fraud and corruption within the <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a>'s generic drugs division and at other generic companies.<sup id="cite_ref-NYTexpose1989_35-2" class="reference"><a href="#cite_note-NYTexpose1989-35">[35]</a></sup>  Two of the companies that had gotten approval to market generic versions of Maxzide,  Vitarine Pharmaceutical and <a href="/wiki/Par_Pharmaceutical" class="mw-redirect" title="Par Pharmaceutical">Par Pharmaceutical</a>, were targets of Mylan's initial investigation and were found to have used Mylan's Maxzide to obtain their bioequivalence data, leading both companies to withdraw its generic competitor to Mylan's product.<sup id="cite_ref-NYTexpose1989_35-3" class="reference"><a href="#cite_note-NYTexpose1989-35">[35]</a></sup><sup id="cite_ref-47" class="reference"><a href="#cite_note-47">[47]</a></sup></p><p>The corruption in the nascent generics industry and at the office in the FDA regulating it was widely covered in the media, and led to widespread concern among doctors and the public in the late 1980s and early 1990s that generic drugs were not really the same as the branded drugs they were meant to replace.<sup id="cite_ref-Siege_41-1" class="reference"><a href="#cite_note-Siege-41">[41]</a></sup><sup id="cite_ref-48" class="reference"><a href="#cite_note-48">[48]</a></sup><sup id="cite_ref-auto_39-1" class="reference"><a href="#cite_note-auto-39">[39]</a></sup></p>
<h4 class="in-block"><span class="mw-headline" id="Acquisitions_begin">Acquisitions begin</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=11" title="Edit section: Acquisitions begin" data-section="11" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h4>
<p>In 1987 Mylan agreed to enter into a joint venture with Bolar to buy Somerset Pharmaceuticals; Mylan wanted access to Somersets' drug discovery capabilities as well as its new drug for Parkinson's, <a href="/wiki/Selegiline" title="Selegiline">selegiline</a>; the deal was completed in 1988 but its consummation was dependent on FDA approval of selegiline, which came in 1989.<sup id="cite_ref-NYTexpose1989_35-4" class="reference"><a href="#cite_note-NYTexpose1989-35">[35]</a></sup><sup id="cite_ref-49" class="reference"><a href="#cite_note-49">[49]</a></sup><sup id="cite_ref-50" class="reference"><a href="#cite_note-50">[50]</a></sup></p>
<h3 class="in-block"><span class="mw-headline" id="1990s">1990s</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=12" title="Edit section: 1990s" data-section="12" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h3>
<p>Mylan acquired Bertek Inc. in 1993 for its <a href="/wiki/Transdermal_patch" title="Transdermal patch">transdermal patch</a> technologies, and kept it as a subsidiary. In 1999 Mylan renamed the company Mylan Technologies Inc. (MTI).<sup id="cite_ref-SpecialtyTrends2015_51-0" class="reference"><a href="#cite_note-SpecialtyTrends2015-51">[51]</a></sup>  MTI eventually came to be the contract manufacturer for the <a href="/wiki/Selegiline" title="Selegiline">selegiline</a> transdermal patch and was the first company to market  generic nitroglycerin, estradiol, clonidine, and fentanyl transdermal patches.<sup id="cite_ref-SpecialtyTrends2015_51-1" class="reference"><a href="#cite_note-SpecialtyTrends2015-51">[51]</a></sup></p><p>In 1996 Mylan acquired UDL Laboratories, a supplier of unit dose generic medications to institutional and <a href="/wiki/Long-term_care" title="Long-term care">long-term care</a> facilities.<sup id="cite_ref-52" class="reference"><a href="#cite_note-52">[52]</a></sup></p><p>In 1998 when it was the world's second largest generics company, Mylan came under investigation from the <a href="/wiki/Federal_Trade_Commission" title="Federal Trade Commission">Federal Trade Commission</a> after it raised the prices of its products, tripling them in the case of <a href="/wiki/Lorazepam" title="Lorazepam">lorazepam</a>.  Mylan had entered into an exclusive agreement with Profarmica, an Italian company that supplied drug ingredients, after which Mylan's competitors had higher prices and a diminished supply of raw ingredients for lorazepam and other drugs.<sup id="cite_ref-NYT1998_53-0" class="reference"><a href="#cite_note-NYT1998-53">[53]</a></sup> Before the round of price increases the price of generic drugs had been 5 - 10% of the price of branded drugs and afterwards it was around 50%.<sup id="cite_ref-NYT1998_53-1" class="reference"><a href="#cite_note-NYT1998-53">[53]</a></sup>  The FTC filed suit at the end of 1998 and 32 states filed parallel actions.  The case was settled in 2000, with Mylan paying a total of $147M --  $100M in disgorged profits into a fund to reimburse consumers and state agencies that had overpaid, $8 million in attorney's fees to the State Attorneys General, $35 million, plus $4 million in attorney's fees, to settle certain class actions with insurers and managed care organizations—and Mylan and three ingredient suppliers (Cambrex Corporation, Profarmaco S.R.L., and Gyma Laboratories) also agreed to an injunction barring them from entering into similar anticompetitive agreements in the future.<sup id="cite_ref-54" class="reference"><a href="#cite_note-54">[54]</a></sup><sup id="cite_ref-nyt_55-0" class="reference"><a href="#cite_note-nyt-55">[55]</a></sup></p>
<h3 class="in-block"><span class="mw-headline" id="2000s">2000s</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=13" title="Edit section: 2000s" data-section="13" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h3>
<h4 class="in-block"><span class="mw-headline" id="Attempted_King_Pharmaceuticals_acquisition">Attempted King Pharmaceuticals acquisition</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=14" title="Edit section: Attempted King Pharmaceuticals acquisition" data-section="14" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h4>
<p>In 2004 Mylan and <a href="/wiki/King_Pharmaceuticals" title="King Pharmaceuticals">King Pharmaceuticals</a> began discussing a deal in which Mylan would acquire King for about $4B; Mylan wanted to expand its presence in branded pharmaceuticals and to acquire King's sales force.<sup id="cite_ref-FortuneKing_56-0" class="reference"><a href="#cite_note-FortuneKing-56">[56]</a></sup>  The deal was complicated by a number of factors, and included an SEC investigation into King's accounting and <a href="/wiki/Carl_Icahn" title="Carl Icahn">Carl Icahn</a> obtaining a 9.8% interest in Mylan and becoming its largest stakeholder in order to kill the deal. The parties called off the deal in February 2005.<sup id="cite_ref-FortuneKing_56-1" class="reference"><a href="#cite_note-FortuneKing-56">[56]</a></sup>  Afterwards, Icahn offered to buy Mylan for $5.4B<sup id="cite_ref-57" class="reference"><a href="#cite_note-57">[57]</a></sup> and nominated a slate of board members to change the direction of Mylan; he won three seats in May 2005.<sup id="cite_ref-58" class="reference"><a href="#cite_note-58">[58]</a></sup>  In June Mylan bought back 25% of its shares in order to fend off Icahn.<sup id="cite_ref-59" class="reference"><a href="#cite_note-59">[59]</a></sup> In July Icahn gave up his bid and sold his shares.<sup id="cite_ref-60" class="reference"><a href="#cite_note-60">[60]</a></sup></p>
<h4 class="in-block"><span class="mw-headline" id="Matrix_acquisition">Matrix acquisition</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=15" title="Edit section: Matrix acquisition" data-section="15" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h4>
<p>In August 2006 Mylan announced that it had reached an agreement to buy a controlling interest in Matrix Laboratories, an Indian supplier of <a href="/wiki/Active_pharmaceutical_ingredients" class="mw-redirect" title="Active pharmaceutical ingredients">active pharmaceutical ingredients</a>. The deal gave Mylan access to markets in India and China and was completed in January the next year.<sup id="cite_ref-61" class="reference"><a href="#cite_note-61">[61]</a></sup><sup id="cite_ref-62" class="reference"><a href="#cite_note-62">[62]</a></sup></p>
<h4 class="in-block"><span class="mw-headline" id="EpiPen_acquisition">EpiPen acquisition</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=16" title="Edit section: EpiPen acquisition" data-section="16" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h4>
<p>In May 2007 Mylan and <a href="/wiki/Merck_KGaA" class="mw-redirect" title="Merck KGaA">Merck KGaA</a> agreed that Mylan would acquire Merck's generics arm for $6.6B. The deal was completed that October and tripled the size of Mylan.<sup id="cite_ref-63" class="reference"><a href="#cite_note-63">[63]</a></sup><sup id="cite_ref-64" class="reference"><a href="#cite_note-64">[64]</a></sup>   Mylan acquired the rights to market the EpiPen in the transaction. At that time annual sales were around $200 million<sup id="cite_ref-BloomMarketing_65-0" class="reference"><a href="#cite_note-BloomMarketing-65">[65]</a></sup> and the EpiPen had about 90% of the market.<sup id="cite_ref-Trib2016_66-0" class="reference"><a href="#cite_note-Trib2016-66">[66]</a></sup></p><p>In 2009, the company filed two lawsuits against the <a href="/wiki/Pittsburgh_Post-Gazette" title="Pittsburgh Post-Gazette">Pittsburgh Post-Gazette</a> after the newspaper ran an article that was critical of the quality control procedures used at the company's Morgantown plant.<sup id="cite_ref-wsj2009_67-0" class="reference"><a href="#cite_note-wsj2009-67">[67]</a></sup><sup id="cite_ref-ppg0709_68-0" class="reference"><a href="#cite_note-ppg0709-68">[68]</a></sup> The company had earlier quality control issues involving the FDA.<sup id="cite_ref-mwcbs09_69-0" class="reference"><a href="#cite_note-mwcbs09-69">[69]</a></sup>  The lawsuits were dropped in 2012 without any damages paid by the Post-Gazette, which stated "The Post-Gazette did not find and did not intend to report that Mylan had manufactured or distributed any defective drugs. The Post-Gazette regrets if any reader of the article thought otherwise."<sup id="cite_ref-ap2012_70-0" class="reference"><a href="#cite_note-ap2012-70">[70]</a></sup></p><p>Also in 2009, Mylan and its subsidiary UDL agreed to pay a $118M to settle a suit filed under the <a href="/wiki/False_Claims_Act" title="False Claims Act">False Claims Act</a> in which Mylan/UDL and two other companies were accused of underpaying states under the <a href="/wiki/Medicaid_Drug_Rebate_Program" title="Medicaid Drug Rebate Program">Medicaid Drug Rebate Program</a>. The program requires drug companies to give rebates to states under Medicaid and the rebates are higher for new drugs than for generics; the suit said that the companies sold new drugs but paid rebates as if they were generics.<sup id="cite_ref-71" class="reference"><a href="#cite_note-71">[71]</a></sup></p>
<h3 class="in-block"><span class="mw-headline" id="2010s">2010s</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=17" title="Edit section: 2010s" data-section="17" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h3>
<h4 class="in-block"><span class="mw-headline" id="Generic_Advair_agreement">Generic Advair agreement</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=18" title="Edit section: Generic Advair agreement" data-section="18" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h4>
<p>In 2011, Mylan entered into an agreement with <a href="/wiki/Pfizer" title="Pfizer">Pfizer</a> for the exclusive worldwide rights to develop, manufacture and commercialize Pfizer's generic equivalent to <a href="/wiki/GlaxoSmithKline" title="GlaxoSmithKline">GlaxoSmithKline</a>'s <a href="/wiki/Advair" class="mw-redirect" title="Advair">Advair</a> (US)/Seretide (UK) Diskus incorporating Pfizer's proprietary dry powder inhaler delivery platform.<sup id="cite_ref-72" class="reference"><a href="#cite_note-72">[72]</a></sup> Mylan launched the product in the UK in 2015<sup id="cite_ref-73" class="reference"><a href="#cite_note-73">[73]</a></sup> and in February 2016 the FDA accepted its ANDA, putting it in line behind Hikma and Sandoz to launch a generic version in the US.<sup id="cite_ref-74" class="reference"><a href="#cite_note-74">[74]</a></sup></p>
<h4 class="in-block"><span class="mw-headline" id="EpiPen4Schools_Launch">EpiPen4Schools Launch</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=19" title="Edit section: EpiPen4Schools Launch" data-section="19" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h4>
<p>In 2012, Mylan launched a program called <i>EpiPen4Schools</i> to sell EpiPens in bulk and with discounts to schools. To participate in the program schools had to agree not to buy epinephrine autoinjectors from any other company for a year, a requirement which a Mylan spokesperson said is no longer part of its program.<sup id="cite_ref-PBSschools_75-0" class="reference"><a href="#cite_note-PBSschools-75">[75]</a></sup></p><p>In December 2012, the <a href="/wiki/National_Association_of_State_Boards_of_Education" title="National Association of State Boards of Education">National Association of State Boards of Education</a> launched a policy initiative designed to "help state boards of education as they develop student health policies regarding anaphylaxis and epinephrine auto-injector access and use," and advocated for state laws protecting school from legal liability for stocking and using epinephrine autoinjectors.  Gayle Manchin, the mother of Mylan's CEO, Heather Bresch, had become president of the association in 2010, and shortly after had discussed donations from her "daughter's company" to the association.  Manchin had been appointed to the West Virginia state school board by her husband, then-governor of the state <a href="/wiki/Joe_Manchin" title="Joe Manchin">Joe Manchin</a>, in 2007. In a statement, Mylan said, "There is no truth to the suggestion that the company's efforts were anything but straightforward or that we are aware of anyone advocating inappropriately for the right of schoolchildren to have access to potential life-saving medicine." <sup id="cite_ref-USAtodayFamily_76-0" class="reference"><a href="#cite_note-USAtodayFamily-76">[76]</a></sup></p><p>After successful lobbying from Mylan,<sup id="cite_ref-BloomMarketing_65-1" class="reference"><a href="#cite_note-BloomMarketing-65">[65]</a></sup> in 2013, the "School Access to Emergency Epinephrine Act" became law after passing Congress with broad and bipartisan support; it protected anyone from liability if they administered epinephrine to a child in a school (previously, only trained professionals or the affected person were allowed to administer the drug, and were open to liability), and it provided some financial incentives for schools that didn’t already stock epinephrine autoinjector to start stocking them.<sup id="cite_ref-77" class="reference"><a href="#cite_note-77">[77]</a></sup> Joe Manchin, the father of Mylan's CEO, was a senator at that time.<sup id="cite_ref-USAtodayFamily_76-1" class="reference"><a href="#cite_note-USAtodayFamily-76">[76]</a></sup></p>
<h4 class="in-block"><span class="mw-headline" id="Agila_acquisition">Agila acquisition</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=20" title="Edit section: Agila acquisition" data-section="20" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h4>
<p>In 2013 Mylan acquired an Indian generic injectable drugs company, Agila Specialties Private, for $1.6 billion in cash.<sup id="cite_ref-78" class="reference"><a href="#cite_note-78">[78]</a></sup>  In 2015 three plants acquired in that deal were issued warning letters by the FDA.<sup id="cite_ref-79" class="reference"><a href="#cite_note-79">[79]</a></sup></p>
<h4 class="in-block"><span class="mw-headline" id="Abbott_acquisition">Abbott acquisition</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=21" title="Edit section: Abbott acquisition" data-section="21" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h4>
<p>In July 2014, Mylan and <a href="/wiki/Abbott_Laboratories" title="Abbott Laboratories">Abbott Laboratories</a> announced an agreement under which Mylan would buy Abbott's generic drugs business in developed markets for stock valued at about $5.3 billion.<sup id="cite_ref-80" class="reference"><a href="#cite_note-80">[80]</a></sup> Mylan acquired Mumbai-based Famy Care and expand its presence in the market for women's contraceptives at about $750 million.<sup id="cite_ref-81" class="reference"><a href="#cite_note-81">[81]</a></sup></p>
<h4 class="in-block"><span class="mw-headline" id="Attempted_Perrigo_acquisition">Attempted Perrigo acquisition</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=22" title="Edit section: Attempted Perrigo acquisition" data-section="22" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h4>
<p>In April 2015, Mylan tried negotiating with the management of <a href="/wiki/Ireland" title="Ireland">Irish</a> pharmaceutical firm <a href="/wiki/Perrigo" title="Perrigo">Perrigo</a> to acquire the company, and when those negotiations failed Mylan attempted a hostile takeover, offering to buy $26B in shares directly from shareholders. Too few shareholders agreed to sell their stock by the deadline set in November 2015 and the effort failed.<sup id="cite_ref-82" class="reference"><a href="#cite_note-82">[82]</a></sup></p>
<h4 class="in-block"><span class="mw-headline" id="Attempted_purchase_by_Teva">Attempted purchase by Teva</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=23" title="Edit section: Attempted purchase by Teva" data-section="23" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h4>
<p>Two weeks after Mylan made its first offer for Perrigo, <a href="/wiki/Teva_Pharmaceutical" class="mw-redirect" title="Teva Pharmaceutical">Teva Pharmaceutical</a> offered to buy Mylan for $40B; the combined companies would have been the world's largest generic company and the 9th biggest drug company in the world.<sup id="cite_ref-83" class="reference"><a href="#cite_note-83">[83]</a></sup>  In July, Teva dropped its bid for Mylan and instead acquired <a href="/wiki/Allergan" title="Allergan">Allergan</a>'s generic drug business for about the same price.<sup id="cite_ref-84" class="reference"><a href="#cite_note-84">[84]</a></sup><sup id="cite_ref-85" class="reference"><a href="#cite_note-85">[85]</a></sup></p>
<h4 class="in-block"><span class="mw-headline" id="New_COPD_drug">New COPD drug</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=24" title="Edit section: New COPD drug" data-section="24" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h4>
<p>In June 2015, Mylan agreed to work with Pulmatrix, a company with a proprietary inhaled drug delivery platform, to co-develop a product to treat for <a href="/wiki/Chronic_obstructive_pulmonary_disease" title="Chronic obstructive pulmonary disease">chronic obstructive pulmonary disease</a>; the product was PUR0200, a generic drug in a Pulmatrix device.<sup id="cite_ref-86" class="reference"><a href="#cite_note-86">[86]</a></sup></p>
<h4 class="in-block"><span class="mw-headline" id="Meda_acquisition">Meda acquisition</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=25" title="Edit section: Meda acquisition" data-section="25" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h4>
<p>In February 2016, the company announced it would acquire <a href="/wiki/Meda_AB" title="Meda AB">Meda</a> for $9.9 billion.<sup id="cite_ref-87" class="reference"><a href="#cite_note-87">[87]</a></sup> In May of the same year the company announced it would acquire Renaissance Acquisition Holdings dermatology division for up to $1 billion.<sup id="cite_ref-88" class="reference"><a href="#cite_note-88">[88]</a></sup></p><p>In December 2016, the <a href="/wiki/State_attorney_general" title="State attorney general">attorneys general</a> of 20 states filed a civil complaint accusing Mylan of a coordinated scheme to artificially maintain high prices for a generic antibiotic and diabetes drug. The complaint alleged <a href="/wiki/Price_fixing" title="Price fixing">price collusion schemes</a> between six pharmaceutical firms including informal gatherings, telephone calls, and text messages.<sup id="cite_ref-89" class="reference"><a href="#cite_note-89">[89]</a></sup></p><p>In October 2017, the company announced the launch of the first FDA-approved generic of Teva’s long-acting Copaxone. Approximately 3 months later, Credit Suisse analyst Vamil Divan cited IMS Health data which showed that the new generic accounted for 10% of the market.<sup id="cite_ref-90" class="reference"><a href="#cite_note-90">[90]</a></sup></p><p>In May 2018, Mylan announced a collaboration with West Virginia University to expose children across West Virginia to STEM educational initiatives.<sup id="cite_ref-91" class="reference"><a href="#cite_note-91">[91]</a></sup></p>
<h4 class="in-block"><span class="mw-headline" id="Generic_Advair_approval">Generic Advair approval</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=26" title="Edit section: Generic Advair approval" data-section="26" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h4>
<p>In January 2019, the <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">FDA</a> announced their approval of Mylan's Wixela Inhub, the first approved generic version of <a href="/wiki/GlaxoSmithKline" title="GlaxoSmithKline">GlaxoSmithKline</a>'s <a href="/wiki/Fluticasone_propionate/salmeterol" class="mw-redirect" title="Fluticasone propionate/salmeterol">Advair Diskus</a>.<sup id="cite_ref-92" class="reference"><a href="#cite_note-92">[92]</a></sup></p>
<h4 class="in-block"><span id="Merger_with_Pfizer.27s_off-patent_drug_business"></span><span class="mw-headline" id="Merger_with_Pfizer's_off-patent_drug_business">Merger with Pfizer's off-patent drug business</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=27" title="Edit section: Merger with Pfizer's off-patent drug business" data-section="27" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h4>
<p>In late July 2019, Mylan and Pfizer announced that Pfizer would spin off and merge its off-patent medicine division, Upjohn, with Mylan, forming a brand new pharmaceutical business with sales of around $20 billion.<sup id="cite_ref-93" class="reference"><a href="#cite_note-93">[93]</a></sup> The new company will be called Viatris, a name held by one of Mylan's subsidiaries.<sup id="cite_ref-94" class="reference"><a href="#cite_note-94">[94]</a></sup> This NewCo will continue sales of Mylan's more than 7,500 products, including biosimilars, generics, brand and over-the-counter remedies, with brands including the <a href="/wiki/Epi-Pen" class="mw-redirect" title="Epi-Pen">Epi-Pen</a>, <a href="/wiki/Viagra" class="mw-redirect" title="Viagra">Viagra</a>, <a href="/wiki/Lipitor" class="mw-redirect" title="Lipitor">Lipitor</a> and <a href="/wiki/Celebrex" class="mw-redirect" title="Celebrex">Celebrex</a>.<sup id="cite_ref-95" class="reference"><a href="#cite_note-95">[95]</a></sup><sup id="cite_ref-96" class="reference"><a href="#cite_note-96">[96]</a></sup><sup id="cite_ref-97" class="reference"><a href="#cite_note-97">[97]</a></sup></p><p>The deal will be structured as an all-stock, Reverse Morris Trust transaction:
</p>
<ul><li>Upjohn will be spun off to Pfizer shareholders and then combined with Mylan</li>
<li>Each share of Mylan’s stock will be converted into one share of the new company</li>
<li>Pfizer shareholders would own 57% of the combined new company and Mylan shareholders will own 43%</li></ul><p>In November 2019, Mylan &amp; Upjohn announced that the name of the new company in the planned transaction would be Viatris.<sup id="cite_ref-98" class="reference"><a href="#cite_note-98">[98]</a></sup></p>
<h4 class="in-block"><span class="mw-headline" id="Valsartan_recall">Valsartan recall</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=28" title="Edit section: Valsartan recall" data-section="28" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h4>
<p>In 2018, <a href="/wiki/Valsartan" title="Valsartan">valsartan</a> manufactured by Mylan was voluntarily recalled due to the detection of trace amounts of <a href="/wiki/N-Nitrosodiethylamine" title="N-Nitrosodiethylamine"><i>N</i>-nitrosodiethylamine</a> (NDEA) which is a probable human carcinogen.<sup id="cite_ref-ucm627647_99-0" class="reference"><a href="#cite_note-ucm627647-99">[99]</a></sup></p>
<h3 class="in-block"><span class="mw-headline" id="Acquisition_history">Acquisition history</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=29" title="Edit section: Acquisition history" data-section="29" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h3>
<p>The following is an illustration of the company's major mergers and acquisitions and historical predecessors:
</p>
<style data-mw-deduplicate="TemplateStyles:r935768785">.mw-parser-output table.clade{border-spacing:0;margin:0;font-size:100%;line-height:100%;border-collapse:separate;width:auto}.mw-parser-output table.clade table.clade{width:100%}.mw-parser-output table.clade td.clade-label{width:0.7em;padding:0 0.15em;vertical-align:bottom;text-align:center;border-left:1px solid;border-bottom:1px solid;white-space:nowrap}.mw-parser-output table.clade td.clade-fixed-width{overflow:hidden;text-overflow:ellipsis}.mw-parser-output table.clade td.clade-fixed-width:hover{overflow:visible}.mw-parser-output table.clade td.clade-label.first{border-left:none;border-right:none}.mw-parser-output table.clade td.clade-label.reverse{border-left:none;border-right:1px solid}.mw-parser-output table.clade td.clade-slabel{padding:0 0.15em;vertical-align:top;text-align:center;border-left:1px solid;white-space:nowrap}.mw-parser-output table.clade td.clade-slabel:hover{overflow:visible}.mw-parser-output table.clade td.clade-slabel.last{border-left:none;border-right:none}.mw-parser-output table.clade td.clade-slabel.reverse{border-left:none;border-right:1px solid}.mw-parser-output table.clade td.clade-bar{vertical-align:middle;text-align:left;padding:0 0.5em;position:relative}.mw-parser-output table.clade td.clade-bar.reverse{text-align:right;position:relative}.mw-parser-output table.clade td.clade-leaf{border:0;padding:0;text-align:left}.mw-parser-output table.clade td.clade-leafR{border:0;padding:0;text-align:right}.mw-parser-output table.clade td.clade-leaf.reverse{text-align:right}.mw-parser-output table.clade:hover span.linkA{background-color:yellow}.mw-parser-output table.clade:hover span.linkB{background-color:green}</style><table class="clade" style="font-size:90%;line-height:110%"><tbody><tr><td class="clade-label first" style="border-left:none;border-right:none;border-bottom:0px solid;"><div style="display:inline;" class="nowrap"><span style="font-size:100%;"></span></div>
</td>
<td rowspan="2" class="clade-leaf">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td class="clade-label first"><b>Mylan</b>
</td>
<td rowspan="2" class="clade-leaf">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td class="clade-label first"> 
</td>
<td rowspan="2" class="clade-leaf">
<p>Renaissance Acquisition Holdings<br><small>(Dermatology div, Acq 2016)</small>
</p>
</td></tr><tr><td class="clade-slabel"> 
</td></tr><tr><td class="clade-label"> 
</td>
<td rowspan="2" class="clade-leaf">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td class="clade-label first"> 
</td>
<td rowspan="2" class="clade-leaf">
<p><a href="/wiki/Meda_AB" title="Meda AB">Meda</a><br><small>(Acq 2016)</small>
</p>
</td></tr><tr><td class="clade-slabel"> 
</td></tr><tr><td class="clade-label"> 
</td>
<td rowspan="2" class="clade-leaf">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td class="clade-label first"> 
</td>
<td rowspan="2" class="clade-leaf">
<p>Famy Care<br><small>(Acq 2014)</small>
</p>
</td></tr><tr><td class="clade-slabel"> 
</td></tr><tr><td class="clade-label"> 
</td>
<td rowspan="2" class="clade-leaf">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td class="clade-label first"> 
</td>
<td rowspan="2" class="clade-leaf">
<p><a href="/wiki/Abbott_Laboratories" title="Abbott Laboratories">Abbott Laboratories</a><br><small>(Generics div, Acq 2014)</small>
</p>
</td></tr><tr><td class="clade-slabel"> 
</td></tr><tr><td class="clade-label"> 
</td>
<td rowspan="2" class="clade-leaf">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td class="clade-label first"> 
</td>
<td rowspan="2" class="clade-leaf">
<p>Agila Specialties<br><small>(Acq 2013)<sup id="cite_ref-100" class="reference"><a href="#cite_note-100">[100]</a></sup></small>
</p>
</td></tr><tr><td class="clade-slabel"> 
</td></tr><tr><td class="clade-label"> 
</td>
<td rowspan="2" class="clade-leaf">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td class="clade-label first"> 
</td>
<td rowspan="2" class="clade-leaf">
<p>Pfizer Respiratory Delivery Platform<br><small>(Acq 2011)<sup id="cite_ref-101" class="reference"><a href="#cite_note-101">[101]</a></sup></small>
</p>
</td></tr><tr><td class="clade-slabel"> 
</td></tr><tr><td class="clade-label"> 
</td>
<td rowspan="2" class="clade-leaf">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td class="clade-label first"> 
</td>
<td rowspan="2" class="clade-leaf">
<p>Bioniche Pharma Holdings<br><small>(Acq 2010)<sup id="cite_ref-102" class="reference"><a href="#cite_note-102">[102]</a></sup></small>
</p>
</td></tr><tr><td class="clade-slabel"> 
</td></tr><tr><td class="clade-label"> 
</td>
<td rowspan="2" class="clade-leaf">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td class="clade-label first"> 
</td>
<td rowspan="2" class="clade-leaf">
<p><a href="/wiki/Merck_KGaA" class="mw-redirect" title="Merck KGaA">Merck KGaA</a><br><small>(Generics div, Acq 2007, renamed Mylan Laboratories Inc)</small>
</p>
</td></tr><tr><td class="clade-slabel"> 
</td></tr><tr><td class="clade-label"> 
</td>
<td rowspan="2" class="clade-leaf">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td class="clade-label first"> 
</td>
<td rowspan="2" class="clade-leaf">
<p>Matrix Laboratories<br><small>(Acq 2007, renamed Mylan Laboratories)<sup id="cite_ref-103" class="reference"><a href="#cite_note-103">[103]</a></sup></small>
</p>
</td></tr><tr><td class="clade-slabel"> 
</td></tr><tr><td class="clade-label"> 
</td>
<td rowspan="2" class="clade-leaf">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td class="clade-label first"> 
</td>
<td rowspan="2" class="clade-leaf">
<p>Penederm Inc.<br><small>(Acq 1998)<sup id="cite_ref-104" class="reference"><a href="#cite_note-104">[104]</a></sup></small>
</p>
</td></tr><tr><td class="clade-slabel"> 
</td></tr><tr><td class="clade-label"> 
</td>
<td rowspan="2" class="clade-leaf">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td class="clade-label first"> 
</td>
<td rowspan="2" class="clade-leaf">
<p>UDL Laboratories<br><small>(Acq 1996)</small>
</p>
</td></tr><tr><td class="clade-slabel"> 
</td></tr><tr><td class="clade-label"> 
</td>
<td rowspan="2" class="clade-leaf">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td class="clade-label first"> 
</td>
<td rowspan="2" class="clade-leaf">
<p>Bertek Inc<br><small>(Acq 1993, renamed Mylan Technologies Inc)</small>
</p>
</td></tr><tr><td class="clade-slabel"> 
</td></tr><tr><td class="clade-label"> 
</td>
<td rowspan="2" class="clade-leaf">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td class="clade-label first"> 
</td>
<td rowspan="2" class="clade-leaf">
<p>Dow B. Hickam<br><small>(Acq 1991)<sup id="cite_ref-105" class="reference"><a href="#cite_note-105">[105]</a></sup></small>
</p>
</td></tr><tr><td class="clade-slabel"> 
</td></tr><tr><td class="clade-label"> 
</td>
<td rowspan="2" class="clade-leaf">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td class="clade-label first"> 
</td>
<td rowspan="2" class="clade-leaf">
<p>Somerset Pharmaceuticals<br><small>(Acq 1989)<sup id="cite_ref-106" class="reference"><a href="#cite_note-106">[106]</a></sup></small>
</p>
</td></tr><tr><td class="clade-slabel"> 
</td></tr><tr><td class="clade-label"> 
</td>
<td rowspan="2" class="clade-leaf">
<link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935768785"><table class="clade"><tbody><tr><td class="clade-label first"> 
</td>
<td rowspan="2" class="clade-leaf">
<p>Milan Pharmaceuticals<br><small>(Founded 1961)</small>
</p>
</td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td></tr><tr><td class="clade-slabel last"> 
</td></tr></tbody></table></td></tr><tr><td class="clade-slabel last" style="border-right:none;border-left:none;"> 
</td></tr></tbody></table></section><h2 class="section-heading" onclick="javascript:mfTempOpenSection(5)"><div class="mw-ui-icon mw-ui-icon-element indicator mw-ui-icon-small mw-ui-icon-flush-left"></div><span class="mw-headline" id="Criticism">Criticism</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=30" title="Edit section: Criticism" data-section="30" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h2><section class="mf-section-5 collapsible-block" id="mf-section-5">
<h3 class="in-block"><span class="mw-headline" id="EpiPen_pricing">EpiPen pricing</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=31" title="Edit section: EpiPen pricing" data-section="31" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h3>
<div role="note" class="hatnote navigation-not-searchable">See also: <a href="/wiki/Epinephrine_autoinjector#Price" title="Epinephrine autoinjector">Epinephrine autoinjector § Price</a></div>
<div role="note" class="hatnote navigation-not-searchable">See also: <a href="/wiki/Heather_Bresch#Mylan_executive" title="Heather Bresch">Heather Bresch § Mylan executive</a></div>
<p>Mylan acquired the right to market and distribute the EpiPen line of <a href="/wiki/Epinephrine_autoinjector" title="Epinephrine autoinjector">epinephrine autoinjector</a> devices from Merck KGaA as part of their 2007 deal;<sup id="cite_ref-NYT2016_107-0" class="reference"><a href="#cite_note-NYT2016-107">[107]</a></sup> that right had formerly been held by Dey LP, a wholly owned subsidiary of Merck.<sup id="cite_ref-108" class="reference"><a href="#cite_note-108">[108]</a></sup> According to Bloomberg the devices deliver about $1 worth of drug.<sup id="cite_ref-BloomMarketing_65-2" class="reference"><a href="#cite_note-BloomMarketing-65">[65]</a></sup> At that time annual sales were around $200M.<sup id="cite_ref-BloomMarketing_65-3" class="reference"><a href="#cite_note-BloomMarketing-65">[65]</a></sup>  Bresch, the company's CEO, saw an opportunity to increase sales through marketing and advocacy, and the company launched a marketing campaign to increase awareness of the dangers of <a href="/wiki/Anaphylaxis" title="Anaphylaxis">anaphylaxis</a> for people with severe allergies that made the brand "EpiPen" as identified with its product as "Kleenex" is with facial tissue. The company also successfully lobbied the FDA to broaden the label to include risk of anaphylaxis and in parallel, successfully lobbied Congress to generate legislation making EpiPens available in schools and in public places like <a href="/wiki/Automated_external_defibrillator" title="Automated external defibrillator">defibrillators</a> are, and hired the same people that <a href="/wiki/Medtronic" title="Medtronic">Medtronic</a> had worked with on defibrillator legislation to do so.<sup id="cite_ref-BloomMarketing_65-4" class="reference"><a href="#cite_note-BloomMarketing-65">[65]</a></sup>  Mylan's efforts to gain market dominance were aided when <a href="/wiki/Sanofi" title="Sanofi">Sanofi</a>'s competing product was recalled in November 2015 and further when Teva's generic competitor was rejected by the FDA in March 2016.<sup id="cite_ref-109" class="reference"><a href="#cite_note-109">[109]</a></sup></p><p>By the first half of 2015, Mylan had an 85% market share of such devices in the US<sup id="cite_ref-BloomMarketing_65-5" class="reference"><a href="#cite_note-BloomMarketing-65">[65]</a></sup> and in that year sales reached around $1.5B and accounted for 40% of Mylan's profit.<sup id="cite_ref-ForbesCould_110-0" class="reference"><a href="#cite_note-ForbesCould-110">[110]</a></sup>  Those profits were also due in part to Mylan's continually raising the price of EpiPens starting in 2009; in 2009 the wholesale price of two EpiPens was about $100, by July 2013 the price was about $265, in May 2015 it was around $461, and in May 2016 the price rose again to around $609,<sup id="cite_ref-NYT2016_107-1" class="reference"><a href="#cite_note-NYT2016-107">[107]</a></sup> around a 500% jump from the price in 2009.<sup id="cite_ref-Baltimore_111-0" class="reference"><a href="#cite_note-Baltimore-111">[111]</a></sup></p><p>Starting in 2014, according to a 2017 report in the <i>New York Times</i>, mid-level executives began questioning the rate at which the company had increased and was planning to continue to increase the price of the Epi-Pen, and raising concerns that the price increases were unethical; the <i>Times</i> reported that when these concerns were brought to Robert Coury, the chairman of the board, Coury "replied that he was untroubled. He raised both his middle fingers and explained, using colorful language, that anyone criticizing Mylan, including its employees, ought to go copulate with themselves. Critics in Congress and on Wall Street, he said, should do the same. And regulators at the Food and Drug Administration? They, too, deserved a round of anatomically challenging self-fulfillment."  The <i>Times</i> reported that Bresch provided similarly dismissive responses.<sup id="cite_ref-NYT2017copulate_112-0" class="reference"><a href="#cite_note-NYT2017copulate-112">[112]</a></sup>  The <i>Times</i> reporter noted that "Those top leaders’ responses are a far cry from the message on Mylan’s website, which says that 'we challenge every member of every team to challenge the status quo,' and that 'we put people and patients first, trusting that profits will follow.'", and also noted that "The firm is a case study in the limits of what consumer and employee activism, as well as government oversight, can achieve." <sup id="cite_ref-NYT2017copulate_112-1" class="reference"><a href="#cite_note-NYT2017copulate-112">[112]</a></sup><sup id="cite_ref-113" class="reference"><a href="#cite_note-113">[113]</a></sup><sup id="cite_ref-114" class="reference"><a href="#cite_note-114">[114]</a></sup><sup id="cite_ref-115" class="reference"><a href="#cite_note-115">[115]</a></sup></p><p>In the summer of 2016, as parents prepared to send their children back to school and went to pharmacies to get new EpiPens, people began to express outrage at the cost of the EpiPen and Mylan was widely and harshly criticized,<sup id="cite_ref-Gold2016_116-0" class="reference"><a href="#cite_note-Gold2016-116">[116]</a></sup><sup id="cite_ref-117" class="reference"><a href="#cite_note-117">[117]</a></sup> including criticism from <a href="/wiki/Martin_Shkreli" title="Martin Shkreli">Martin Shkreli</a>, "poster boy for grasping pharma greed," letters from two Senators and initiation of Congressional investigations.<sup id="cite_ref-ForbesCould_110-1" class="reference"><a href="#cite_note-ForbesCould-110">[110]</a></sup><sup id="cite_ref-118" class="reference"><a href="#cite_note-118">[118]</a></sup> Mylan's pricing of the EpiPen was widely referred to as <a href="/wiki/Price_gouging" title="Price gouging">price gouging</a>.<sup id="cite_ref-119" class="reference"><a href="#cite_note-119">[119]</a></sup><sup id="cite_ref-120" class="reference"><a href="#cite_note-120">[120]</a></sup><sup id="cite_ref-121" class="reference"><a href="#cite_note-121">[121]</a></sup> The last price increase coincided with Mylan's airing of a new line of TV commercials that were described as "shocking" and "no holds barred", depicting an anaphylactic reaction from the point of view of the young woman having it at a party, and ending with the young woman seeing her swollen and hive-covered face in the mirror before she collapses.<sup id="cite_ref-122" class="reference"><a href="#cite_note-122">[122]</a></sup>  In response to criticism, Mylan increased financial assistance available for some patients to purchase EpiPens,<sup id="cite_ref-123" class="reference"><a href="#cite_note-123">[123]</a></sup> a gesture that was called a "classic public relations move" by Harvard Medical School professor Aaron Kesselheim.<sup id="cite_ref-Post_124-0" class="reference"><a href="#cite_note-Post-124">[124]</a></sup> The up to $300 saving cards can only be used by a small number of people who need the drug, and no one on <a href="/wiki/Medicaid" title="Medicaid">Medicaid</a>. They do nothing about the high price which is still being paid by insurers, who ultimately pass the cost onto consumers.<sup id="cite_ref-Post_124-1" class="reference"><a href="#cite_note-Post-124">[124]</a></sup> Mylan further responded by releasing the first authorized generic version of the EpiPen in December 2016 at a more than 50% discount.<sup id="cite_ref-Business_Insider:The_$300_generic_EpiPen_is_here_125-0" class="reference"><a href="#cite_note-Business_Insider:The_%24300_generic_EpiPen_is_here-125">[125]</a></sup></p><p>In September 2016, the New York State Attorney General began an investigation into Mylan's <i>EpiPen4Schools</i> program in New York to determine if the program's contracts violated <a href="/wiki/Competition_law" title="Competition law">antitrust law</a><sup id="cite_ref-bloom9616_126-0" class="reference"><a href="#cite_note-bloom9616-126">[126]</a></sup> and the West Virginia State Attorney General opened an investigation into whether Mylan had given the state the correct discount under the <a href="/wiki/Medicaid_Drug_Rebate_Program" title="Medicaid Drug Rebate Program">Medicaid Drug Rebate Program</a> and subpoenaed the company when it refused to provide the documentation the state requested.<sup id="cite_ref-127" class="reference"><a href="#cite_note-127">[127]</a></sup></p><p>In October 2016 the CEO of Mylan testified to Congress that Pfizer/King charged Mylan about $34.50 for one device.<sup id="cite_ref-NBCdevice2016_128-0" class="reference"><a href="#cite_note-NBCdevice2016-128">[128]</a></sup> In September 2016, a Silicon Valley engineering consultancy performed a teardown analysis of the EpiPen and estimated the manufacturing and packaging costs at about $10 for a two-pack.<sup id="cite_ref-129" class="reference"><a href="#cite_note-129">[129]</a></sup></p><p>According to the Department of Health and Human Services' Office of Inspector General analysis, the U.S. government may have overpaid "as much as $1.27 billion between 2006 and 2016" to drugmaker Mylan N.V. for the EpiPen emergency allergy treatment. This represents three times the proposed settlement of $465 million announced by Mylan in October 2016. In October 2016, Mylan announced a settlement with the <a href="/wiki/US_Department_of_Justice" class="mw-redirect" title="US Department of Justice">US Department of Justice</a> over rebates paid by Mylan to states under the Medicaid Drug Rebate Program.<sup id="cite_ref-NYToctRebate_130-0" class="reference"><a href="#cite_note-NYToctRebate-130">[130]</a></sup>  Questions had been raised by Congress and others about why EpiPen had been classified as a generic rather a proprietary product in the program since 1997; generic drugs have lower rebates (13%) than proprietary drugs (23%), and price hikes for generic drugs cannot be passed onto states, and a common form of <a href="/wiki/Pharmaceutical_fraud" title="Pharmaceutical fraud">pharmaceutical fraud</a> involves misclassifying proprietary drugs as generic under the program.<sup id="cite_ref-131" class="reference"><a href="#cite_note-131">[131]</a></sup>  Under the agreement Mylan agreed to pay a $465 million payment and to a sign a corporate integrity agreement requiring it to perform better in the future;<sup id="cite_ref-NYToctRebate_130-1" class="reference"><a href="#cite_note-NYToctRebate-130">[130]</a></sup> the settlement also resolved cases brought by states related to the rebates.<sup id="cite_ref-132" class="reference"><a href="#cite_note-132">[132]</a></sup> Simultaneously with the settlement Mylan also announced it was being investigated by the <a href="/wiki/Securities_and_Exchange_Commission" class="mw-redirect" title="Securities and Exchange Commission">Securities and Exchange Commission</a> related to the drug rebate program.<sup id="cite_ref-133" class="reference"><a href="#cite_note-133">[133]</a></sup> Republican Senator Chuck Grassley, chair of the Senate Judiciary Committee that launched the "probe of EpiPen pricing probe in 2016, released the analysis on May 30, 2017.<sup id="cite_ref-Mylan_epipen_analysis_2017_134-0" class="reference"><a href="#cite_note-Mylan_epipen_analysis_2017-134">[134]</a></sup> On the same day, a group of Mylan "investment funds urged shareholders to vote against the re-election of the company's directors after it paid Chairman Robert Coury over $97 million last year."<sup id="cite_ref-Mylan_epipen_analysis_2017_134-1" class="reference"><a href="#cite_note-Mylan_epipen_analysis_2017-134">[134]</a></sup></p>
<h3 class="in-block"><span class="mw-headline" id="Execution_drugs">Execution drugs</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=32" title="Edit section: Execution drugs" data-section="32" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h3>
<p>Mylan manufactures <a href="/wiki/Rocuronium_bromide" title="Rocuronium bromide">rocuronium bromide</a>, which is approved by the state of <a href="/wiki/Alabama" title="Alabama">Alabama</a> for use in executions by <a href="/wiki/Lethal_injection" title="Lethal injection">lethal injection</a>. European manufacturers refuse to sell drugs which can be used for executions to the United States, except to distributors or users who sign legally binding agreements that the drug will not be used for executions down the delivery chain.<sup id="cite_ref-execution_135-0" class="reference"><a href="#cite_note-execution-135">[135]</a></sup></p><p>In September 2014, the <a href="/wiki/London" title="London">London</a>-based <a href="/wiki/Human_rights" title="Human rights">human rights</a> organization <a href="/wiki/Reprieve_(organisation)" title="Reprieve (organisation)">Reprieve</a> told Mylan that they were the only <a href="/wiki/FDA" class="mw-redirect" title="FDA">FDA</a>-approved manufacturer of <a href="/wiki/Rocuronium_bromide" title="Rocuronium bromide">rocuronium bromide</a> without legal controls in place to prevent its use in executions, and there was "a very real risk that Mylan may soon become the go-to provider of execution drugs for states across the country". The German asset manager <a href="/w/index.php?title=DJE_Kapital&amp;action=edit&amp;redlink=1" class="new" title="DJE Kapital (page does not exist)">DJE Kapital</a><span class="noprint" style="font-size:85%; font-style: normal;"> [<a href="https://de.wikipedia.org/wiki/DJE_Kapital" class="extiw" title="de:DJE Kapital">de</a>]</span> <a href="/wiki/Divested" class="mw-redirect" title="Divested">divested</a> itself of $70 million in Mylan shares for that reason. Mylan said that their distribution was "legally compliant," <sup id="cite_ref-execution_135-1" class="reference"><a href="#cite_note-execution-135">[135]</a></sup> and that their restrictions did "prohibit resale to correctional facilities for use in lethal injections." <sup id="cite_ref-Newsroom:_Mylan_Statement_on_its_Policy_Against_the_Use_of_Mylan_Products_in_Capital_Punishment_136-0" class="reference"><a href="#cite_note-Newsroom:_Mylan_Statement_on_its_Policy_Against_the_Use_of_Mylan_Products_in_Capital_Punishment-136">[136]</a></sup></p>
</section><h2 class="section-heading" onclick="javascript:mfTempOpenSection(6)"><div class="mw-ui-icon mw-ui-icon-element indicator mw-ui-icon-small mw-ui-icon-flush-left"></div><span class="mw-headline" id="Products">Products</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=33" title="Edit section: Products" data-section="33" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h2><section class="mf-section-6 collapsible-block" id="mf-section-6">
<h3 class="in-block"><span class="mw-headline" id="Generic_Medicines">Generic Medicines</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=34" title="Edit section: Generic Medicines" data-section="34" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h3>
<table class="wikitable"><tbody><tr><th>Name</th>
<th>Indication</th>
<th>Year Introduced
</th></tr><tr><td>Penicillin G tablets</td>
<td>Antibiotic</td>
<td>1966<sup id="cite_ref-137" class="reference"><a href="#cite_note-137">[137]</a></sup></td></tr><tr><td>Tetracycline</td>
<td>Antibiotic</td>
<td>1968<sup id="cite_ref-138" class="reference"><a href="#cite_note-138">[138]</a></sup></td></tr><tr><td>Cimetidine</td>
<td>Ulcer</td>
<td>1994<sup id="cite_ref-139" class="reference"><a href="#cite_note-139">[139]</a></sup></td></tr><tr><td>Cipro (Ciprofloxacin)</td>
<td>Antibiotic</td>
<td>2004<sup id="cite_ref-140" class="reference"><a href="#cite_note-140">[140]</a></sup></td></tr></tbody></table><h3 class="in-block"><span class="mw-headline" id="Branded_Medicines">Branded Medicines</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=35" title="Edit section: Branded Medicines" data-section="35" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h3>
<table class="wikitable"><tbody><tr><th>Name</th>
<th>Indication</th>
<th>Year Introduced
</th></tr><tr><td>Maxzide</td>
<td>Blood pressure</td>
<td>1984<sup id="cite_ref-141" class="reference"><a href="#cite_note-141">[141]</a></sup></td></tr><tr><td>Eldepryl</td>
<td>Parkinson's</td>
<td>1989<sup id="cite_ref-142" class="reference"><a href="#cite_note-142">[142]</a></sup></td></tr><tr><td>EpiPen</td>
<td>Allergy</td>
<td>2007<sup id="cite_ref-143" class="reference"><a href="#cite_note-143">[143]</a></sup></td></tr></tbody></table></section><h2 class="section-heading" onclick="javascript:mfTempOpenSection(7)"><div class="mw-ui-icon mw-ui-icon-element indicator mw-ui-icon-small mw-ui-icon-flush-left"></div><span class="mw-headline" id="Management">Management</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=36" title="Edit section: Management" data-section="36" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h2><section class="mf-section-7 collapsible-block" id="mf-section-7">
<p>Heather Bresch is Executive Director and has served as the CEO of Mylan since 2012.<sup id="cite_ref-144" class="reference"><a href="#cite_note-144">[144]</a></sup> Robert Coury serves as Chairman,<sup id="cite_ref-145" class="reference"><a href="#cite_note-145">[145]</a></sup> and Rajiv Malik is President.<sup id="cite_ref-146" class="reference"><a href="#cite_note-146">[146]</a></sup></p>
</section><h2 class="section-heading" onclick="javascript:mfTempOpenSection(8)"><div class="mw-ui-icon mw-ui-icon-element indicator mw-ui-icon-small mw-ui-icon-flush-left"></div><span class="mw-headline" id="References">References</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=37" title="Edit section: References" data-section="37" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h2><section class="mf-section-8 collapsible-block" id="mf-section-8">
<div class="reflist columns references-column-width" style="-moz-column-width: 35em; -webkit-column-width: 35em; column-width: 35em; list-style-type: decimal;">
<ol class="references"><li id="cite_note-10-K-1"><span class="mw-cite-backlink">^ <a href="#cite_ref-10-K_1-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-10-K_1-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-10-K_1-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-10-K_1-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-10-K_1-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-10-K_1-5"><sup><i><b>f</b></i></sup></a></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://last10k.com/sec-filings/myl#link_fullReport">"Mylan N.V. 2018 Annual Report (Form 10-K)"</a>. <i>last10k.com</i>. <a href="/wiki/U.S._Securities_and_Exchange_Commission" title="U.S. Securities and Exchange Commission">U.S. Securities and Exchange Commission</a>. February 2019.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=last10k.com&amp;rft.atitle=Mylan+N.V.+2018+Annual+Report+%28Form+10-K%29&amp;rft.date=2019-02&amp;rft_id=https%3A%2F%2Flast10k.com%2Fsec-filings%2Fmyl%23link_fullReport&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><style data-mw-deduplicate="TemplateStyles:r935243608">.mw-parser-output cite.citation{font-style:inherit}.mw-parser-output .citation q{quotes:"\"""\"""'""'"}.mw-parser-output .id-lock-free a,.mw-parser-output .citation .cs1-lock-free a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/6/65/Lock-green.svg/9px-Lock-green.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .id-lock-limited a,.mw-parser-output .id-lock-registration a,.mw-parser-output .citation .cs1-lock-limited a,.mw-parser-output .citation .cs1-lock-registration a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/d/d6/Lock-gray-alt-2.svg/9px-Lock-gray-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .id-lock-subscription a,.mw-parser-output .citation .cs1-lock-subscription a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/a/aa/Lock-red-alt-2.svg/9px-Lock-red-alt-2.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration{color:#555}.mw-parser-output .cs1-subscription span,.mw-parser-output .cs1-registration span{border-bottom:1px dotted;cursor:help}.mw-parser-output .cs1-ws-icon a{background:url("//upload.wikimedia.org/wikipedia/commons/thumb/4/4c/Wikisource-logo.svg/12px-Wikisource-logo.svg.png")no-repeat;background-position:right .1em center}.mw-parser-output code.cs1-code{color:inherit;background:inherit;border:inherit;padding:inherit}.mw-parser-output .cs1-hidden-error{display:none;font-size:100%}.mw-parser-output .cs1-visible-error{font-size:100%}.mw-parser-output .cs1-maint{display:none;color:#33aa33;margin-left:0.3em}.mw-parser-output .cs1-subscription,.mw-parser-output .cs1-registration,.mw-parser-output .cs1-format{font-size:95%}.mw-parser-output .cs1-kern-left,.mw-parser-output .cs1-kern-wl-left{padding-left:0.2em}.mw-parser-output .cs1-kern-right,.mw-parser-output .cs1-kern-wl-right{padding-right:0.2em}</style></span>
</li>
<li id="cite_note-201510K-2"><span class="mw-cite-backlink"><b><a href="#cite_ref-201510K_2-0">^</a></b></span> <span class="reference-text">Mylan NV <a rel="nofollow" class="external text" href="https://www.sec.gov/Archives/edgar/data/1623613/000162361316000046/myl10k_20151231xdoc.htm">10-K for the Fiscal Year Ended December 31, 2015</a></span>
</li>
<li id="cite_note-Pittsburgh_Biz_Times-3"><span class="mw-cite-backlink"><b><a href="#cite_ref-Pittsburgh_Biz_Times_3-0">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="http://pittsburgh.bizjournals.com/pittsburgh/stories/2006/12/18/daily19.html">"Mylan buys part of drug maker"</a>. <a href="/wiki/Pittsburgh_Business_Times" title="Pittsburgh Business Times">Pittsburgh Business Times</a>. December 30, 2013.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Mylan+buys+part+of+drug+maker&amp;rft.date=2013-12-30&amp;rft_id=http%3A%2F%2Fpittsburgh.bizjournals.com%2Fpittsburgh%2Fstories%2F2006%2F12%2F18%2Fdaily19.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-Medical_News_Today-4"><span class="mw-cite-backlink"><b><a href="#cite_ref-Medical_News_Today_4-0">^</a></b></span> <span class="reference-text">
<cite class="citation news"><a rel="nofollow" class="external text" href="http://www.medicalnewstoday.com/articles/72133.php">"Mylan Laboratories To Acquire Generics Business Of Merck KGaA For 4.9 Billion Euros"</a>. <a href="/wiki/Medical_News_Today" title="Medical News Today">Medical News Today</a>. May 26, 2007.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Mylan+Laboratories+To+Acquire+Generics+Business+Of+Merck+KGaA+For+4.9+Billion+Euros&amp;rft.date=2007-05-26&amp;rft_id=http%3A%2F%2Fwww.medicalnewstoday.com%2Farticles%2F72133.php&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-Pittsburgh_Trib-5"><span class="mw-cite-backlink"><b><a href="#cite_ref-Pittsburgh_Trib_5-0">^</a></b></span> <span class="reference-text">
<cite class="citation news"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20080908010555/http://www.pittsburghlive.com/x/pittsburghtrib/business/s_582510.html">"Pharmaceutical giants tracking Mylan's prosperity"</a>. <a href="/wiki/The_Pittsburgh_Tribune-Review" class="mw-redirect" title="The Pittsburgh Tribune-Review">The Pittsburgh Tribune-Review</a>. August 13, 2008. Archived from <a rel="nofollow" class="external text" href="http://www.pittsburghlive.com/x/pittsburghtrib/business/s_582510.html">the original</a> on September 8, 2008.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Pharmaceutical+giants+tracking+Mylan%27s+prosperity&amp;rft.date=2008-08-13&amp;rft_id=http%3A%2F%2Fwww.pittsburghlive.com%2Fx%2Fpittsburghtrib%2Fbusiness%2Fs_582510.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-6"><span class="mw-cite-backlink"><b><a href="#cite_ref-6">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.fundinguniverse.com/company-histories/mylan-laboratories-inc-history/">"History of Mylan Laboratories Inc. – FundingUniverse"</a>. <i>www.fundinguniverse.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">June 11,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.fundinguniverse.com&amp;rft.atitle=History+of+Mylan+Laboratories+Inc.+%E2%80%93+FundingUniverse&amp;rft_id=http%3A%2F%2Fwww.fundinguniverse.com%2Fcompany-histories%2Fmylan-laboratories-inc-history%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-7"><span class="mw-cite-backlink"><b><a href="#cite_ref-7">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.marketwatch.com/investing/stock/myl">"Mylan N.V."</a> <i>MarketWatch</i><span class="reference-accessdate">. Retrieved <span class="nowrap">June 11,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=MarketWatch&amp;rft.atitle=Mylan+N.V.&amp;rft_id=http%3A%2F%2Fwww.marketwatch.com%2Finvesting%2Fstock%2Fmyl&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-8"><span class="mw-cite-backlink"><b><a href="#cite_ref-8">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.nasdaq.com/symbol/ibb">"iShares Nasdaq Biotechnology Index Fund (IBB)"</a>. <i>NASDAQ.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">June 11,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=NASDAQ.com&amp;rft.atitle=iShares+Nasdaq+Biotechnology+Index+Fund+%28IBB%29&amp;rft_id=http%3A%2F%2Fwww.nasdaq.com%2Fsymbol%2Fibb&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-9"><span class="mw-cite-backlink"><b><a href="#cite_ref-9">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://marketrealist.com/2017/10/mylan-inc-sp-500s-top-gainer-october-4/">"Market Realist"</a>. <i>marketrealist.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">June 11,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=marketrealist.com&amp;rft.atitle=Market+Realist&amp;rft_id=http%3A%2F%2Fmarketrealist.com%2F2017%2F10%2Fmylan-inc-sp-500s-top-gainer-october-4%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-10"><span class="mw-cite-backlink"><b><a href="#cite_ref-10">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.mylan.com/en/products/therapeutic-innovation">"Therapeutic Innovation"</a>. <i>www.mylan.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">August 8,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.mylan.com&amp;rft.atitle=Therapeutic+Innovation&amp;rft_id=http%3A%2F%2Fwww.mylan.com%2Fen%2Fproducts%2Ftherapeutic-innovation&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-CNN_CEO_revolt-11"><span class="mw-cite-backlink"><b><a href="#cite_ref-CNN_CEO_revolt_11-0">^</a></b></span> <span class="reference-text"><cite class="citation news">Egan, Matt. <a rel="nofollow" class="external text" href="http://money.cnn.com/2017/06/13/investing/epipen-mylan-exec-pay-shareholder-revolt/index.html?sr=twCNN061417epipen-mylan-exec-pay-shareholder-revolt0246AMStoryLink&amp;linkId=38675750">"EpiPen maker faces revolt over exec's $98 million pay package"</a>. <i>CNN Money</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=CNN+Money&amp;rft.atitle=EpiPen+maker+faces+revolt+over+exec%27s+%2498+million+pay+package&amp;rft.aulast=Egan&amp;rft.aufirst=Matt&amp;rft_id=http%3A%2F%2Fmoney.cnn.com%2F2017%2F06%2F13%2Finvesting%2Fepipen-mylan-exec-pay-shareholder-revolt%2Findex.html%3Fsr%3DtwCNN061417epipen-mylan-exec-pay-shareholder-revolt0246AMStoryLink%26linkId%3D38675750&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-12"><span class="mw-cite-backlink"><b><a href="#cite_ref-12">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.theet.com/news/free/mylan-s-morgantown-facility-is-mammoth-state-of-the-art/article_8604ad38-aabc-5144-b372-4788a94d1ce5.html">"Mylan's Morgantown Facility is Mammoth State of the Art"</a><span class="reference-accessdate">. Retrieved <span class="nowrap">June 11,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Mylan%27s+Morgantown+Facility+is+Mammoth+State+of+the+Art&amp;rft_id=https%3A%2F%2Fwww.theet.com%2Fnews%2Ffree%2Fmylan-s-morgantown-facility-is-mammoth-state-of-the-art%2Farticle_8604ad38-aabc-5144-b372-4788a94d1ce5.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-13"><span class="mw-cite-backlink"><b><a href="#cite_ref-13">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=6470453">"Mylan Pharmaceuticals ULC: Private Company Information - Bloomberg"</a>. <i>www.bloomberg.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">June 11,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.bloomberg.com&amp;rft.atitle=Mylan+Pharmaceuticals+ULC%3A+Private+Company+Information+-+Bloomberg&amp;rft_id=https%3A%2F%2Fwww.bloomberg.com%2Fresearch%2Fstocks%2Fprivate%2Fsnapshot.asp%3FprivcapId%3D6470453&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-14"><span class="mw-cite-backlink"><b><a href="#cite_ref-14">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="https://www.biospace.com/article/releases/mylan-technologies-inc-expands-adds-160-new-jobs-/">"Mylan Technologies Inc. Expands, Adds 160 New Jobs | BioSpace"</a>. <i>BioSpace</i><span class="reference-accessdate">. Retrieved <span class="nowrap">June 11,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=BioSpace&amp;rft.atitle=Mylan+Technologies+Inc.+Expands%2C+Adds+160+New+Jobs+%7C+BioSpace&amp;rft_id=https%3A%2F%2Fwww.biospace.com%2Farticle%2Freleases%2Fmylan-technologies-inc-expands-adds-160-new-jobs-%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-15"><span class="mw-cite-backlink"><b><a href="#cite_ref-15">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=34541">"Somerset Pharmaceuticals, Inc.: Private Company Information - Bloomberg"</a>. <i>www.bloomberg.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">June 11,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.bloomberg.com&amp;rft.atitle=Somerset+Pharmaceuticals%2C+Inc.%3A+Private+Company+Information+-+Bloomberg&amp;rft_id=https%3A%2F%2Fwww.bloomberg.com%2Fresearch%2Fstocks%2Fprivate%2Fsnapshot.asp%3FprivcapId%3D34541&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-16"><span class="mw-cite-backlink"><b><a href="#cite_ref-16">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.dey.com/">"Brand Name Medicines - Mylan"</a>. <i>dey.com</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=dey.com&amp;rft.atitle=Brand+Name+Medicines+-+Mylan&amp;rft_id=http%3A%2F%2Fwww.dey.com%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-17"><span class="mw-cite-backlink"><b><a href="#cite_ref-17">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.mylan.com/global_reach/other_areas.aspx">"About Us"</a>. <i>mylan.com</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=mylan.com&amp;rft.atitle=About+Us&amp;rft_id=http%3A%2F%2Fwww.mylan.com%2Fglobal_reach%2Fother_areas.aspx&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-18"><span class="mw-cite-backlink"><b><a href="#cite_ref-18">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.bizjournals.com/pittsburgh/news/2012/02/15/dey-pharma-to-change-to-mylan-specialty.html">"Dey Pharma to Change to Mylan"</a>. <i>www.bizjournals.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">June 11,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.bizjournals.com&amp;rft.atitle=Dey+Pharma+to+Change+to+Mylan&amp;rft_id=https%3A%2F%2Fwww.bizjournals.com%2Fpittsburgh%2Fnews%2F2012%2F02%2F15%2Fdey-pharma-to-change-to-mylan-specialty.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-19"><span class="mw-cite-backlink"><b><a href="#cite_ref-19">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.mylan.com.br/pt-br/contactar-a-mylan">"Contatar | Mylan"</a>. <i>www.mylan.com.br</i><span class="reference-accessdate">. Retrieved <span class="nowrap">June 11,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.mylan.com.br&amp;rft.atitle=Contatar+%7C+Mylan&amp;rft_id=http%3A%2F%2Fwww.mylan.com.br%2Fpt-br%2Fcontactar-a-mylan&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-20"><span class="mw-cite-backlink"><b><a href="#cite_ref-20">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.mylan.in/-/media/mylanin/documents/english/india-mylan-fact-sheet-march-2016.pdf?la=en">"Better health for a better world"</a> <span class="cs1-format">(PDF)</span>. March 2016<span class="reference-accessdate">. Retrieved <span class="nowrap">June 11,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Better+health+for+a+better+world&amp;rft.date=2016-03&amp;rft_id=http%3A%2F%2Fwww.mylan.in%2F-%2Fmedia%2Fmylanin%2Fdocuments%2Fenglish%2Findia-mylan-fact-sheet-march-2016.pdf%3Fla%3Den&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-21"><span class="mw-cite-backlink"><b><a href="#cite_ref-21">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.jpma.or.jp/english/about_us/member_lib/m050007.html?height=170&amp;width=420">"Japan Pharmaceutical Manufacturers Association (JPMA)"</a>. <i>www.jpma.or.jp</i><span class="reference-accessdate">. Retrieved <span class="nowrap">June 11,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.jpma.or.jp&amp;rft.atitle=Japan+Pharmaceutical+Manufacturers+Association+%28JPMA%29&amp;rft_id=http%3A%2F%2Fwww.jpma.or.jp%2Fenglish%2Fabout_us%2Fmember_lib%2Fm050007.html%3Fheight%3D170%26width%3D420&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-22"><span class="mw-cite-backlink"><b><a href="#cite_ref-22">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.mylan.com.au/en-au/contact-mylan">"Contact | Mylan"</a>. <i>www.mylan.com.au</i><span class="reference-accessdate">. Retrieved <span class="nowrap">June 11,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.mylan.com.au&amp;rft.atitle=Contact+%7C+Mylan&amp;rft_id=http%3A%2F%2Fwww.mylan.com.au%2Fen-au%2Fcontact-mylan&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-23"><span class="mw-cite-backlink"><b><a href="#cite_ref-23">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=116852053">"Agila Specialties Private Limited: Private Company Information - Bloomberg"</a>. <i>www.bloomberg.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">June 11,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.bloomberg.com&amp;rft.atitle=Agila+Specialties+Private+Limited%3A+Private+Company+Information+-+Bloomberg&amp;rft_id=https%3A%2F%2Fwww.bloomberg.com%2Fresearch%2Fstocks%2Fprivate%2Fsnapshot.asp%3FprivcapId%3D116852053&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-24"><span class="mw-cite-backlink"><b><a href="#cite_ref-24">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="http://www.dnaindia.com/business/report-mylan-recalls-bangalore-unit-cancer-drug-2095955">"Mylan recalls Bangalore unit cancer drug"</a>. <i>dna</i>. June 16, 2015<span class="reference-accessdate">. Retrieved <span class="nowrap">June 11,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=dna&amp;rft.atitle=Mylan+recalls+Bangalore+unit+cancer+drug&amp;rft.date=2015-06-16&amp;rft_id=http%3A%2F%2Fwww.dnaindia.com%2Fbusiness%2Freport-mylan-recalls-bangalore-unit-cancer-drug-2095955&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-Global-25"><span class="mw-cite-backlink">^ <a href="#cite_ref-Global_25-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Global_25-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.mylan.com/global_reach/APAC.aspx">"About Us"</a>. <i>mylan.com</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=mylan.com&amp;rft.atitle=About+Us&amp;rft_id=http%3A%2F%2Fwww.mylan.com%2Fglobal_reach%2FAPAC.aspx&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-26"><span class="mw-cite-backlink"><b><a href="#cite_ref-26">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.bloomberg.com/research/stocks/private/snapshot.asp?privcapId=53343528">"Generics Pharma Hellas E.P.E.: Private Company Information - Bloomberg"</a>. <i>www.bloomberg.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">June 11,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.bloomberg.com&amp;rft.atitle=Generics+Pharma+Hellas+E.P.E.%3A+Private+Company+Information+-+Bloomberg&amp;rft_id=https%3A%2F%2Fwww.bloomberg.com%2Fresearch%2Fstocks%2Fprivate%2Fsnapshot.asp%3FprivcapId%3D53343528&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-27"><span class="mw-cite-backlink"><b><a href="#cite_ref-27">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external free" href="http://www.manta.com/coms2/dnbcompany_wsklv1">http://www.manta.com/coms2/dnbcompany_wsklv1</a></span>
</li>
<li id="cite_note-28"><span class="mw-cite-backlink"><b><a href="#cite_ref-28">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="https://www.rte.ie/news/2012/0418/317502-major-jobs-announcement-set-for-later-today/">"Mylan to create 500 jobs in €380m expansion"</a>. <i>RTE.ie</i>. April 18, 2012<span class="reference-accessdate">. Retrieved <span class="nowrap">June 11,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=RTE.ie&amp;rft.atitle=Mylan+to+create+500+jobs+in+%E2%82%AC380m+expansion&amp;rft.date=2012-04-18&amp;rft_id=https%3A%2F%2Fwww.rte.ie%2Fnews%2F2012%2F0418%2F317502-major-jobs-announcement-set-for-later-today%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-29"><span class="mw-cite-backlink"><b><a href="#cite_ref-29">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://archives-energycommerce.house.gov/sites/republicans.energycommerce.house.gov/files/Hearings/Health/20120209/HHRG-112-IF14-TTF-HBresch-20120209.pdf">"Committee on Energy and Commerce"</a> <span class="cs1-format">(PDF)</span><span class="reference-accessdate">. Retrieved <span class="nowrap">June 11,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Committee+on+Energy+and+Commerce&amp;rft_id=https%3A%2F%2Farchives-energycommerce.house.gov%2Fsites%2Frepublicans.energycommerce.house.gov%2Ffiles%2FHearings%2FHealth%2F20120209%2FHHRG-112-IF14-TTF-HBresch-20120209.pdf&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-PuskarObit-30"><span class="mw-cite-backlink">^ <a href="#cite_ref-PuskarObit_30-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-PuskarObit_30-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-PuskarObit_30-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text"><cite class="citation news">Dearment, Alaric (October 10, 2011). <a rel="nofollow" class="external text" href="http://www.drugstorenews.com/article/milan-puskar-co-founder-mylan-dies">"Milan Puskar, co-founder of Mylan, dies"</a>. <i>Drug Store News</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Drug+Store+News&amp;rft.atitle=Milan+Puskar%2C+co-founder+of+Mylan%2C+dies&amp;rft.date=2011-10-10&amp;rft.aulast=Dearment&amp;rft.aufirst=Alaric&amp;rft_id=http%3A%2F%2Fwww.drugstorenews.com%2Farticle%2Fmilan-puskar-co-founder-mylan-dies&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-31"><span class="mw-cite-backlink"><b><a href="#cite_ref-31">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.wvexecutive.com/a-tale-of-two-entrepreneurs/">"A Tale of Two Entrepreneurs"</a>. <i>www.wvexecutive.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">July 1,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.wvexecutive.com&amp;rft.atitle=A+Tale+of+Two+Entrepreneurs&amp;rft_id=http%3A%2F%2Fwww.wvexecutive.com%2Fa-tale-of-two-entrepreneurs%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-32"><span class="mw-cite-backlink"><b><a href="#cite_ref-32">^</a></b></span> <span class="reference-text"><cite class="citation book">Seaman, John T.; Landry, John T. (April 10, 2012). <a rel="nofollow" class="external text" href="https://books.google.com/?id=bDubfivyILEC&amp;pg=PA7&amp;lpg=PA7&amp;dq=Pennsauken+mylan#v=onepage&amp;q=Pennsauken%20mylan&amp;f=false"><i>Mylan: 50 Years of Unconventional Success : Making Quality Medicine Affordable and Accessible</i></a>. UPNE. <a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a> <a href="/wiki/Special:BookSources/9781611682700" title="Special:BookSources/9781611682700"><bdi>9781611682700</bdi></a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=book&amp;rft.btitle=Mylan%3A+50+Years+of+Unconventional+Success+%3A+Making+Quality+Medicine+Affordable+and+Accessible&amp;rft.pub=UPNE&amp;rft.date=2012-04-10&amp;rft.isbn=9781611682700&amp;rft.aulast=Seaman&amp;rft.aufirst=John+T.&amp;rft.au=Landry%2C+John+T.&amp;rft_id=https%3A%2F%2Fbooks.google.com%2F%3Fid%3DbDubfivyILEC%26pg%3DPA7%26lpg%3DPA7%26dq%3DPennsauken%2Bmylan%23v%3Donepage%26q%3DPennsauken%2520mylan%26f%3Dfalse&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-33"><span class="mw-cite-backlink"><b><a href="#cite_ref-33">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.mylan.com/about_us/company_history.aspx">"Mylan 50 years young and still making history"</a>. Mylan<span class="reference-accessdate">. Retrieved <span class="nowrap">April 18,</span> 2012</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Mylan+50+years+young+and+still+making+history&amp;rft.pub=Mylan&amp;rft_id=http%3A%2F%2Fwww.mylan.com%2Fabout_us%2Fcompany_history.aspx&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-34"><span class="mw-cite-backlink"><b><a href="#cite_ref-34">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.mylan.com/en/investors/stock-history#">"MYL Stock History - Mylan"</a><span class="reference-accessdate">. Retrieved <span class="nowrap">August 25,</span> 2016</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=MYL+Stock+History+-+Mylan&amp;rft_id=http%3A%2F%2Fwww.mylan.com%2Fen%2Finvestors%2Fstock-history%23&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-NYTexpose1989-35"><span class="mw-cite-backlink">^ <a href="#cite_ref-NYTexpose1989_35-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-NYTexpose1989_35-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-NYTexpose1989_35-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-NYTexpose1989_35-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-NYTexpose1989_35-4"><sup><i><b>e</b></i></sup></a></span> <span class="reference-text"><cite class="citation news">Freudenheim, Milt (September 10, 1989). <a rel="nofollow" class="external text" href="https://www.nytimes.com/1989/09/10/business/exposing-the-fda.html?pagewanted=all">"Exposing the F.D.A."</a> <i>New York Times</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=New+York+Times&amp;rft.atitle=Exposing+the+F.D.A.&amp;rft.date=1989-09-10&amp;rft.aulast=Freudenheim&amp;rft.aufirst=Milt&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F1989%2F09%2F10%2Fbusiness%2Fexposing-the-fda.html%3Fpagewanted%3Dall&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-36"><span class="mw-cite-backlink"><b><a href="#cite_ref-36">^</a></b></span> <span class="reference-text"><cite class="citation web">Letter, The Pharma. <a rel="nofollow" class="external text" href="https://www.thepharmaletter.com/company/mylan-laboratories">"Mylan Laboratories"</a>. <i>www.thepharmaletter.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">April 27,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.thepharmaletter.com&amp;rft.atitle=Mylan+Laboratories&amp;rft.aulast=Letter&amp;rft.aufirst=The+Pharma&amp;rft_id=https%3A%2F%2Fwww.thepharmaletter.com%2Fcompany%2Fmylan-laboratories&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-37"><span class="mw-cite-backlink"><b><a href="#cite_ref-37">^</a></b></span> <span class="reference-text"><cite class="citation journal">Lewis, Ralph A. (1992). <a rel="nofollow" class="external text" href="http://scholarship.law.edu/cgi/viewcontent.cgi?article=1539&amp;context=jchlp">"The Emerging Effects of the Drug Price Competition and Patent Term Restoration Act of 1984"</a>. <i>Journal of Contemporary Health Law &amp; Policy</i>. <b>8</b> (1): 361–378.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Contemporary+Health+Law+%26+Policy&amp;rft.atitle=The+Emerging+Effects+of+the+Drug+Price+Competition+and+Patent+Term+Restoration+Act+of+1984&amp;rft.volume=8&amp;rft.issue=1&amp;rft.pages=361-378&amp;rft.date=1992&amp;rft.aulast=Lewis&amp;rft.aufirst=Ralph+A.&amp;rft_id=http%3A%2F%2Fscholarship.law.edu%2Fcgi%2Fviewcontent.cgi%3Farticle%3D1539%26context%3Djchlp&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-Philly1987-38"><span class="mw-cite-backlink">^ <a href="#cite_ref-Philly1987_38-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Philly1987_38-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text">Ron Wolf for the Philadelphia Inquirer. August 22, 1987 <a rel="nofollow" class="external text" href="http://articles.philly.com/1987-08-22/news/26170137_1_smithkline-stock-smithkline-earnings-generic-version">Smithkline Loses Exclusive Rights To Drug</a></span>
</li>
<li id="cite_note-auto-39"><span class="mw-cite-backlink">^ <a href="#cite_ref-auto_39-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-auto_39-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Boehm, Garth; Yao, Lixin; Han, Liang; Zheng, Qiang (September 2013). "Development of the generic drug industry in the US after the Hatch-Waxman Act of 1984". <i>Acta Pharmaceutica Sinica B</i>. <b>3</b> (5): 297–311. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.apsb.2013.07.004">10.1016/j.apsb.2013.07.004</a></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Acta+Pharmaceutica+Sinica+B&amp;rft.atitle=Development+of+the+generic+drug+industry+in+the+US+after+the+Hatch-Waxman+Act+of+1984&amp;rft.volume=3&amp;rft.issue=5&amp;rft.pages=297-311&amp;rft.date=2013-09&amp;rft_id=info%3Adoi%2F10.1016%2Fj.apsb.2013.07.004&amp;rft.aulast=Boehm&amp;rft.aufirst=Garth&amp;rft.au=Yao%2C+Lixin&amp;rft.au=Han%2C+Liang&amp;rft.au=Zheng%2C+Qiang&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-MylanHistDyazide-40"><span class="mw-cite-backlink">^ <a href="#cite_ref-MylanHistDyazide_40-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-MylanHistDyazide_40-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text">John Seaman and John T. Landry. Mylan 50 Years of Unconventional Success. Mylan, in association with University Press of New England, 2011. <link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"><a href="/wiki/International_Standard_Book_Number" title="International Standard Book Number">ISBN</a> <a href="/wiki/Special:BookSources/9781611682700" title="Special:BookSources/9781611682700">9781611682700</a>. <a rel="nofollow" class="external text" href="https://books.google.com/books?id=Q4OHtqPMjvYC&amp;pg=PT50">Page 50</a></span>
</li>
<li id="cite_note-Siege-41"><span class="mw-cite-backlink">^ <a href="#cite_ref-Siege_41-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Siege_41-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation news">Strickland, Carol (October 15, 1989). <a rel="nofollow" class="external text" href="https://www.nytimes.com/1989/10/15/nyregion/bolar-a-drug-company-under-siege.html?pagewanted=all">"Bolar: A Drug Company Under Siege"</a>. <i>The New York Times</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+York+Times&amp;rft.atitle=Bolar%3A+A+Drug+Company+Under+Siege&amp;rft.date=1989-10-15&amp;rft.aulast=Strickland&amp;rft.aufirst=Carol&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F1989%2F10%2F15%2Fnyregion%2Fbolar-a-drug-company-under-siege.html%3Fpagewanted%3Dall&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-42"><span class="mw-cite-backlink"><b><a href="#cite_ref-42">^</a></b></span> <span class="reference-text"><cite class="citation news">Shaw, Donna (February 27, 1991). <a rel="nofollow" class="external text" href="http://articles.philly.com/1991-02-27/business/25775782_1_generic-drug-generic-drug-industry-bolar-pharmaceutical">"U.s. Charges Bolar Pharmaceutical With Misrepresenting Its Products"</a>. <i>Philadelphia Inquirer</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Philadelphia+Inquirer&amp;rft.atitle=U.s.+Charges+Bolar+Pharmaceutical+With+Misrepresenting+Its+Products&amp;rft.date=1991-02-27&amp;rft.aulast=Shaw&amp;rft.aufirst=Donna&amp;rft_id=http%3A%2F%2Farticles.philly.com%2F1991-02-27%2Fbusiness%2F25775782_1_generic-drug-generic-drug-industry-bolar-pharmaceutical&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-43"><span class="mw-cite-backlink"><b><a href="#cite_ref-43">^</a></b></span> <span class="reference-text"><cite class="citation news">Freudenheim, Milt (February 28, 1991). <a rel="nofollow" class="external text" href="https://www.nytimes.com/1991/02/28/business/bolar-plans-guilty-plea-on-generics.html">"Bolar Plans Guilty Plea On Generics"</a>. <i>The New York Times</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+York+Times&amp;rft.atitle=Bolar+Plans+Guilty+Plea+On+Generics&amp;rft.date=1991-02-28&amp;rft.aulast=Freudenheim&amp;rft.aufirst=Milt&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F1991%2F02%2F28%2Fbusiness%2Fbolar-plans-guilty-plea-on-generics.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-MaxApprovable-44"><span class="mw-cite-backlink">^ <a href="#cite_ref-MaxApprovable_44-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-MaxApprovable_44-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-MaxApprovable_44-2"><sup><i><b>c</b></i></sup></a></span> <span class="reference-text">Pink Sheet October 22, 1984 <a rel="nofollow" class="external text" href="https://pink.pharmamedtechbi.com/PS007364/MYLANs-MAXZIDE-IS-APPROVABLE-AT-FDA-LEDERLE-TO-MARKET-BRAND-COMPETITION-TO-SMITHKLINEs-No-3RANKED-DYAZIDE-FINAL-APPROVAL-ANTICIPATED-IMMINENTLY">Mylan's Maxzide is "Approvable" at FDA: Lederle To Market Brand Competition to Smithkline's No. 3-Ranked Dyazide; Final Approval Anticipated "Imminently"</a></span>
</li>
<li id="cite_note-45"><span class="mw-cite-backlink"><b><a href="#cite_ref-45">^</a></b></span> <span class="reference-text">FDA <a rel="nofollow" class="external text" href="http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Set_Current_Drug&amp;ApplNo=019129&amp;DrugName=MAXZIDE&amp;ActiveIngred=HYDROCHLOROTHIAZIDE%3B%20TRIAMTERENE&amp;SponsorApplicant=MYLAN%20PHARMS%20INC&amp;ProductMktStatus=1&amp;goto=Search.Label_ApprovalHistory">Approval History NDA 019129: Maxzide</a> Page accessed September 8, 2016</span>
</li>
<li id="cite_note-46"><span class="mw-cite-backlink"><b><a href="#cite_ref-46">^</a></b></span> <span class="reference-text"><cite class="citation news">Reid, Kenneth (November 17, 1987). <a rel="nofollow" class="external text" href="http://www.joc.com/us-judge-rule-drug-marketing_19871117.html">"US Judge to Rule on Drug Marketing"</a>. Journal of Commerce.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=US+Judge+to+Rule+on+Drug+Marketing&amp;rft.date=1987-11-17&amp;rft.aulast=Reid&amp;rft.aufirst=Kenneth&amp;rft_id=http%3A%2F%2Fwww.joc.com%2Fus-judge-rule-drug-marketing_19871117.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-47"><span class="mw-cite-backlink"><b><a href="#cite_ref-47">^</a></b></span> <span class="reference-text"><cite class="citation news">Andrews, Edmund L. (July 31, 1989). <a rel="nofollow" class="external text" href="https://www.nytimes.com/1989/07/31/us/fda-inquiry-on-generic-drugs-focuses-on-changes-in-ingredients.html">"F.D.A. Inquiry on Generic Drugs Focuses on Changes in Ingredients"</a>. <i>The New York Times</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+York+Times&amp;rft.atitle=F.D.A.+Inquiry+on+Generic+Drugs+Focuses+on+Changes+in+Ingredients&amp;rft.date=1989-07-31&amp;rft.aulast=Andrews&amp;rft.aufirst=Edmund+L.&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F1989%2F07%2F31%2Fus%2Ffda-inquiry-on-generic-drugs-focuses-on-changes-in-ingredients.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-48"><span class="mw-cite-backlink"><b><a href="#cite_ref-48">^</a></b></span> <span class="reference-text"><cite class="citation news">Cimons, Marlene (August 29, 1989). <a rel="nofollow" class="external text" href="https://articles.latimes.com/1989-08-29/news/mn-1184_1_generic-drug">"FDA to Lift OK of Last Dyazide Generic Version"</a>. <i>Los Angeles Times</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Los+Angeles+Times&amp;rft.atitle=FDA+to+Lift+OK+of+Last+Dyazide+Generic+Version&amp;rft.date=1989-08-29&amp;rft.aulast=Cimons&amp;rft.aufirst=Marlene&amp;rft_id=https%3A%2F%2Farticles.latimes.com%2F1989-08-29%2Fnews%2Fmn-1184_1_generic-drug&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-49"><span class="mw-cite-backlink"><b><a href="#cite_ref-49">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="https://pink.pharmamedtechbi.com/PS014590/BOLAR-AND-MYLAN-TEAM-TO-PURCHASE-SOMERSET-LABS">"Bolar and Mylan Team to Purchase Somerset Labs"</a>. <i>Pink Sheet</i>. November 14, 1988.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Pink+Sheet&amp;rft.atitle=Bolar+and+Mylan+Team+to+Purchase+Somerset+Labs&amp;rft.date=1988-11-14&amp;rft_id=https%3A%2F%2Fpink.pharmamedtechbi.com%2FPS014590%2FBOLAR-AND-MYLAN-TEAM-TO-PURCHASE-SOMERSET-LABS&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-50"><span class="mw-cite-backlink"><b><a href="#cite_ref-50">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="https://pink.pharmamedtechbi.com/PS015763/SOMERSET-ELDEPRYL-JUNE-5-APPROVAL-CLEARS-WAY-FOR-MYLANBOLAR-ACQUISITION">"Somerset Eldepryl June 5 Approval Clears Way For Mylan/Bolar Acquisition"</a>. <i>Pink Sheet</i>. June 12, 1989.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Pink+Sheet&amp;rft.atitle=Somerset+Eldepryl+June+5+Approval+Clears+Way+For+Mylan%2FBolar+Acquisition&amp;rft.date=1989-06-12&amp;rft_id=https%3A%2F%2Fpink.pharmamedtechbi.com%2FPS015763%2FSOMERSET-ELDEPRYL-JUNE-5-APPROVAL-CLEARS-WAY-FOR-MYLANBOLAR-ACQUISITION&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-SpecialtyTrends2015-51"><span class="mw-cite-backlink">^ <a href="#cite_ref-SpecialtyTrends2015_51-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-SpecialtyTrends2015_51-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Ku, Mannching Sherry (December 1, 2015). "Recent trends in specialty pharma business model". <i>Journal of Food and Drug Analysis</i>. <b>23</b> (4): 595–608. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<span class="cs1-lock-free" title="Freely accessible"><a rel="nofollow" class="external text" href="https://doi.org/10.1016%2Fj.jfda.2015.04.008">10.1016/j.jfda.2015.04.008</a></span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Journal+of+Food+and+Drug+Analysis&amp;rft.atitle=Recent+trends+in+specialty+pharma+business+model&amp;rft.volume=23&amp;rft.issue=4&amp;rft.pages=595-608&amp;rft.date=2015-12-01&amp;rft_id=info%3Adoi%2F10.1016%2Fj.jfda.2015.04.008&amp;rft.aulast=Ku&amp;rft.aufirst=Mannching+Sherry&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-52"><span class="mw-cite-backlink"><b><a href="#cite_ref-52">^</a></b></span> <span class="reference-text">Mylan <a rel="nofollow" class="external text" href="ftp://ftp.sec.gov/edgar/data/69499/0000069499-96-000033.txt">Form 10-K (annual report))</a><sup class="noprint Inline-Template"><span style="white-space: nowrap;">[<i><a href="/wiki/Wikipedia:Link_rot" title="Wikipedia:Link rot"><span title=" Dead link since April 2020">permanent dead link</span></a></i>]</span></sup> for the Financial year ending March 31, 1996, filed June 26, 1996</span>
</li>
<li id="cite_note-NYT1998-53"><span class="mw-cite-backlink">^ <a href="#cite_ref-NYT1998_53-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-NYT1998_53-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation news">Labaton, Stephen (December 5, 1998). <a rel="nofollow" class="external text" href="https://www.nytimes.com/1998/12/05/business/a-drug-maker-is-said-to-face-a-suit-on-prices.html">"A Drug Maker Is Said to Face A Suit on Prices"</a>. <i>The New York Times</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+York+Times&amp;rft.atitle=A+Drug+Maker+Is+Said+to+Face+A+Suit+on+Prices&amp;rft.date=1998-12-05&amp;rft.aulast=Labaton&amp;rft.aufirst=Stephen&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F1998%2F12%2F05%2Fbusiness%2Fa-drug-maker-is-said-to-face-a-suit-on-prices.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-54"><span class="mw-cite-backlink"><b><a href="#cite_ref-54">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="https://www.ftc.gov/news-events/press-releases/2000/11/ftc-reaches-record-financial-settlement-settle-charges-price">"Press release: FTC Reaches Record Financial Settlement To Settle Charges of Price-fixing in Generic Drug Market | Federal Trade Commission"</a>. <i>FTC</i>. November 29, 2000.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=FTC&amp;rft.atitle=Press+release%3A+FTC+Reaches+Record+Financial+Settlement+To+Settle+Charges+of+Price-fixing+in+Generic+Drug+Market+%7C+Federal+Trade+Commission&amp;rft.date=2000-11-29&amp;rft_id=https%3A%2F%2Fwww.ftc.gov%2Fnews-events%2Fpress-releases%2F2000%2F11%2Fftc-reaches-record-financial-settlement-settle-charges-price&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-nyt-55"><span class="mw-cite-backlink"><b><a href="#cite_ref-nyt_55-0">^</a></b></span> <span class="reference-text">
<cite class="citation news">Labaton, Stephen (July 13, 2000). <a rel="nofollow" class="external text" href="https://www.nytimes.com/2000/07/13/business/generic-drug-maker-agrees-to-settlement-in-price-fixing-case.html">"Generic-Drug Maker Agrees to Settlement In Price-Fixing Case"</a>. <i><a href="/wiki/The_New_York_Times" title="The New York Times">The New York Times</a></i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+York+Times&amp;rft.atitle=Generic-Drug+Maker+Agrees+to+Settlement+In+Price-Fixing+Case&amp;rft.date=2000-07-13&amp;rft.aulast=Labaton&amp;rft.aufirst=Stephen&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2000%2F07%2F13%2Fbusiness%2Fgeneric-drug-maker-agrees-to-settlement-in-price-fixing-case.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-FortuneKing-56"><span class="mw-cite-backlink">^ <a href="#cite_ref-FortuneKing_56-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-FortuneKing_56-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation news">Creswell, Julie (March 21, 2005). <a rel="nofollow" class="external text" href="http://archive.fortune.com/magazines/fortune/fortune_archive/2005/03/21/8254845/index.htm">"Icahn the Spoiler"</a>. <i>Fortune</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Fortune&amp;rft.atitle=Icahn+the+Spoiler&amp;rft.date=2005-03-21&amp;rft.aulast=Creswell&amp;rft.aufirst=Julie&amp;rft_id=http%3A%2F%2Farchive.fortune.com%2Fmagazines%2Ffortune%2Ffortune_archive%2F2005%2F03%2F21%2F8254845%2Findex.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-57"><span class="mw-cite-backlink"><b><a href="#cite_ref-57">^</a></b></span> <span class="reference-text"><cite class="citation news">Pollack, Andrew (November 20, 2004). <a rel="nofollow" class="external text" href="https://www.nytimes.com/2004/11/20/business/icahn-offers-54-billion-for-mylan-drug-maker.html">"Icahn Offers $5.4 Billion for Mylan, Drug Maker"</a>. <i>The New York Times</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+York+Times&amp;rft.atitle=Icahn+Offers+%245.4+Billion+for+Mylan%2C+Drug+Maker&amp;rft.date=2004-11-20&amp;rft.aulast=Pollack&amp;rft.aufirst=Andrew&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2004%2F11%2F20%2Fbusiness%2Ficahn-offers-54-billion-for-mylan-drug-maker.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-58"><span class="mw-cite-backlink"><b><a href="#cite_ref-58">^</a></b></span> <span class="reference-text"><cite class="citation news">O'keefe, Eric (May 12, 2005). <a rel="nofollow" class="external text" href="https://www.nytimes.com/2005/05/12/business/icahn-slate-wins-seats-on-blockbuster-board.html">"Icahn Slate Wins Seats on Blockbuster Board"</a>. <i>The New York Times</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+York+Times&amp;rft.atitle=Icahn+Slate+Wins+Seats+on+Blockbuster+Board&amp;rft.date=2005-05-12&amp;rft.aulast=O%27keefe&amp;rft.aufirst=Eric&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2005%2F05%2F12%2Fbusiness%2Ficahn-slate-wins-seats-on-blockbuster-board.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-59"><span class="mw-cite-backlink"><b><a href="#cite_ref-59">^</a></b></span> <span class="reference-text"><cite class="citation news">Lazo, Shirley A. <a rel="nofollow" class="external text" href="http://www.barrons.com/articles/SB111905080477763147">"Survival Strategy"</a>. <i>Barrons</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Barrons&amp;rft.atitle=Survival+Strategy&amp;rft.aulast=Lazo&amp;rft.aufirst=Shirley+A.&amp;rft_id=http%3A%2F%2Fwww.barrons.com%2Farticles%2FSB111905080477763147&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-60"><span class="mw-cite-backlink"><b><a href="#cite_ref-60">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="https://articles.latimes.com/2005/jul/19/business/fi-mylan19">"Icahn Drops Bid for Mylan"</a>. <i>Los Angeles Times</i>. Bloomberg News. July 29, 2005.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Los+Angeles+Times&amp;rft.atitle=Icahn+Drops+Bid+for+Mylan&amp;rft.date=2005-07-29&amp;rft_id=https%3A%2F%2Farticles.latimes.com%2F2005%2Fjul%2F19%2Fbusiness%2Ffi-mylan19&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-61"><span class="mw-cite-backlink"><b><a href="#cite_ref-61">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="https://www.ihs.com/country-industry-forecasting.html?ID=106599002">"Mylan Signs US$736-mil. Takeover Deal for India's Matrix Laboratories"</a>. <i>IHS</i>. August 28, 2006.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=IHS&amp;rft.atitle=Mylan+Signs+US%24736-mil.+Takeover+Deal+for+India%27s+Matrix+Laboratories&amp;rft.date=2006-08-28&amp;rft_id=https%3A%2F%2Fwww.ihs.com%2Fcountry-industry-forecasting.html%3FID%3D106599002&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-62"><span class="mw-cite-backlink"><b><a href="#cite_ref-62">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="http://www.icmrindia.org/casestudies/catalogue/Business%20Strategy/BSTR279.htm">"Mylan's Acquisition of Matrix: Business Strategy Case Study"</a>. <i>ICRM</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=ICRM&amp;rft.atitle=Mylan%27s+Acquisition+of+Matrix%3A+Business+Strategy+Case+Study&amp;rft_id=http%3A%2F%2Fwww.icmrindia.org%2Fcasestudies%2Fcatalogue%2FBusiness%2520Strategy%2FBSTR279.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-63"><span class="mw-cite-backlink"><b><a href="#cite_ref-63">^</a></b></span> <span class="reference-text"><cite class="citation news">Massey, Steve (May 13, 2007). <a rel="nofollow" class="external text" href="http://www.post-gazette.com/business/businessnews/2007/05/13/Mylan-buys-Merck-generic-drug-unit-for-6-6-billion/stories/200705130184">"Mylan buys Merck generic drug unit for $6.6 billion"</a>. <i>Pittsburgh Post-Gazette</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Pittsburgh+Post-Gazette&amp;rft.atitle=Mylan+buys+Merck+generic+drug+unit+for+%246.6+billion&amp;rft.date=2007-05-13&amp;rft.aulast=Massey&amp;rft.aufirst=Steve&amp;rft_id=http%3A%2F%2Fwww.post-gazette.com%2Fbusiness%2Fbusinessnews%2F2007%2F05%2F13%2FMylan-buys-Merck-generic-drug-unit-for-6-6-billion%2Fstories%2F200705130184&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-64"><span class="mw-cite-backlink"><b><a href="#cite_ref-64">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="http://newsroom.mylan.com/press-releases?item=122513">"Press release: Mylan Completes Acquisition of Generics Business of Merck KGaA"</a>. <i>Mylan</i>. October 2, 2007.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Mylan&amp;rft.atitle=Press+release%3A+Mylan+Completes+Acquisition+of+Generics+Business+of+Merck+KGaA&amp;rft.date=2007-10-02&amp;rft_id=http%3A%2F%2Fnewsroom.mylan.com%2Fpress-releases%3Fitem%3D122513&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-BloomMarketing-65"><span class="mw-cite-backlink">^ <a href="#cite_ref-BloomMarketing_65-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-BloomMarketing_65-1"><sup><i><b>b</b></i></sup></a> <a href="#cite_ref-BloomMarketing_65-2"><sup><i><b>c</b></i></sup></a> <a href="#cite_ref-BloomMarketing_65-3"><sup><i><b>d</b></i></sup></a> <a href="#cite_ref-BloomMarketing_65-4"><sup><i><b>e</b></i></sup></a> <a href="#cite_ref-BloomMarketing_65-5"><sup><i><b>f</b></i></sup></a></span> <span class="reference-text">Cynthia Koons and Robert Langreth for Bloomberg Businessweek. September 23, 2015 <a rel="nofollow" class="external text" href="https://www.bloomberg.com/news/articles/2015-09-23/how-marketing-turned-the-epipen-into-a-billion-dollar-business">How Marketing Turned the EpiPen Into a Billion-Dollar Business</a></span>
</li>
<li id="cite_note-Trib2016-66"><span class="mw-cite-backlink"><b><a href="#cite_ref-Trib2016_66-0">^</a></b></span> <span class="reference-text"><cite class="citation news">Johnson, Carolyn Y.; Ho, Catherine (August 25, 2016). <a rel="nofollow" class="external text" href="https://www.chicagotribune.com/business/ct-mylan-epipen-monopoly-20160825-story.html">"How Mylan, the EpiPen company, maneuvered to create a virtual monopoly"</a>. <i>The Washington Post via The Chicago Tribune</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Washington+Post+via+The+Chicago+Tribune&amp;rft.atitle=How+Mylan%2C+the+EpiPen+company%2C+maneuvered+to+create+a+virtual+monopoly&amp;rft.date=2016-08-25&amp;rft.aulast=Johnson&amp;rft.aufirst=Carolyn+Y.&amp;rft.au=Ho%2C+Catherine&amp;rft_id=https%3A%2F%2Fwww.chicagotribune.com%2Fbusiness%2Fct-mylan-epipen-monopoly-20160825-story.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-wsj2009-67"><span class="mw-cite-backlink"><b><a href="#cite_ref-wsj2009_67-0">^</a></b></span> <span class="reference-text"><cite class="citation news">Adams, Russell (October 30, 2009). <a rel="nofollow" class="external text" href="https://www.wsj.com/articles/SB10001424052748704746304574505972491633900">"Mylan Again Sues Pittsburgh Post-Gazette"</a>. <a href="/wiki/Wall_Street_Journal" class="mw-redirect" title="Wall Street Journal">Wall Street Journal</a><span class="reference-accessdate">. Retrieved <span class="nowrap">August 26,</span> 2016</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Mylan+Again+Sues+Pittsburgh+Post-Gazette&amp;rft.date=2009-10-30&amp;rft.aulast=Adams&amp;rft.aufirst=Russell&amp;rft_id=https%3A%2F%2Fwww.wsj.com%2Farticles%2FSB10001424052748704746304574505972491633900&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-ppg0709-68"><span class="mw-cite-backlink"><b><a href="#cite_ref-ppg0709_68-0">^</a></b></span> <span class="reference-text"><cite class="citation web">Sabatini, Patricia; Boselovic, Len (July 26, 2009). <a rel="nofollow" class="external text" href="http://www.post-gazette.com/business/businessnews/2009/07/26/Mylan-workers-overrode-drug-quality-controls/stories/200907260233">"Mylan workers overrode drug quality controls Internal report detailed 'pervasive' practice of ignoring safety procedures"</a>. <a href="/wiki/Pittsburgh_Post-Gazette" title="Pittsburgh Post-Gazette">Pittsburgh Post-Gazette</a><span class="reference-accessdate">. Retrieved <span class="nowrap">August 26,</span> 2016</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Mylan+workers+overrode+drug+quality+controls+Internal+report+detailed+%27pervasive%27+practice+of+ignoring+safety+procedures&amp;rft.pub=Pittsburgh+Post-Gazette&amp;rft.date=2009-07-26&amp;rft.aulast=Sabatini&amp;rft.aufirst=Patricia&amp;rft.au=Boselovic%2C+Len&amp;rft_id=http%3A%2F%2Fwww.post-gazette.com%2Fbusiness%2Fbusinessnews%2F2009%2F07%2F26%2FMylan-workers-overrode-drug-quality-controls%2Fstories%2F200907260233&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-mwcbs09-69"><span class="mw-cite-backlink"><b><a href="#cite_ref-mwcbs09_69-0">^</a></b></span> <span class="reference-text"><cite class="citation news">Edwards, Jim (July 28, 2009). <a rel="nofollow" class="external text" href="https://www.cbsnews.com/news/its-not-mylans-first-quality-control-beef-with-fda/">"It's Not Mylan's First Quality Control Beef With FDA"</a>. <i>Money Watch</i>. CBS News<span class="reference-accessdate">. Retrieved <span class="nowrap">August 26,</span> 2016</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Money+Watch&amp;rft.atitle=It%27s+Not+Mylan%27s+First+Quality+Control+Beef+With+FDA&amp;rft.date=2009-07-28&amp;rft.aulast=Edwards&amp;rft.aufirst=Jim&amp;rft_id=https%3A%2F%2Fwww.cbsnews.com%2Fnews%2Fits-not-mylans-first-quality-control-beef-with-fda%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-ap2012-70"><span class="mw-cite-backlink"><b><a href="#cite_ref-ap2012_70-0">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="http://www.cnsnews.com/news/article/mylan-pittsburgh-post-gazette-settle-lawsuits">"Mylan, Pittsburgh Post-Gazette settle lawsuits"</a>. CBS News. Associated Press. February 17, 2012<span class="reference-accessdate">. Retrieved <span class="nowrap">August 26,</span> 2016</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Mylan%2C+Pittsburgh+Post-Gazette+settle+lawsuits&amp;rft.date=2012-02-17&amp;rft_id=http%3A%2F%2Fwww.cnsnews.com%2Fnews%2Farticle%2Fmylan-pittsburgh-post-gazette-settle-lawsuits&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-71"><span class="mw-cite-backlink"><b><a href="#cite_ref-71">^</a></b></span> <span class="reference-text">US Department of Justice. October 19, 2009 <a rel="nofollow" class="external text" href="https://www.justice.gov/opa/pr/four-pharmaceutical-companies-pay-124-million-submission-false-claims-medicaid">Press Release: Four Pharmaceutical Companies Pay $124 Million for Submission of False Claims to Medicaid</a></span>
</li>
<li id="cite_note-72"><span class="mw-cite-backlink"><b><a href="#cite_ref-72">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://web.archive.org/web/20150509122338/http://www.drugstorenews.com/article/mylan-acquires-rights-pfizers-inhaler-technology">"Mylan acquires rights to Pfizer's inhaler technology"</a>. <i>drugstorenews.com</i>. Archived from <a rel="nofollow" class="external text" href="http://www.drugstorenews.com/article/mylan-acquires-rights-pfizers-inhaler-technology">the original</a> on May 9, 2015<span class="reference-accessdate">. Retrieved <span class="nowrap">May 1,</span> 2012</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=drugstorenews.com&amp;rft.atitle=Mylan+acquires+rights+to+Pfizer%27s+inhaler+technology&amp;rft_id=http%3A%2F%2Fwww.drugstorenews.com%2Farticle%2Fmylan-acquires-rights-pfizers-inhaler-technology&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-73"><span class="mw-cite-backlink"><b><a href="#cite_ref-73">^</a></b></span> <span class="reference-text"><cite class="citation news">Stanton, Dan (June 8, 2015). <a rel="nofollow" class="external text" href="http://www.in-pharmatechnologist.com/Drug-Delivery/GSK-breathes-freely-as-Mylan-launches-Advair-generic-in-UK">"GSK breathes freely as Mylan launches Seretide generic in UK"</a>. <i>in-Pharma Technologist</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=in-Pharma+Technologist&amp;rft.atitle=GSK+breathes+freely+as+Mylan+launches+Seretide+generic+in+UK&amp;rft.date=2015-06-08&amp;rft.aulast=Stanton&amp;rft.aufirst=Dan&amp;rft_id=http%3A%2F%2Fwww.in-pharmatechnologist.com%2FDrug-Delivery%2FGSK-breathes-freely-as-Mylan-launches-Advair-generic-in-UK&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-74"><span class="mw-cite-backlink"><b><a href="#cite_ref-74">^</a></b></span> <span class="reference-text"><cite class="citation news">Helfand, Carly (February 22, 2016). <a rel="nofollow" class="external text" href="http://www.fiercepharma.com/sales-and-marketing/mylan-joins-advair-copycat-queue-but-approval-could-be-a-long-slog">"Mylan joins the Advair-copycat queue, but approval could be a long slog"</a>. <i>FiercePharma</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=FiercePharma&amp;rft.atitle=Mylan+joins+the+Advair-copycat+queue%2C+but+approval+could+be+a+long+slog&amp;rft.date=2016-02-22&amp;rft.aulast=Helfand&amp;rft.aufirst=Carly&amp;rft_id=http%3A%2F%2Fwww.fiercepharma.com%2Fsales-and-marketing%2Fmylan-joins-advair-copycat-queue-but-approval-could-be-a-long-slog&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-PBSschools-75"><span class="mw-cite-backlink"><b><a href="#cite_ref-PBSschools_75-0">^</a></b></span> <span class="reference-text"><cite class="citation news">Swetlitz, Ike; Silverman, Ed (August 26, 2016). <a rel="nofollow" class="external text" href="https://www.pbs.org/newshour/rundown/mylan-may-violated-antitrust-law-epipen-sales-schools-legal-experts-say/">"Mylan may have violated antitrust law in its EpiPen sales to schools"</a>. <i>PBS Newshour</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=PBS+Newshour&amp;rft.atitle=Mylan+may+have+violated+antitrust+law+in+its+EpiPen+sales+to+schools&amp;rft.date=2016-08-26&amp;rft.aulast=Swetlitz&amp;rft.aufirst=Ike&amp;rft.au=Silverman%2C+Ed&amp;rft_id=https%3A%2F%2Fwww.pbs.org%2Fnewshour%2Frundown%2Fmylan-may-violated-antitrust-law-epipen-sales-schools-legal-experts-say%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-USAtodayFamily-76"><span class="mw-cite-backlink">^ <a href="#cite_ref-USAtodayFamily_76-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-USAtodayFamily_76-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation news">O'Donnell, Jayne (September 21, 2016). <a rel="nofollow" class="external text" href="https://www.usatoday.com/story/news/politics/2016/09/20/family-matters-epipens-had-help-getting-schools-manchin-bresch/90435218/">"Family matters: EpiPens had high-level help getting into schools"</a>. <i>USA Today</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=USA+Today&amp;rft.atitle=Family+matters%3A+EpiPens+had+high-level+help+getting+into+schools&amp;rft.date=2016-09-21&amp;rft.aulast=O%27Donnell&amp;rft.aufirst=Jayne&amp;rft_id=https%3A%2F%2Fwww.usatoday.com%2Fstory%2Fnews%2Fpolitics%2F2016%2F09%2F20%2Ffamily-matters-epipens-had-help-getting-schools-manchin-bresch%2F90435218%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-77"><span class="mw-cite-backlink"><b><a href="#cite_ref-77">^</a></b></span> <span class="reference-text"><cite class="citation news">Novak, Matt (August 23, 2016). <a rel="nofollow" class="external text" href="https://gizmodo.com/how-congress-the-fda-and-sarah-jessica-parker-helped-1785568792">"How Congress, the FDA, and Sarah Jessica Parker Helped EpiPen Become a $1 Billion Business"</a>. Gizmodo.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=How+Congress%2C+the+FDA%2C+and+Sarah+Jessica+Parker+Helped+EpiPen+Become+a+%241+Billion+Business&amp;rft.date=2016-08-23&amp;rft.aulast=Novak&amp;rft.aufirst=Matt&amp;rft_id=https%3A%2F%2Fgizmodo.com%2Fhow-congress-the-fda-and-sarah-jessica-parker-helped-1785568792&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-78"><span class="mw-cite-backlink"><b><a href="#cite_ref-78">^</a></b></span> <span class="reference-text"><cite class="citation news">Thomas, Katie (February 27, 2013). <a rel="nofollow" class="external text" href="https://dealbook.nytimes.com/2013/02/27/mylan-to-acquire-injectable-drug-maker-for-1-6-billion/?_r=0">"Mylan Buys Drug Maker of Generic Injectables"</a>. <i>New York Times</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=New+York+Times&amp;rft.atitle=Mylan+Buys+Drug+Maker+of+Generic+Injectables&amp;rft.date=2013-02-27&amp;rft.aulast=Thomas&amp;rft.aufirst=Katie&amp;rft_id=https%3A%2F%2Fdealbook.nytimes.com%2F2013%2F02%2F27%2Fmylan-to-acquire-injectable-drug-maker-for-1-6-billion%2F%3F_r%3D0&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-79"><span class="mw-cite-backlink"><b><a href="#cite_ref-79">^</a></b></span> <span class="reference-text"><cite class="citation news">Palmer, Eric (August 18, 2015). <a rel="nofollow" class="external text" href="http://www.fiercepharma.com/regulatory/updated-fda-castigates-three-mylan-sterile-drug-plants-warning-letter">"UPDATED: FDA castigates three Mylan sterile drug plants in warning letter"</a>. FiercePharma.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=UPDATED%3A+FDA+castigates+three+Mylan+sterile+drug+plants+in+warning+letter&amp;rft.date=2015-08-18&amp;rft.aulast=Palmer&amp;rft.aufirst=Eric&amp;rft_id=http%3A%2F%2Fwww.fiercepharma.com%2Fregulatory%2Fupdated-fda-castigates-three-mylan-sterile-drug-plants-warning-letter&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-80"><span class="mw-cite-backlink"><b><a href="#cite_ref-80">^</a></b></span> <span class="reference-text"><cite class="citation web">ABC News. <a rel="nofollow" class="external text" href="https://abcnews.go.com/Business/wireStory/mylan-buy-abbott-business-line-53b-deal-24547698">"Business News, Personal Finance and Money News - ABC News"</a>. <i>ABC News</i><span class="reference-accessdate">. Retrieved <span class="nowrap">July 14,</span> 2014</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=ABC+News&amp;rft.atitle=Business+News%2C+Personal+Finance+and+Money+News+-+ABC+News&amp;rft.au=ABC+News&amp;rft_id=https%3A%2F%2Fabcnews.go.com%2FBusiness%2FwireStory%2Fmylan-buy-abbott-business-line-53b-deal-24547698&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-81"><span class="mw-cite-backlink"><b><a href="#cite_ref-81">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="http://articles.economictimes.indiatimes.com/2015-02-03/news/58751406_1_drugmaker-mylan-contraceptives-urban-indian-women">"US drugmaker Mylan to acquire Famy Care for $750 Million"</a>. <i>timesofindia-economictimes</i>. February 3, 2015.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=timesofindia-economictimes&amp;rft.atitle=US+drugmaker+Mylan+to+acquire+Famy+Care+for+%24750+Million&amp;rft.date=2015-02-03&amp;rft_id=http%3A%2F%2Farticles.economictimes.indiatimes.com%2F2015-02-03%2Fnews%2F58751406_1_drugmaker-mylan-contraceptives-urban-indian-women&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-82"><span class="mw-cite-backlink"><b><a href="#cite_ref-82">^</a></b></span> <span class="reference-text"><cite class="citation news">Koons, Cynthia (November 13, 2015). <a rel="nofollow" class="external text" href="https://www.bloomberg.com/news/articles/2015-11-13/mylan-s-hostile-bid-for-perrigo-fails-as-40-of-shares-tendered">"Mylan's Hostile Bid for Perrigo Fails"</a>. <i>Bloomberg</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Bloomberg&amp;rft.atitle=Mylan%27s+Hostile+Bid+for+Perrigo+Fails&amp;rft.date=2015-11-13&amp;rft.aulast=Koons&amp;rft.aufirst=Cynthia&amp;rft_id=https%3A%2F%2Fwww.bloomberg.com%2Fnews%2Farticles%2F2015-11-13%2Fmylan-s-hostile-bid-for-perrigo-fails-as-40-of-shares-tendered&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-83"><span class="mw-cite-backlink"><b><a href="#cite_ref-83">^</a></b></span> <span class="reference-text"><cite class="citation news">Rockoff, Jonathan D.; Mattioli, Dana (April 22, 2015). <a rel="nofollow" class="external text" href="https://www.wsj.com/articles/teva-offers-to-buy-mylan-for-82-a-share-1429620984">"Teva Offers to Buy Mylan for $40 Billion"</a>. <i>Wall Street Journal</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Wall+Street+Journal&amp;rft.atitle=Teva+Offers+to+Buy+Mylan+for+%2440+Billion&amp;rft.date=2015-04-22&amp;rft.aulast=Rockoff&amp;rft.aufirst=Jonathan+D.&amp;rft.au=Mattioli%2C+Dana&amp;rft_id=https%3A%2F%2Fwww.wsj.com%2Farticles%2Fteva-offers-to-buy-mylan-for-82-a-share-1429620984&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-84"><span class="mw-cite-backlink"><b><a href="#cite_ref-84">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="https://www.bloomberg.com/news/videos/2015-07-27/teva-to-buy-allergan-s-generic-drug-unit">"Teva to Buy Allergan's Generic Drug Unit"</a>. <i>Bloomberg.com</i>. July 27, 2015.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Bloomberg.com&amp;rft.atitle=Teva+to+Buy+Allergan%27s+Generic+Drug+Unit&amp;rft.date=2015-07-27&amp;rft_id=https%3A%2F%2Fwww.bloomberg.com%2Fnews%2Fvideos%2F2015-07-27%2Fteva-to-buy-allergan-s-generic-drug-unit&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-85"><span class="mw-cite-backlink"><b><a href="#cite_ref-85">^</a></b></span> <span class="reference-text"><cite class="citation news">Chitra Somayaji (July 27, 2015). <a rel="nofollow" class="external text" href="https://www.bloomberg.com/news/articles/2015-07-27/teva-snaps-up-allergan-s-generics-arm-dumping-mylan">"Teva Snaps Up Allergan's Generics Arm, Dumping Mylan"</a>. <i>Bloomberg.com</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Bloomberg.com&amp;rft.atitle=Teva+Snaps+Up+Allergan%27s+Generics+Arm%2C+Dumping+Mylan&amp;rft.date=2015-07-27&amp;rft.au=Chitra+Somayaji&amp;rft_id=https%3A%2F%2Fwww.bloomberg.com%2Fnews%2Farticles%2F2015-07-27%2Fteva-snaps-up-allergan-s-generics-arm-dumping-mylan&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-86"><span class="mw-cite-backlink"><b><a href="#cite_ref-86">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.genengnews.com/gen-news-highlights/mylan-to-co-develop-pulmatrix-copd-candidate/81251395/">"Mylan to Co-Develop Pulmatrix' COPD Candidate"</a>. <i>GEN</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=GEN&amp;rft.atitle=Mylan+to+Co-Develop+Pulmatrix%27+COPD+Candidate&amp;rft_id=http%3A%2F%2Fwww.genengnews.com%2Fgen-news-highlights%2Fmylan-to-co-develop-pulmatrix-copd-candidate%2F81251395%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-87"><span class="mw-cite-backlink"><b><a href="#cite_ref-87">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.genengnews.com/gen-news-highlights/mylan-to-acquire-meda-for-9-9b/81252356/">"Mylan to Acquire Meda for $9.9B - GEN News Highlights - GEN"</a><span class="reference-accessdate">. Retrieved <span class="nowrap">August 25,</span> 2016</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Mylan+to+Acquire+Meda+for+%249.9B+-+GEN+News+Highlights+-+GEN&amp;rft_id=http%3A%2F%2Fwww.genengnews.com%2Fgen-news-highlights%2Fmylan-to-acquire-meda-for-9-9b%2F81252356%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-88"><span class="mw-cite-backlink"><b><a href="#cite_ref-88">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.fiercepharma.com/pharma/mylan-snaps-up-dermatology-biz-from-investors-1b-deal">"Mylan snaps up dermatology biz from investors in $1B deal - FiercePharma"</a><span class="reference-accessdate">. Retrieved <span class="nowrap">August 25,</span> 2016</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Mylan+snaps+up+dermatology+biz+from+investors+in+%241B+deal+-+FiercePharma&amp;rft_id=http%3A%2F%2Fwww.fiercepharma.com%2Fpharma%2Fmylan-snaps-up-dermatology-biz-from-investors-1b-deal&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-89"><span class="mw-cite-backlink"><b><a href="#cite_ref-89">^</a></b></span> <span class="reference-text"><cite class="citation news">Thomas, Katie (December 15, 2016). <a rel="nofollow" class="external text" href="https://www.nytimes.com/2016/12/15/business/generic-drug-price-lawsuit-teva-mylan.html">"20 States Accuse Generic Drug Companies of Price Fixing"</a>. <i><a href="/wiki/The_New_York_Times" title="The New York Times">The New York Times</a></i><span class="reference-accessdate">. Retrieved <span class="nowrap">December 16,</span> 2016</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+York+Times&amp;rft.atitle=20+States+Accuse+Generic+Drug+Companies+of+Price+Fixing&amp;rft.date=2016-12-15&amp;rft.aulast=Thomas&amp;rft.aufirst=Katie&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2016%2F12%2F15%2Fbusiness%2Fgeneric-drug-price-lawsuit-teva-mylan.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-90"><span class="mw-cite-backlink"><b><a href="#cite_ref-90">^</a></b></span> <span class="reference-text"><cite class="citation news">Helfand, Carly (January 4, 2018). <a rel="nofollow" class="external text" href="https://www.fiercepharma.com/marketing/look-out-teva-mylan-s-copaxone-copy-has-already-captured-serious-share">"Look out, Teva: Mylan's Copaxone copy has already captured serious share"</a>. FiercePharma<span class="reference-accessdate">. Retrieved <span class="nowrap">July 9,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Look+out%2C+Teva%3A+Mylan%27s+Copaxone+copy+has+already+captured+serious+share&amp;rft.date=2018-01-04&amp;rft.aulast=Helfand&amp;rft.aufirst=Carly&amp;rft_id=https%3A%2F%2Fwww.fiercepharma.com%2Fmarketing%2Flook-out-teva-mylan-s-copaxone-copy-has-already-captured-serious-share&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-91"><span class="mw-cite-backlink"><b><a href="#cite_ref-91">^</a></b></span> <span class="reference-text"><cite class="citation news">Hudock, Megan (May 14, 2018). <a rel="nofollow" class="external text" href="http://www.wboy.com/news/business/mylan-and-wvu-announce-10-year-collaboration/1178903614">"Mylan and WVU announce 10 year collaboration"</a>. <i>WBOY</i><span class="reference-accessdate">. Retrieved <span class="nowrap">June 11,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=WBOY&amp;rft.atitle=Mylan+and+WVU+announce+10+year+collaboration&amp;rft.date=2018-05-14&amp;rft.aulast=Hudock&amp;rft.aufirst=Megan&amp;rft_id=http%3A%2F%2Fwww.wboy.com%2Fnews%2Fbusiness%2Fmylan-and-wvu-announce-10-year-collaboration%2F1178903614&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-92"><span class="mw-cite-backlink"><b><a href="#cite_ref-92">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm630151.htm">"FDA approves first generic Advair Diskus"</a>. <a href="/wiki/Food_and_Drug_Administration" title="Food and Drug Administration">Food and Drug Administration</a>. January 30, 2019<span class="reference-accessdate">. Retrieved <span class="nowrap">February 1,</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=FDA+approves+first+generic+Advair+Diskus&amp;rft.date=2019-01-30&amp;rft_id=https%3A%2F%2Fwww.fda.gov%2FNewsEvents%2FNewsroom%2FPressAnnouncements%2Fucm630151.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-93"><span class="mw-cite-backlink"><b><a href="#cite_ref-93">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external free" href="https://uk.reuters.com/article/us-mylan-nl-m-a-pfizer/pfizer-in-talks-to-merge-off-patent-drugs-business-with-mylan-source-idUKKCN1UM0DP">https://uk.reuters.com/article/us-mylan-nl-m-a-pfizer/pfizer-in-talks-to-merge-off-patent-drugs-business-with-mylan-source-idUKKCN1UM0DP</a></span>
</li>
<li id="cite_note-94"><span class="mw-cite-backlink"><b><a href="#cite_ref-94">^</a></b></span> <span class="reference-text"><cite class="citation web">Blankenship, Kyle (November 12, 2019). <a rel="nofollow" class="external text" href="https://www.fiercepharma.com/pharma/pfizer-s-upjohn-and-mylan-will-become-viatris-wait-haven-t-we-heard-name-before">"Pfizer's Upjohn and Mylan will become Viatris. Wait, haven't we heard that name before?"</a>. <i>FiercePharma</i><span class="reference-accessdate">. Retrieved <span class="nowrap">December 10,</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=FiercePharma&amp;rft.atitle=Pfizer%27s+Upjohn+and+Mylan+will+become+Viatris.+Wait%2C+haven%27t+we+heard+that+name+before%3F&amp;rft.date=2019-11-12&amp;rft.aulast=Blankenship&amp;rft.aufirst=Kyle&amp;rft_id=https%3A%2F%2Fwww.fiercepharma.com%2Fpharma%2Fpfizer-s-upjohn-and-mylan-will-become-viatris-wait-haven-t-we-heard-name-before&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-95"><span class="mw-cite-backlink"><b><a href="#cite_ref-95">^</a></b></span> <span class="reference-text"><cite class="citation web">Brozak, Steve (July 29, 2019). <a rel="nofollow" class="external text" href="https://www.forbes.com/sites/stephenbrozak/2019/07/29/the-pfizer-mylan-deal-what-this-means-for-phama/">"What The Pfizer-Mylan Deal Means For Pharma"</a>. <i>Forbes</i><span class="reference-accessdate">. Retrieved <span class="nowrap">December 10,</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=Forbes&amp;rft.atitle=What+The+Pfizer-Mylan+Deal+Means+For+Pharma&amp;rft.date=2019-07-29&amp;rft.aulast=Brozak&amp;rft.aufirst=Steve&amp;rft_id=https%3A%2F%2Fwww.forbes.com%2Fsites%2Fstephenbrozak%2F2019%2F07%2F29%2Fthe-pfizer-mylan-deal-what-this-means-for-phama%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-96"><span class="mw-cite-backlink"><b><a href="#cite_ref-96">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external free" href="https://www.biospace.com/article/pfizer-merges-off-patent-upjohn-business-with-mylan/?s=79">https://www.biospace.com/article/pfizer-merges-off-patent-upjohn-business-with-mylan/?s=79</a></span>
</li>
<li id="cite_note-97"><span class="mw-cite-backlink"><b><a href="#cite_ref-97">^</a></b></span> <span class="reference-text"><a rel="nofollow" class="external free" href="https://uk.reuters.com/article/us-mylan-pfizer/pfizer-to-spinoff-merge-off-patent-drugs-unit-with-mylan-idUKKCN1UO185">https://uk.reuters.com/article/us-mylan-pfizer/pfizer-to-spinoff-merge-off-patent-drugs-unit-with-mylan-idUKKCN1UO185</a></span>
</li>
<li id="cite_note-98"><span class="mw-cite-backlink"><b><a href="#cite_ref-98">^</a></b></span> <span class="reference-text"><cite class="citation news">Sabatini, Patricia (November 12, 2019). <a rel="nofollow" class="external text" href="https://www.post-gazette.com/business/healthcare-business/2019/11/12/Viatris-Mylan-Upjohn-merger-Pfizer-generic-drug-healthcare/stories/201911120101">"Viatris picked as new name for a merged Mylan/Upjohn"</a>. <a href="/wiki/Pittsburgh_Post-Gazette" title="Pittsburgh Post-Gazette">Pittsburgh Post-Gazette</a><span class="reference-accessdate">. Retrieved <span class="nowrap">November 14,</span> 2019</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Viatris+picked+as+new+name+for+a+merged+Mylan%2FUpjohn&amp;rft.date=2019-11-12&amp;rft.aulast=Sabatini&amp;rft.aufirst=Patricia&amp;rft_id=https%3A%2F%2Fwww.post-gazette.com%2Fbusiness%2Fhealthcare-business%2F2019%2F11%2F12%2FViatris-Mylan-Upjohn-merger-Pfizer-generic-drug-healthcare%2Fstories%2F201911120101&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-ucm627647-99"><span class="mw-cite-backlink"><b><a href="#cite_ref-ucm627647_99-0">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.fda.gov/Safety/Recalls/ucm627647.htm">"Mylan Expands Its Voluntary Nationwide Recall of Valsartan Tablets, USP, Amlodipine and Valsartan Tablets, USP, and Valsartan and Hydrochlorothiazide Tablets, USP, to all Lots Within Expiry Due to The Detection of Trace Amounts of NDEA (N-Nitrosodiethylamine) Impurity Found in the Active Pharmaceutical Ingredient"</a>. 2018. <q>Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is expanding its consumer-level voluntary nationwide recall to include all lots of Valsartan-containing products within expiry. The 104 additional lots include 26 lots of Amlodipine and Valsartan Tablets, USP (including the 5mg/160mg, 10mg/160mg, 5mg/320mg and 10mg/320mg strengths), 51 lots of Valsartan Tablets, USP (including 40 mg, 80 mg, 160 mg and 320 mg strengths), and 27 lots of Valsartan and Hydrochlorothiazide Tablets, USP (80mg/12.5mg, 160mg/12.5mg, 160mg/25mg, 320mg/12.5mg and 320mg/25mg strengths).<br>Out of an abundance of caution, these products are being recalled due to detected trace amounts of an impurity, N-nitrosodiethylamine (NDEA) contained in the API Valsartan, USP, manufactured by Mylan Laboratories Limited. NDEA is a substance that occurs naturally in certain foods, drinking water, air pollution, and industrial processes, and has been classified as a probable human carcinogen according to the International Agency for Research on Cancer (IARC).</q></cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Mylan+Expands+Its+Voluntary+Nationwide+Recall+of+Valsartan+Tablets%2C+USP%2C+Amlodipine+and+Valsartan+Tablets%2C+USP%2C+and+Valsartan+and+Hydrochlorothiazide+Tablets%2C+USP%2C+to+all+Lots+Within+Expiry+Due+to+The+Detection+of+Trace+Amounts+of+NDEA+%28N-Nitrosodiethylamine%29+Impurity+Found+in+the+Active+Pharmaceutical+Ingredient&amp;rft.date=2018&amp;rft_id=https%3A%2F%2Fwww.fda.gov%2FSafety%2FRecalls%2Fucm627647.htm&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-100"><span class="mw-cite-backlink"><b><a href="#cite_ref-100">^</a></b></span> <span class="reference-text"><cite class="citation news">Editorial, Reuters. <a rel="nofollow" class="external text" href="https://www.reuters.com/article/mylan-offer-idUSL4N0BR91R20130227">"Mylan to buy Agila Specialties from India's Strides for $1.6 bln"</a>. <i>U.S</i><span class="reference-accessdate">. Retrieved <span class="nowrap">June 11,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=U.S.&amp;rft.atitle=Mylan+to+buy+Agila+Specialties+from+India%27s+Strides+for+%241.6+bln&amp;rft.aulast=Editorial&amp;rft.aufirst=Reuters&amp;rft_id=https%3A%2F%2Fwww.reuters.com%2Farticle%2Fmylan-offer-idUSL4N0BR91R20130227&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-101"><span class="mw-cite-backlink"><b><a href="#cite_ref-101">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.fiercepharma.com/partnering/mylan-to-acquire-pfizer-respiratory-tech-for-17-5m">"Mylan to acquire Pfizer respiratory tech for $17.5M | FiercePharma"</a>. <i>www.fiercepharma.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">June 11,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.fiercepharma.com&amp;rft.atitle=Mylan+to+acquire+Pfizer+respiratory+tech+for+%2417.5M+%7C+FiercePharma&amp;rft_id=https%3A%2F%2Fwww.fiercepharma.com%2Fpartnering%2Fmylan-to-acquire-pfizer-respiratory-tech-for-17-5m&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-102"><span class="mw-cite-backlink"><b><a href="#cite_ref-102">^</a></b></span> <span class="reference-text"><cite class="citation web">Grogan, Kevin (July 15, 2010). <a rel="nofollow" class="external text" href="http://www.pharmatimes.com/news/mylan_acquires_irelands_bioniche_pharma_982920">"Mylan acquires Ireland's Bioniche Pharma"</a>. <i>www.pharmatimes.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">June 11,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.pharmatimes.com&amp;rft.atitle=Mylan+acquires+Ireland%27s+Bioniche+Pharma&amp;rft.date=2010-07-15&amp;rft.aulast=Grogan&amp;rft.aufirst=Kevin&amp;rft_id=http%3A%2F%2Fwww.pharmatimes.com%2Fnews%2Fmylan_acquires_irelands_bioniche_pharma_982920&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-103"><span class="mw-cite-backlink"><b><a href="#cite_ref-103">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/us-pharma-major-mylan-buys-matrix-labs/articleshow/1933573.cms">"US pharma major Mylan buys Matrix Labs"</a>. <i>The Economic Times</i>. August 29, 2006<span class="reference-accessdate">. Retrieved <span class="nowrap">June 11,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Economic+Times&amp;rft.atitle=US+pharma+major+Mylan+buys+Matrix+Labs&amp;rft.date=2006-08-29&amp;rft_id=https%3A%2F%2Feconomictimes.indiatimes.com%2Findustry%2Fhealthcare%2Fbiotech%2Fpharmaceuticals%2Fus-pharma-major-mylan-buys-matrix-labs%2Farticleshow%2F1933573.cms&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-104"><span class="mw-cite-backlink"><b><a href="#cite_ref-104">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="https://www.sfgate.com/business/article/Mylan-Fleshing-Out-Deal-for-Penederm-Skin-drug-3002788.php">"Mylan Fleshing Out Deal for Penederm / Skin-drug firm to sell for $205 million"</a>. <i>SFGate</i><span class="reference-accessdate">. Retrieved <span class="nowrap">June 11,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=SFGate&amp;rft.atitle=Mylan+Fleshing+Out+Deal+for+Penederm+%2F+Skin-drug+firm+to+sell+for+%24205+million&amp;rft_id=https%3A%2F%2Fwww.sfgate.com%2Fbusiness%2Farticle%2FMylan-Fleshing-Out-Deal-for-Penederm-Skin-drug-3002788.php&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-105"><span class="mw-cite-backlink"><b><a href="#cite_ref-105">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="https://www.upi.com/Archives/1991/06/27/Mylan-Labs-Dow-B-Hickam-set-plans-for-stock-swap-merger/6384677995200/">"Mylan Labs, Dow B. Hickam set plans for stock-swap merger"</a>. <i>UPI</i><span class="reference-accessdate">. Retrieved <span class="nowrap">June 11,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=UPI&amp;rft.atitle=Mylan+Labs%2C+Dow+B.+Hickam+set+plans+for+stock-swap+merger&amp;rft_id=https%3A%2F%2Fwww.upi.com%2FArchives%2F1991%2F06%2F27%2FMylan-Labs-Dow-B-Hickam-set-plans-for-stock-swap-merger%2F6384677995200%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-106"><span class="mw-cite-backlink"><b><a href="#cite_ref-106">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.bizjournals.com/tampabay/stories/2008/07/28/daily16.html">"Mylan buys out Watson's interest in Somerset Pharmaceuticals"</a>. <i>www.bizjournals.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">June 11,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.bizjournals.com&amp;rft.atitle=Mylan+buys+out+Watson%27s+interest+in+Somerset+Pharmaceuticals&amp;rft_id=https%3A%2F%2Fwww.bizjournals.com%2Ftampabay%2Fstories%2F2008%2F07%2F28%2Fdaily16.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-NYT2016-107"><span class="mw-cite-backlink">^ <a href="#cite_ref-NYT2016_107-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-NYT2016_107-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text">Tara Parker-Pope and Rachel Rabkin Peachman for the New York Times.  August 22, 2016 <a rel="nofollow" class="external text" href="http://well.blogs.nytimes.com/2016/08/22/epipen-price-rise-sparks-concern-for-allergy-sufferers/?_r=1">EpiPen Price Rise Sparks Concern for Allergy Sufferers</a></span>
</li>
<li id="cite_note-108"><span class="mw-cite-backlink"><b><a href="#cite_ref-108">^</a></b></span> <span class="reference-text">King Pharmaceuticals October 21, 2002. <a rel="nofollow" class="external text" href="http://www.prnewswire.com/news-releases/king-pharmaceuticals-to-acquire-meridian-medical-technologies-76364227.html">Press Release: King Pharmaceuticals to Acquire Meridian Medical Technologies</a></span>
</li>
<li id="cite_note-109"><span class="mw-cite-backlink"><b><a href="#cite_ref-109">^</a></b></span> <span class="reference-text">Carly Helfand for FiercePharma March 1, 2016 <a rel="nofollow" class="external text" href="http://www.fiercepharma.com/sales-and-marketing/fda-swats-down-teva-s-epipen-copy-putting-mylan-cruise-control">FDA swats down Teva's EpiPen copy, putting Mylan in cruise control</a></span>
</li>
<li id="cite_note-ForbesCould-110"><span class="mw-cite-backlink">^ <a href="#cite_ref-ForbesCould_110-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-ForbesCould_110-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text">Emily Willingham  for Forbes. August 21, 2016 <a rel="nofollow" class="external text" href="https://www.forbes.com/sites/emilywillingham/2016/08/21/why-did-mylan-hike-epipen-prices-400-because-they-could/#310c6822477a">Why Did Mylan Hike EpiPen Prices 400%? Because They Could</a></span>
</li>
<li id="cite_note-Baltimore-111"><span class="mw-cite-backlink"><b><a href="#cite_ref-Baltimore_111-0">^</a></b></span> <span class="reference-text"><cite class="citation web">Bartolotta, Devin (August 18, 2016). <a rel="nofollow" class="external text" href="http://baltimore.cbslocal.com/2016/08/18/cost-jumps-nearly-500-percent-for-life-saving-epipens/">"Cost Jumps Nearly 500-Percent For Life-Saving EpiPens"</a>. CBS Baltimore<span class="reference-accessdate">. Retrieved <span class="nowrap">August 19,</span> 2016</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Cost+Jumps+Nearly+500-Percent+For+Life-Saving+EpiPens&amp;rft.pub=CBS+Baltimore&amp;rft.date=2016-08-18&amp;rft.aulast=Bartolotta&amp;rft.aufirst=Devin&amp;rft_id=http%3A%2F%2Fbaltimore.cbslocal.com%2F2016%2F08%2F18%2Fcost-jumps-nearly-500-percent-for-life-saving-epipens%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-NYT2017copulate-112"><span class="mw-cite-backlink">^ <a href="#cite_ref-NYT2017copulate_112-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-NYT2017copulate_112-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation news">Duhigg, Charles (June 4, 2017). <a rel="nofollow" class="external text" href="https://www.nytimes.com/2017/06/04/business/angry-about-epipen-prices-executive-dont-care-much.html?_r=1">"Outcry Over EpiPen Prices Hasn't Made Them Lower"</a>. <i>The New York Times</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+York+Times&amp;rft.atitle=Outcry+Over+EpiPen+Prices+Hasn%27t+Made+Them+Lower&amp;rft.date=2017-06-04&amp;rft.aulast=Duhigg&amp;rft.aufirst=Charles&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2017%2F06%2F04%2Fbusiness%2Fangry-about-epipen-prices-executive-dont-care-much.html%3F_r%3D1&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-113"><span class="mw-cite-backlink"><b><a href="#cite_ref-113">^</a></b></span> <span class="reference-text"><cite class="citation news">Novak, Matt (June 5, 2017). <a rel="nofollow" class="external text" href="https://gizmodo.com/drug-company-chairman-to-america-go-fuck-yourself-1795816263">"Drug Company Chairman to America: Go Fuck Yourself"</a>. <i>Gizmodo</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Gizmodo&amp;rft.atitle=Drug+Company+Chairman+to+America%3A+Go+Fuck+Yourself&amp;rft.date=2017-06-05&amp;rft.aulast=Novak&amp;rft.aufirst=Matt&amp;rft_id=https%3A%2F%2Fgizmodo.com%2Fdrug-company-chairman-to-america-go-fuck-yourself-1795816263&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-114"><span class="mw-cite-backlink"><b><a href="#cite_ref-114">^</a></b></span> <span class="reference-text"><cite class="citation news">Mole, Beth (June 5, 2017). <a rel="nofollow" class="external text" href="https://arstechnica.com/science/2017/06/mylan-chairman-drug-pricing-critics-ought-to-go-copulate-with-themselves/">"Mylan chairman: Drug pricing critics ought to go copulate with themselves"</a>. <i>Ars Technica</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Ars+Technica&amp;rft.atitle=Mylan+chairman%3A+Drug+pricing+critics+ought+to+go+copulate+with+themselves&amp;rft.date=2017-06-05&amp;rft.aulast=Mole&amp;rft.aufirst=Beth&amp;rft_id=https%3A%2F%2Farstechnica.com%2Fscience%2F2017%2F06%2Fmylan-chairman-drug-pricing-critics-ought-to-go-copulate-with-themselves%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-115"><span class="mw-cite-backlink"><b><a href="#cite_ref-115">^</a></b></span> <span class="reference-text"><cite class="citation news">Loew, Derek (June 12, 2017). <a rel="nofollow" class="external text" href="http://blogs.sciencemag.org/pipeline/archives/2017/06/12/mylan-begins-harvesting-the-crop-its-sown">"Mylan Begins Harvesting the Crop It's Sown"</a>. <i>In the Pipeline</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=In+the+Pipeline&amp;rft.atitle=Mylan+Begins+Harvesting+the+Crop+It%27s+Sown&amp;rft.date=2017-06-12&amp;rft.aulast=Loew&amp;rft.aufirst=Derek&amp;rft_id=http%3A%2F%2Fblogs.sciencemag.org%2Fpipeline%2Farchives%2F2017%2F06%2F12%2Fmylan-begins-harvesting-the-crop-its-sown&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-Gold2016-116"><span class="mw-cite-backlink"><b><a href="#cite_ref-Gold2016_116-0">^</a></b></span> <span class="reference-text"><cite class="citation web">Goldberg, Kenny. <a rel="nofollow" class="external text" href="http://www.kpbs.org/news/2016/feb/18/food-allergies-life-saving-drug-too-expensive/">"People With Food Allergies Say Life-Saving Drug Too Expensive"</a>. <i>KPBS Public Media</i><span class="reference-accessdate">. Retrieved <span class="nowrap">June 8,</span> 2016</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=KPBS+Public+Media&amp;rft.atitle=People+With+Food+Allergies+Say+Life-Saving+Drug+Too+Expensive&amp;rft.aulast=Goldberg&amp;rft.aufirst=Kenny&amp;rft_id=http%3A%2F%2Fwww.kpbs.org%2Fnews%2F2016%2Ffeb%2F18%2Ffood-allergies-life-saving-drug-too-expensive%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-117"><span class="mw-cite-backlink"><b><a href="#cite_ref-117">^</a></b></span> <span class="reference-text"><cite class="citation news">Walker, Joseph; Winslow, Ron; Steele, Anne (August 30, 2016). <a rel="nofollow" class="external text" href="https://www.wsj.com/articles/mylan-to-launch-cheaper-generic-epipen-alternative-1472467730">"Mylan to Launch Cheaper Generic EpiPen Alternative"</a>. <i>Wall Street Journal</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Wall+Street+Journal&amp;rft.atitle=Mylan+to+Launch+Cheaper+Generic+EpiPen+Alternative&amp;rft.date=2016-08-30&amp;rft.aulast=Walker&amp;rft.aufirst=Joseph&amp;rft.au=Winslow%2C+Ron&amp;rft.au=Steele%2C+Anne&amp;rft_id=https%3A%2F%2Fwww.wsj.com%2Farticles%2Fmylan-to-launch-cheaper-generic-epipen-alternative-1472467730&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-118"><span class="mw-cite-backlink"><b><a href="#cite_ref-118">^</a></b></span> <span class="reference-text">Emma Court for MarketWatch.  August 18, 2016 <a rel="nofollow" class="external text" href="http://www.marketwatch.com/story/mylans-epipen-price-increases-are-valeant-like-in-size-shkreli-like-in-approach-2016-07-20">Mylan’s EpiPen price increases are Valeant-like in size, Shkreli-like in approach</a></span>
</li>
<li id="cite_note-119"><span class="mw-cite-backlink"><b><a href="#cite_ref-119">^</a></b></span> <span class="reference-text">Brad Tuttle for Time  August 22, 2016 <a rel="nofollow" class="external text" href="http://time.com/money/4461494/epipen-prices-mylan-out-of-control/">5 Signs That EpiPen Prices Are Completely Out of Control</a></span>
</li>
<li id="cite_note-120"><span class="mw-cite-backlink"><b><a href="#cite_ref-120">^</a></b></span> <span class="reference-text">Michael Hiltzik for the Los Angeles Times. August 23, 2016 <a rel="nofollow" class="external text" href="https://www.latimes.com/business/hiltzik/la-fi-hiltzik-mylan-inversion-20160823-snap-story.html">Another reason to hate Mylan, which jacked up the price of life-saving EpiPens: It's a tax dodger</a></span>
</li>
<li id="cite_note-121"><span class="mw-cite-backlink"><b><a href="#cite_ref-121">^</a></b></span> <span class="reference-text">Matt Novak for Gizmodo. August 23, 2016 <a rel="nofollow" class="external text" href="https://gizmodo.com/how-congress-the-fda-and-sarah-jessica-parker-helped-1785568792">How Congress, the FDA, and Sarah Jessica Parker Helped EpiPen Become a $1 Billion Business</a></span>
</li>
<li id="cite_note-122"><span class="mw-cite-backlink"><b><a href="#cite_ref-122">^</a></b></span> <span class="reference-text">Beth Snyder Bulik for FiercePharma.  May 1, 2016 <a rel="nofollow" class="external text" href="http://www.fiercepharma.com/marketing/no-holds-barred-mylan-s-ultra-realistic-peanut-allergy-campaign">No holds barred in Mylan’s ultra-realistic peanut allergy campaign</a></span>
</li>
<li id="cite_note-123"><span class="mw-cite-backlink"><b><a href="#cite_ref-123">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="https://www.theguardian.com/business/2016/aug/25/epipen-price-hike-savings-card-mylan-heather-bresch-congress">"Mylan to provide EpiPen cost assistance as CEO is asked to testify on price hike"</a>. <i>The Guardian</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+Guardian&amp;rft.atitle=Mylan+to+provide+EpiPen+cost+assistance+as+CEO+is+asked+to+testify+on+price+hike&amp;rft_id=https%3A%2F%2Fwww.theguardian.com%2Fbusiness%2F2016%2Faug%2F25%2Fepipen-price-hike-savings-card-mylan-heather-bresch-congress&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-Post-124"><span class="mw-cite-backlink">^ <a href="#cite_ref-Post_124-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Post_124-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation news">Carolyn Y. Johnson (August 25, 2016). <a rel="nofollow" class="external text" href="https://www.washingtonpost.com/news/wonk/wp/2016/08/25/under-pressure-mylan-will-expand-patient-assistance-for-epipen/">"Why Mylan's 'savings card' won't make EpiPen cheaper for all patients"</a>. <i>Washington Post</i>. Washington Post.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Washington+Post&amp;rft.atitle=Why+Mylan%27s+%27savings+card%27+won%27t+make+EpiPen+cheaper+for+all+patients&amp;rft.date=2016-08-25&amp;rft.au=Carolyn+Y.+Johnson&amp;rft_id=https%3A%2F%2Fwww.washingtonpost.com%2Fnews%2Fwonk%2Fwp%2F2016%2F08%2F25%2Funder-pressure-mylan-will-expand-patient-assistance-for-epipen%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-Business_Insider:The_$300_generic_EpiPen_is_here-125"><span class="mw-cite-backlink"><b><a href="#cite_ref-Business_Insider:The_%24300_generic_EpiPen_is_here_125-0">^</a></b></span> <span class="reference-text"><cite class="citation web">Ramsey, Lydia (December 16, 2016). <a rel="nofollow" class="external text" href="http://www.businessinsider.com/mylan-launches-authorized-generic-epipen-for-300-2016-12">"The $300 generic EpiPen is here"</a>. Business Insider<span class="reference-accessdate">. Retrieved <span class="nowrap">August 16,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=The+%24300+generic+EpiPen+is+here&amp;rft.pub=Business+Insider&amp;rft.date=2016-12-16&amp;rft.aulast=Ramsey&amp;rft.aufirst=Lydia&amp;rft_id=http%3A%2F%2Fwww.businessinsider.com%2Fmylan-launches-authorized-generic-epipen-for-300-2016-12&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-bloom9616-126"><span class="mw-cite-backlink"><b><a href="#cite_ref-bloom9616_126-0">^</a></b></span> <span class="reference-text"><cite class="citation news">Larson, Erik; Hopkins, Jared S. (September 6, 2016). <a rel="nofollow" class="external text" href="https://www.bloomberg.com/news/articles/2016-09-06/n-y-s-schneiderman-launches-probe-into-mylan-epipen-sales">"Mylan's EpiPen School Sales Trigger N.Y. Antitrust Probe"</a>. Bloomberg<span class="reference-accessdate">. Retrieved <span class="nowrap">September 7,</span> 2016</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Mylan%27s+EpiPen+School+Sales+Trigger+N.Y.+Antitrust+Probe&amp;rft.date=2016-09-06&amp;rft.aulast=Larson&amp;rft.aufirst=Erik&amp;rft.au=Hopkins%2C+Jared+S.&amp;rft_id=https%3A%2F%2Fwww.bloomberg.com%2Fnews%2Farticles%2F2016-09-06%2Fn-y-s-schneiderman-launches-probe-into-mylan-epipen-sales&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-127"><span class="mw-cite-backlink"><b><a href="#cite_ref-127">^</a></b></span> <span class="reference-text"><cite class="citation news">Feeley, Jef; Langreth, Robert (September 20, 2016). <a rel="nofollow" class="external text" href="https://www.bloomberg.com/news/articles/2016-09-20/mylan-epipen-files-sought-as-west-virginia-opens-fraud-probe">"Mylan Investigations Mount as West Virginia Opens Fraud Probe"</a>. <i>Bloomberg News</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Bloomberg+News&amp;rft.atitle=Mylan+Investigations+Mount+as+West+Virginia+Opens+Fraud+Probe&amp;rft.date=2016-09-20&amp;rft.aulast=Feeley&amp;rft.aufirst=Jef&amp;rft.au=Langreth%2C+Robert&amp;rft_id=https%3A%2F%2Fwww.bloomberg.com%2Fnews%2Farticles%2F2016-09-20%2Fmylan-epipen-files-sought-as-west-virginia-opens-fraud-probe&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-NBCdevice2016-128"><span class="mw-cite-backlink"><b><a href="#cite_ref-NBCdevice2016_128-0">^</a></b></span> <span class="reference-text"><cite class="citation news">Popken, Ben (September 30, 2016). <a rel="nofollow" class="external text" href="https://www.nbcnews.com/business/consumer/mylan-says-it-upgraded-epipen-2009-so-experts-looked-inside-n652651">"Upgraded EpiPens torn apart. Tech firm: "It's the same core device<span class="cs1-kern-right">"</span>"</a>. <i>NBC News</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=NBC+News&amp;rft.atitle=Upgraded+EpiPens+torn+apart.+Tech+firm%3A+%22It%27s+the+same+core+device%22&amp;rft.date=2016-09-30&amp;rft.aulast=Popken&amp;rft.aufirst=Ben&amp;rft_id=https%3A%2F%2Fwww.nbcnews.com%2Fbusiness%2Fconsumer%2Fmylan-says-it-upgraded-epipen-2009-so-experts-looked-inside-n652651&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-129"><span class="mw-cite-backlink"><b><a href="#cite_ref-129">^</a></b></span> <span class="reference-text"><cite class="citation news">Tracy, Seipel. <a rel="nofollow" class="external text" href="http://www.mercurynews.com/2016/10/01/epipen-outrage-silicon-valley-engineers-figure-true-cost-to-make-lifesaving-auto-injector-about-10/">"Silicon Valley engineers figure real cost to make lifesaving auto-injector two-pack"</a>. The Mercury News<span class="reference-accessdate">. Retrieved <span class="nowrap">October 1,</span> 2016</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=Silicon+Valley+engineers+figure+real+cost+to+make+lifesaving+auto-injector+two-pack&amp;rft.aulast=Tracy&amp;rft.aufirst=Seipel&amp;rft_id=http%3A%2F%2Fwww.mercurynews.com%2F2016%2F10%2F01%2Fepipen-outrage-silicon-valley-engineers-figure-true-cost-to-make-lifesaving-auto-injector-about-10%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-NYToctRebate-130"><span class="mw-cite-backlink">^ <a href="#cite_ref-NYToctRebate_130-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-NYToctRebate_130-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation news">Thomas, Katie (October 7, 2016). <a rel="nofollow" class="external text" href="https://www.nytimes.com/2016/10/08/business/epipen-mylan-justice-department-settlement.html?ref=topics&amp;_r=0">"Mylan to Settle EpiPen Overpricing Case for $465 Million"</a>. <i>The New York Times</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+York+Times&amp;rft.atitle=Mylan+to+Settle+EpiPen+Overpricing+Case+for+%24465+Million&amp;rft.date=2016-10-07&amp;rft.aulast=Thomas&amp;rft.aufirst=Katie&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2016%2F10%2F08%2Fbusiness%2Fepipen-mylan-justice-department-settlement.html%3Fref%3Dtopics%26_r%3D0&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-131"><span class="mw-cite-backlink"><b><a href="#cite_ref-131">^</a></b></span> <span class="reference-text"><cite class="citation news">Thomas, Katie (September 2, 2016). <a rel="nofollow" class="external text" href="https://www.nytimes.com/2016/09/03/business/is-epipen-a-brand-name-or-a-generic-drug-mylan-casts-it-both-ways.html">"Is EpiPen a Brand-Name or a Generic Drug? Mylan Casts It Both Ways"</a>. <i>The New York Times</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=The+New+York+Times&amp;rft.atitle=Is+EpiPen+a+Brand-Name+or+a+Generic+Drug%3F+Mylan+Casts+It+Both+Ways&amp;rft.date=2016-09-02&amp;rft.aulast=Thomas&amp;rft.aufirst=Katie&amp;rft_id=https%3A%2F%2Fwww.nytimes.com%2F2016%2F09%2F03%2Fbusiness%2Fis-epipen-a-brand-name-or-a-generic-drug-mylan-casts-it-both-ways.html&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-132"><span class="mw-cite-backlink"><b><a href="#cite_ref-132">^</a></b></span> <span class="reference-text"><cite class="citation news">Mole, Beth (October 7, 2016). <a rel="nofollow" class="external text" href="https://arstechnica.com/science/2016/10/for-ripping-off-medicaid-epipen-maker-mylan-pays-feds-465-million/">"For ripping off Medicaid, EpiPen maker Mylan pays Feds $465 million"</a>. Ars Technica<span class="reference-accessdate">. Retrieved <span class="nowrap">October 8,</span> 2016</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.atitle=For+ripping+off+Medicaid%2C+EpiPen+maker+Mylan+pays+Feds+%24465+million&amp;rft.date=2016-10-07&amp;rft.aulast=Mole&amp;rft.aufirst=Beth&amp;rft_id=https%3A%2F%2Farstechnica.com%2Fscience%2F2016%2F10%2Ffor-ripping-off-medicaid-epipen-maker-mylan-pays-feds-465-million%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-133"><span class="mw-cite-backlink"><b><a href="#cite_ref-133">^</a></b></span> <span class="reference-text"><cite class="citation news">ZTracer, Zachary Tracer (October 7, 2016). <a rel="nofollow" class="external text" href="https://www.bloomberg.com/news/articles/2016-10-07/mylan-agrees-to-465-million-settlement-with-u-s-over-epipen">"Mylan Agrees to $465 Million EpiPen Settlement With U.S."</a> <i>Bloomberg.com</i>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Bloomberg.com&amp;rft.atitle=Mylan+Agrees+to+%24465+Million+EpiPen+Settlement+With+U.S.&amp;rft.date=2016-10-07&amp;rft.aulast=ZTracer&amp;rft.aufirst=Zachary+Tracer&amp;rft_id=https%3A%2F%2Fwww.bloomberg.com%2Fnews%2Farticles%2F2016-10-07%2Fmylan-agrees-to-465-million-settlement-with-u-s-over-epipen&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-Mylan_epipen_analysis_2017-134"><span class="mw-cite-backlink">^ <a href="#cite_ref-Mylan_epipen_analysis_2017_134-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-Mylan_epipen_analysis_2017_134-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation news">Erman, Michael (May 31, 2017). <a rel="nofollow" class="external text" href="https://www.reuters.com/article/us-mylan-epipen-idUSKBN18R2ZN">"Mylan may have overcharged U.S. for EpiPen by $1.27 billion: HHS"</a>. <i>Reuters</i>. New York<span class="reference-accessdate">. Retrieved <span class="nowrap">May 31,</span> 2017</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Reuters&amp;rft.atitle=Mylan+may+have+overcharged+U.S.+for+EpiPen+by+%241.27+billion%3A+HHS&amp;rft.date=2017-05-31&amp;rft.aulast=Erman&amp;rft.aufirst=Michael&amp;rft_id=https%3A%2F%2Fwww.reuters.com%2Farticle%2Fus-mylan-epipen-idUSKBN18R2ZN&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-execution-135"><span class="mw-cite-backlink">^ <a href="#cite_ref-execution_135-0"><sup><i><b>a</b></i></sup></a> <a href="#cite_ref-execution_135-1"><sup><i><b>b</b></i></sup></a></span> <span class="reference-text"><cite class="citation journal">Owen Dyer (October 24, 2014). <a rel="nofollow" class="external text" href="http://www.bmj.com/content/349/bmj.g6452.short">"Drug company is targeted for refusing to adopt ban on distribution of execution drug"</a>. <i>BMJ</i>. <b>2014</b> (349): g6452. <a href="/wiki/Digital_object_identifier" title="Digital object identifier">doi</a>:<a rel="nofollow" class="external text" href="https://doi.org/10.1136%2Fbmj.g6452">10.1136/bmj.g6452</a>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=BMJ&amp;rft.atitle=Drug+company+is+targeted+for+refusing+to+adopt+ban+on+distribution+of+execution+drug&amp;rft.volume=2014&amp;rft.issue=349&amp;rft.pages=g6452&amp;rft.date=2014-10-24&amp;rft_id=info%3Adoi%2F10.1136%2Fbmj.g6452&amp;rft.au=Owen+Dyer&amp;rft_id=http%3A%2F%2Fwww.bmj.com%2Fcontent%2F349%2Fbmj.g6452.short&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-Newsroom:_Mylan_Statement_on_its_Policy_Against_the_Use_of_Mylan_Products_in_Capital_Punishment-136"><span class="mw-cite-backlink"><b><a href="#cite_ref-Newsroom:_Mylan_Statement_on_its_Policy_Against_the_Use_of_Mylan_Products_in_Capital_Punishment_136-0">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://newsroom.mylan.com/press-releases?item=123361">"Mylan Statement on its Policy Against the Use of Mylan Products in Capital Punishment"</a>. Mylan<span class="reference-accessdate">. Retrieved <span class="nowrap">June 25,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Abook&amp;rft.genre=unknown&amp;rft.btitle=Mylan+Statement+on+its+Policy+Against+the+Use+of+Mylan+Products+in+Capital+Punishment&amp;rft.pub=Mylan&amp;rft_id=http%3A%2F%2Fnewsroom.mylan.com%2Fpress-releases%3Fitem%3D123361&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-137"><span class="mw-cite-backlink"><b><a href="#cite_ref-137">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="https://www.drugstorenews.com/article/milan-puskar-co-founder-mylan-dies/">"Milan Puskar, co-founder of Mylan, dies - Drug Store News"</a>. <i>Drug Store News</i>. October 10, 2011<span class="reference-accessdate">. Retrieved <span class="nowrap">July 17,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Drug+Store+News&amp;rft.atitle=Milan+Puskar%2C+co-founder+of+Mylan%2C+dies+-+Drug+Store+News&amp;rft.date=2011-10-10&amp;rft_id=https%3A%2F%2Fwww.drugstorenews.com%2Farticle%2Fmilan-puskar-co-founder-mylan-dies%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-138"><span class="mw-cite-backlink"><b><a href="#cite_ref-138">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=reportsSearch.process&amp;rptName=0&amp;reportSelectMonth=7&amp;reportSelectYear=1968&amp;nav">"Drugs@FDA: FDA Approved Drug Products"</a>. <i>www.accessdata.fda.gov</i><span class="reference-accessdate">. Retrieved <span class="nowrap">July 17,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.accessdata.fda.gov&amp;rft.atitle=Drugs%40FDA%3A+FDA+Approved+Drug+Products&amp;rft_id=https%3A%2F%2Fwww.accessdata.fda.gov%2Fscripts%2Fcder%2Fdaf%2Findex.cfm%3Fevent%3DreportsSearch.process%26rptName%3D0%26reportSelectMonth%3D7%26reportSelectYear%3D1968%26nav&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-139"><span class="mw-cite-backlink"><b><a href="#cite_ref-139">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;ApplNo=074246">"Drugs@FDA: FDA Approved Drug Products"</a>. <i>www.accessdata.fda.gov</i><span class="reference-accessdate">. Retrieved <span class="nowrap">July 17,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.accessdata.fda.gov&amp;rft.atitle=Drugs%40FDA%3A+FDA+Approved+Drug+Products&amp;rft_id=https%3A%2F%2Fwww.accessdata.fda.gov%2Fscripts%2Fcder%2Fdaf%2Findex.cfm%3Fevent%3Doverview.process%26ApplNo%3D074246&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-140"><span class="mw-cite-backlink"><b><a href="#cite_ref-140">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="http://www.cidrap.umn.edu/news-perspective/2004/06/fda-approves-generic-forms-ciprofloxacin">"FDA approves generic forms of ciprofloxacin"</a>. <i>CIDRAP</i><span class="reference-accessdate">. Retrieved <span class="nowrap">July 17,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=CIDRAP&amp;rft.atitle=FDA+approves+generic+forms+of+ciprofloxacin&amp;rft_id=http%3A%2F%2Fwww.cidrap.umn.edu%2Fnews-perspective%2F2004%2F06%2Ffda-approves-generic-forms-ciprofloxacin&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-141"><span class="mw-cite-backlink"><b><a href="#cite_ref-141">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="https://pink.pharmamedtechbi.com/PS007364/MYLANs-MAXZIDE-IS-APPROVABLE-AT-FDA-LEDERLE-TO-MARKET-BRAND-COMPETITION-TO-SMITHKLINEs-No-3RANKED-DYAZIDE-FINAL-APPROVAL-ANTICIPATED-IMMINENTLY">"MYLAN's MAXZIDE IS "APPROVABLE" AT FDA: LEDERLE TO MARKET BRAND COMPETITION TO SMITHKLINE's No. 3-RANKED DYAZIDE; FINAL APPROVAL ANTICIPATED "IMMINENTLY<span class="cs1-kern-right">"</span>"</a>. <i>Pink Sheet</i>. October 22, 1984<span class="reference-accessdate">. Retrieved <span class="nowrap">July 17,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Pink+Sheet&amp;rft.atitle=MYLAN%27s+MAXZIDE+IS+%22APPROVABLE%22+AT+FDA%3A+LEDERLE+TO+MARKET+BRAND+COMPETITION+TO+SMITHKLINE%27s+No.+3-RANKED+DYAZIDE%3B+FINAL+APPROVAL+ANTICIPATED+%22IMMINENTLY%22&amp;rft.date=1984-10-22&amp;rft_id=https%3A%2F%2Fpink.pharmamedtechbi.com%2FPS007364%2FMYLANs-MAXZIDE-IS-APPROVABLE-AT-FDA-LEDERLE-TO-MARKET-BRAND-COMPETITION-TO-SMITHKLINEs-No-3RANKED-DYAZIDE-FINAL-APPROVAL-ANTICIPATED-IMMINENTLY&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-142"><span class="mw-cite-backlink"><b><a href="#cite_ref-142">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="https://pink.pharmamedtechbi.com/PS015763/SOMERSET-ELDEPRYL-JUNE-5-APPROVAL-CLEARS-WAY-FOR-MYLANBOLAR-ACQUISITION">"SOMERSET ELDEPRYL JUNE 5 APPROVAL CLEARS WAY FOR MYLAN/BOLAR ACQUISITION"</a>. <i>Pink Sheet</i>. June 12, 1989<span class="reference-accessdate">. Retrieved <span class="nowrap">July 17,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Pink+Sheet&amp;rft.atitle=SOMERSET+ELDEPRYL+JUNE+5+APPROVAL+CLEARS+WAY+FOR+MYLAN%2FBOLAR+ACQUISITION&amp;rft.date=1989-06-12&amp;rft_id=https%3A%2F%2Fpink.pharmamedtechbi.com%2FPS015763%2FSOMERSET-ELDEPRYL-JUNE-5-APPROVAL-CLEARS-WAY-FOR-MYLANBOLAR-ACQUISITION&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-143"><span class="mw-cite-backlink"><b><a href="#cite_ref-143">^</a></b></span> <span class="reference-text"><cite class="citation news">Kusjanto, Mantik. <a rel="nofollow" class="external text" href="https://www.reuters.com/article/us-merck-mylan-idUSL1332538820070513">"Merck KGaA sells generics unit to Mylan for $6.6 bln"</a>. <i>U.S</i><span class="reference-accessdate">. Retrieved <span class="nowrap">July 17,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=U.S.&amp;rft.atitle=Merck+KGaA+sells+generics+unit+to+Mylan+for+%246.6+bln&amp;rft.aulast=Kusjanto&amp;rft.aufirst=Mantik&amp;rft_id=https%3A%2F%2Fwww.reuters.com%2Farticle%2Fus-merck-mylan-idUSL1332538820070513&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-144"><span class="mw-cite-backlink"><b><a href="#cite_ref-144">^</a></b></span> <span class="reference-text"><cite class="citation news"><a rel="nofollow" class="external text" href="http://fortune.com/2016/09/08/epipen-mylan-ceo-heather-bresch-fortune-mpw/">"Why the CEO Behind the EpiPen Controversy Is on Fortune's Most Powerful Women List"</a>. <i>Fortune</i><span class="reference-accessdate">. Retrieved <span class="nowrap">July 17,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Fortune&amp;rft.atitle=Why+the+CEO+Behind+the+EpiPen+Controversy+Is+on+Fortune%27s+Most+Powerful+Women+List&amp;rft_id=http%3A%2F%2Ffortune.com%2F2016%2F09%2F08%2Fepipen-mylan-ceo-heather-bresch-fortune-mpw%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-145"><span class="mw-cite-backlink"><b><a href="#cite_ref-145">^</a></b></span> <span class="reference-text"><cite class="citation web"><a rel="nofollow" class="external text" href="http://www.fiercepharma.com/pharma/as-rebel-mylan-investors-win-more-backing-ceo-bresch-champions-her-board-0">"As rebel Mylan investors win more backing, CEO Bresch champions her board | FiercePharma"</a>. <i>www.fiercepharma.com</i><span class="reference-accessdate">. Retrieved <span class="nowrap">July 17,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=unknown&amp;rft.jtitle=www.fiercepharma.com&amp;rft.atitle=As+rebel+Mylan+investors+win+more+backing%2C+CEO+Bresch+champions+her+board+%7C+FiercePharma&amp;rft_id=http%3A%2F%2Fwww.fiercepharma.com%2Fpharma%2Fas-rebel-mylan-investors-win-more-backing-ceo-bresch-champions-her-board-0&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
<li id="cite_note-146"><span class="mw-cite-backlink"><b><a href="#cite_ref-146">^</a></b></span> <span class="reference-text"><cite class="citation news">Daily, Investor's Business (September 22, 2017). <a rel="nofollow" class="external text" href="http://www.investors.com/news/technology/generic-drug-makers-face-pricing-issues-unlike-other-pharma-companies/">"Generic Drug Makers Face Pricing Issues Unlike Other Pharmaceutical Companies | Stock News &amp; Stock Market Analysis - IBD"</a>. <i>Investor's Business Daily</i><span class="reference-accessdate">. Retrieved <span class="nowrap">July 17,</span> 2018</span>.</cite><span title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&amp;rft.genre=article&amp;rft.jtitle=Investor%27s+Business+Daily&amp;rft.atitle=Generic+Drug+Makers+Face+Pricing+Issues+Unlike+Other+Pharmaceutical+Companies+%7C+Stock+News+%26+Stock+Market+Analysis+-+IBD&amp;rft.date=2017-09-22&amp;rft.aulast=Daily&amp;rft.aufirst=Investor%27s+Business&amp;rft_id=http%3A%2F%2Fwww.investors.com%2Fnews%2Ftechnology%2Fgeneric-drug-makers-face-pricing-issues-unlike-other-pharma-companies%2F&amp;rfr_id=info%3Asid%2Fen.wikipedia.org%3AMylan" class="Z3988"></span><link rel="mw-deduplicated-inline-style" href="mw-data:TemplateStyles:r935243608"></span>
</li>
</ol></div>
</section><h2 class="section-heading" onclick="javascript:mfTempOpenSection(9)"><div class="mw-ui-icon mw-ui-icon-element indicator mw-ui-icon-small mw-ui-icon-flush-left"></div><span class="mw-headline" id="External_links">External links</span><span class="mw-editsection"><a href="/w/index.php?title=Mylan&amp;action=edit&amp;section=38" title="Edit section: External links" data-section="38" class="mw-ui-icon mw-ui-icon-element mw-ui-icon-wikimedia-edit-base20 edit-page mw-ui-icon-flush-right">Edit</a></span></h2><section class="mf-section-9 collapsible-block" id="mf-section-9">
<ul><li><span class="official-website"><span class="url"><a rel="nofollow" class="external text" href="https://www.mylan.com">Official website</a></span></span></li>
<li><a href="/wiki/File:Commons-logo.svg" class="image"><noscript><img alt="" src="//upload.wikimedia.org/wikipedia/en/thumb/4/4a/Commons-logo.svg/12px-Commons-logo.svg.png" decoding="async" width="12" height="16" class="noviewer" data-file-width="1024" data-file-height="1376"></noscript><span class="lazy-image-placeholder" style="width: 12px;height: 16px;" data-src="//upload.wikimedia.org/wikipedia/en/thumb/4/4a/Commons-logo.svg/12px-Commons-logo.svg.png" data-alt="" data-width="12" data-height="16" data-srcset="//upload.wikimedia.org/wikipedia/en/thumb/4/4a/Commons-logo.svg/18px-Commons-logo.svg.png 1.5x, //upload.wikimedia.org/wikipedia/en/thumb/4/4a/Commons-logo.svg/24px-Commons-logo.svg.png 2x" data-class="noviewer"> </span></a> Media related to <a href="https://commons.wikimedia.org/wiki/Category:Mylan" class="extiw" title="commons:Category:Mylan"><span style="">Mylan</span></a> at Wikimedia Commons</li>
<li>Business data for Mylan: <div class="hlist hlist-separated inline"><ul><li><a rel="nofollow" class="external text" href="https://www.google.com/finance?q=MYL">Google Finance</a></li><li><a rel="nofollow" class="external text" href="https://finance.yahoo.com/q?s=MYL">Yahoo! Finance</a></li><li><a rel="nofollow" class="external text" href="https://www.bloomberg.com/quote/MYL:US">Bloomberg</a></li><li><a rel="nofollow" class="external text" href="https://www.reuters.com/finance/stocks/overview?symbol=MYL.OQ">Reuters</a></li><li><a rel="nofollow" class="external text" href="https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&amp;CIK=MYL">SEC filings</a></li></ul></div></li></ul>




</section></div><noscript><img src="//en.wikipedia.org/wiki/Special:CentralAutoLogin/start?type=1x1&amp;mobile=1" alt="" title="" width="1" height="1" style="border: none; position: absolute;" /></noscript></div><div class="printfooter">
Retrieved from "<a dir="ltr" href="https://en.wikipedia.org/w/index.php?title=Mylan&amp;oldid=951205826">https://en.wikipedia.org/w/index.php?title=Mylan&amp;oldid=951205826</a>"</div>
</div>
			<div class="post-content" id="page-secondary-actions">
			
			</div>
		</main>
		<footer class="minerva-footer">
		<div class="last-modified-bar">
	<div class="post-content last-modified-bar__content">
		<span class="last-modified-bar__icon mw-ui-icon mw-ui-icon-mw-ui-icon-small mw-ui-icon-wikimedia-history-base20 "></span>
		<a class="last-modified-bar__text" href="/wiki/Special:History/Mylan"
				data-user-name="DemonDays64 Bot"
				data-user-gender="unknown"
				data-timestamp="1586998046">
				<span>Last edited on 16 April 2020, at 00:47</span>
		</a>
		<span class="mw-ui-icon mw-ui-icon-small mw-ui-icon-mf-expand-gray mf-mw-ui-icon-rotate-anti-clockwise indicator"></span>
	</div>
</div>

		<div class="post-content footer-content">
			<div id='mw-data-after-content'>
	<div class="read-more-container"></div>
</div>

			<h2><img src="/static/images/mobile/copyright/wikipedia-wordmark-en.svg" width="116" height="18" alt="Wikipedia"/></h2>
			<div class="license">Content is available under <a class="external" rel="nofollow" href="https://creativecommons.org/licenses/by-sa/3.0/">CC BY-SA 3.0</a> unless otherwise noted.</div>
			<ul class="footer-places hlist hlist-separated">
				<li id="footer-places-terms-use"><a href="//m.wikimediafoundation.org/wiki/Terms_of_Use">Terms of Use</a></li><li id="footer-places-privacy"><a href="https://foundation.wikimedia.org/wiki/Privacy_policy" class="extiw" title="wmf:Privacy policy">Privacy</a></li><li id="footer-places-desktop-toggle"><a id="mw-mf-display-toggle" href="//en.wikipedia.org/w/index.php?title=Mylan&amp;mobileaction=toggle_view_desktop">Desktop</a></li>
			</ul>
		</div>
		</footer>
	</div>
</div>
<div class="mw-notification-area" data-mw="interface"></div>
<!-- v:8.3.0 -->

<script>(RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgPageParseReport":{"limitreport":{"cputime":"1.356","walltime":"1.598","ppvisitednodes":{"value":7248,"limit":1000000},"postexpandincludesize":{"value":343636,"limit":2097152},"templateargumentsize":{"value":6674,"limit":2097152},"expansiondepth":{"value":36,"limit":40},"expensivefunctioncount":{"value":4,"limit":500},"unstrip-depth":{"value":1,"limit":20},"unstrip-size":{"value":436807,"limit":5000000},"entityaccesscount":{"value":2,"limit":400},"timingprofile":["100.00% 1434.084      1 -total"," 60.63%  869.477      1 Template:Reflist"," 57.38%  822.809     17 Template:Clade"," 25.01%  358.628     77 Template:Cite_news"," 19.10%  273.890     43 Template:Cite_web","  9.77%  140.164      1 Template:Infobox_company","  8.51%  121.971      1 Template:Infobox","  4.71%   67.583      1 Template:Short_description","  3.53%   50.556      1 Template:Pagetype","  3.52%   50.414      4 Template:Cite_journal"]},"scribunto":{"limitreport-timeusage":{"value":"0.768","limit":"10.000"},"limitreport-memusage":{"value":8145399,"limit":52428800}},"cachereport":{"origin":"mw1373","timestamp":"20200417190851","ttl":86400,"transientcontent":true}}});});</script>
<script type="application/ld+json">{"@context":"https:\/\/schema.org","@type":"Article","name":"Mylan","url":"https:\/\/en.wikipedia.org\/wiki\/Mylan","sameAs":"http:\/\/www.wikidata.org\/entity\/Q899010","mainEntity":"http:\/\/www.wikidata.org\/entity\/Q899010","author":{"@type":"Organization","name":"Contributors to Wikimedia projects"},"publisher":{"@type":"Organization","name":"Wikimedia Foundation, Inc.","logo":{"@type":"ImageObject","url":"https:\/\/www.wikimedia.org\/static\/images\/wmf-hor-googpub.png"}},"datePublished":"2005-08-29T04:55:28Z","dateModified":"2020-04-16T00:47:26Z","headline":"pharmaceutical company"}</script><script>(window.NORLQ=window.NORLQ||[]).push(function(){var ns,i,p,img;ns=document.getElementsByTagName('noscript');for(i=0;i<ns.length;i++){p=ns[i].nextSibling;if(p&&p.className&&p.className.indexOf('lazy-image-placeholder')>-1){img=document.createElement('img');img.setAttribute('src',p.getAttribute('data-src'));img.setAttribute('width',p.getAttribute('data-width'));img.setAttribute('height',p.getAttribute('data-height'));img.setAttribute('alt',p.getAttribute('data-alt'));p.parentNode.replaceChild(img,p);}}});</script>
<script>(RLQ=window.RLQ||[]).push(function(){mw.config.set({"wgBackendResponseTime":177,"wgHostname":"mw1275"});});</script>		</body>
		</html>
		